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Sjögren’s syndrome (SS) is a systemic, chronic, autoimmune inflammatory disease that 
affects the exocrine glands. The absence of early diagnostic markers contributes to delays in 
its diagnosis. Furthermore, SS patients have an increased incidence of lymphoma and there 
is a need for biomarkers to identify its development. To enable a better understanding of 
disease activity and progression, the following aims were undertaken; 1. Investigate the 
potential use of the salivary gland assessment tests (whole flow rates (WFR), parotid flow 
rates (PFR), clinical oral dryness score (CODS) and ultrasound score (USS)) in discriminating 
SS and non- SS sicca patients as well as to differentiate between the different subgroups of 
SS. 2. Determine the diagnostic accuracy of USS. 3. Complete a longitudinal study on dry 
mouth patients at 5 and 10-year time-points. 4. Identify salivary markers of disease activity 
and progression in SS; MALT-L risk and MALT-L subgroups. 
Methodology: Clinical parameters (WFR, PFR, CODS and USS) of 244 patients involved in 
the cross- sectional study were recorded for SS of different subgroups as well as for disease 
controls and ROC curves were constructed to determine an optimal cut- off USS. Five-year 
follow- up of 80 patients was done while only 16 were involved in the 10-year follow- up. 
Salivary (parotid) proteomic analysis was done followed with initial candidate biomarker 
selection (S100A8/A9) and verification via immunoassay (ELISA) involving SS of different 
subgroups, disease and healthy controls (n=83). Salivary (parotid) cytokine array analysis was 
done followed by further screening of cytokines via multiplex bead- based assay on 76 
samples and verification of the cytokines with significantly altered levels via a more sensitive 
multiplex bead- based performance assay on 82 samples. 
Results: 1. All parameters (WFR, PFR, USS and CODS) of the overall SS group showed a 
significant difference when compared to the disease control group. This was attributed mainly 
to the advanced subgroups of SS (SS at risk and MALT-L groups) (p<0.0001 for all 
parameters). 2. USS would be an ideal non-invasive test to differentiate and monitor SS 
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patients in general; an optimal cut- off of 4 yielded 81% sensitivity and 94% specificity and 
odds ratio of 70.5% with a negative predictive value of 66% while the positive predictive value 
was 97%. 3. The follow- up of patients over 5 and 10 years has proven that in patients with a 
longer disease duration SS is a slowly progressing disease where all the parameters remained 
relatively stable, although some individuals may display flare ups and remissions as in any 
other rheumatic diseases. 
S100A8/A9 ELISA analysis of parotid saliva showed significant differences between the 
overall SS group and both disease and healthy controls (p=0.001 and 0.031 respectively). SS 
at risk of MALT-L and those with MALT-L also demonstrated increased levels when compared 
to healthy controls (p=0.019 and 0.014). 
IL-1α, -4, -6, and MCP-1 were significantly different in the overall SS group when compared 
to the disease control group but only IL-6 was increased when compared to the healthy control 
group. Further verification via more sensitive assays revealed that IL-6 and IL -4 continued to 
show significance compared to the disease control group and IL-6 compared to the healthy 
group.  
Conclusion: the results of the above-mentioned studies suggest that several clinical 
parameters can aid in differentiating between SS and non- SS sicca especially the subgroups 
of SS (MALT-L risk and MALT-L sub groups) with attention to USS as a valuable diagnostic 
tool.  Salivary biomarkers showed differences between SS and the other groups as well.  
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Sjögren’s syndrome (SS) (also known as autoimmune exocrinopathy and autoimmune 
epitheliitis) is a systemic, chronic, inflammatory, autoimmune disease that affects the exocrine 
glands, particularly the salivary and the lacrimal glands. The pathogenesis of the disease 
remains not fully understood and to date no universally effective therapy is available. Clinically, 
dry mouth (stomatitis sicca or xerostomia), dry eyes (keratoconjunctivitis sicca (KCS) or 
xerophthalmia) and fatigue with /without inflammatory arthritis are among the most common 
manifestations.  Extra glandular manifestations can occur in SS along with glandular 
manifestations which may affect the patients’ quality of life. Occurrence of mucosa associated 
lymphoid tissue lymphoma (MALT-L) is one of the most serious manifestations of SS. 
Histologically SS, is characterised by focal lymphocytic infiltration of the salivary and lacrimal 
gland with concomitant destruction of the glandular tissue as shown in figure 1-1. The disease 
can occur by itself or with an accompanying autoimmune disease (AID), most commonly 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (Fox, 2005).  
 
Figure 1-1 Histopathological lesion in minor salivary glands of a patient with SS.  
The hallmark of SS is periductal lymphocyte infiltration of the salivary glands  





 Historical view of Sjögren’s syndrome   
The history of Sjögren’s (Mikulicz, Gougerot's, Houwer, and Sicca amongst others) syndrome 
goes back to more than 100 years ago; a German physician named Leber, first described one 
of its components (Filamentary keratitis) in 1882. Between that year and 1927, several 
clinicians [Hadden in 1888, Fischer in 1889, Gougerot in 1925, Houwer in 1927 and others] 
reported similar cases with similar features.  Mikulicz in 1892, reported a case of bilateral 
parotid and lacrimal enlargements with round cell infiltrations. The term Mikulicz’s syndrome 
could cover many different entities thus it did not provide sufficient prognostic or therapeutic 
information. However, the term is still used intermittently to describe the histological 
appearance of focal lymphocytic infiltrates in salivary-gland biopsy samples. In 1933, a full 
description was made by a Swedish ophthalmologist named Henrik Sjögren in his doctoral 
thesis in which he presented clinical and pathological findings of 19 patients (reached 80 in 
1951) complaining of dry mouth, dry eyes and arthritis, the term keratoconjunctivis sicca was 
first introduced by him as well.  Ten years later (1943), Hamilton translated it into English 
under the name of ‘a new concept of keratoconjunctivitis sicca’ (Bunim, 1961, Fox, 2005).  
 Epidemiology  
Incidence and prevalence rates of SS vary widely around the world depending on the 
classification criteria used (Qin et al., 2015). Few global studies have been conducted, 
describing the epidemiology of SS and the regional difference are largely not known.  The use 
of different sample sizes and criteria across these studies probably lead to the variation in the 
reported incidence and prevalence rates (being higher in earlier studies than in newer studies), 
which causes difficulty in interpretation and comparison of their results. In Europe, Bolstad 
and Skarstein, (2016) reported a prevalence of ~0.04 % from an oral perspective when the 
American European Consensus group (AECG) criteria were only used (Vitali et al., 2002). 
However, when different criteria were combined from different countries, it was found to be 
from 0.03 to 2.7 (95%CI 1- 4.5) (Patel and Shahane, 2014). In the United States, prevalence 
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of 0.02-0.1 was reported (Maciel et al., 2016). Another study reported a prevalence range of 
0.2‐3.0% which was generated from previous studies with a yearly incidence of 3.9 per 
100.000 reported by other 2 studies . The female-to-male ratio of SS is 9:1 SS with an onset 
that typically occurs in the fourth to sixth decades of life (Reksten and Jonsson, 2014).  
 Clinical features 
The clinical manifestations of SS may vary and the onset is often insidious, it can be non-
specific during the early stages of the disease which might be overlooked or mistaken; 
accordingly, diagnosis may therefore be delayed for many years. The main clinical 
characteristic features of primary SS are the sicca symptoms which are progressive dryness 
of the eyes (KCS) and dryness of the mouth (xerostomia). Both of which are part of the 
exocrine glandular features (lacrimal and salivary glands) (Kassan and Moutsopoulos, 2004). 
 Exocrine glandular manifestations: 
Ocular manifestations: include dryness of the eye; sensation of gritty (sandy), itchy or sore 
eyes which can appear as normal or red eyes, discharge from the eyes, eye fatigue, inability 
to cry, eyelid adherent in morning and increased sensitivity to light, all of which affecting the 
person’s ability to watch and read.  Superficial corneal erosions may occur and may become 
as severe as filamentary keratitis, which is caused by the adherence of mucus filaments to the 
eroded (damaged) areas of the eyes. In addition, patients may develop conjunctivitis via 
Staphylococcus aureus infection and rarely manifest lacrimal gland enlargement (Kassan and 
Moutsopoulos, 2004). 
Oral manifestations: xerostomia (dry mouth) is the main symptom and although this 
subjective complaint of xerostomia does not necessarily correlate with objective measures of 
hyposalivation, it is rather correlated with compositional change of saliva (Billings et al., 2016). 
Fox et al., (2008) reported xerostomia in 90% of their patients and if dry mouth is truly present 
it may lead to numerous complications summarized in table 1-1; extra- oral findings include 
cracked lip and angular cheilitis and intra- oral signs that range from subtle to obvious. Vissink 
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et al., (2003) reported a strong correlation between tear and saliva quality and secretion rate. 
It is well known that xerostomia has a huge effect on the person’s quality of life in terms of its 
physical, psychological, and social aspects. Patients might not complain of dryness but of 
unpleasant taste and mouth soreness which might obscure the diagnosis for a period of time. 
Salivary gland enlargement might occur alongside as well; which might be associated with the 
increase risk of lymphoma development (Kassan and Moutsopoulos, 2004)(figure 1-2).  
Other oral lesions of autoimmune aetiology (e.g. lichen planus and pemphigus vulgaris) might 
occur in 12% of SS patients. These disorders often cause ulceration and irritation of the oral 
tissues ranging from mild to severe (Likar‐Manookin et al., 2013). 
Additional exocrine glands: other glands are affected as well and appear as respiratory, 
vaginal and skin reduced glandular-secretions; nose, throat, tracheal dryness resulting in 
nasal crusting, epistaxis, recurrent sinusitis, dry cough and dyspnoea. Vaginal dryness might 
cause dyspareunia and pruritus whilst skin dryness may result in skin rash or burning and 












Table 1-1 Clinical features of xerostomia 


















Oral consequences of xerostomia  
Dry sore mucosa (stringy saliva) Gross accumulation of plaque 
Difficult swallowing and speaking Increased frequency of caries(cervical) 
Reduce denture retention Liability to Candidal infection 
Burning fissured/lobulated tongue                                                   Gingivitis
Dry cracked sore lips                                       Traumatic oral lesions 
Ascending sialadenitis Mucosal atrophy 
Salivary gland enlargement  Halitosis  
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 Extra-glandular manifestations 
Typical but rarely diagnostic, extra-glandular manifestations can occur due to the typical 
lymphocytic infiltration around the epithelium of target organs and because of the circulating 
autoantibodies.  They develop slowly with variable outcome, and in some cases the on-going 
pathologic process may lead to severe organ damage and end-stage organ failure (Kassan 
and Moutsopoulos, 2004). 
 The prevalence of these manifestations varied greatly between the studies with a range of 
>10- 50% of SS patients. They include non -specific features such as fever, fatigue, malaise, 
lymphadenopathy and musculoskeletal involvement such as arthralgias, myalgias and 
myopathy. Some of the visceral manifestations include the following: pulmonary 
(bronchitis/bronchiolitis), renal (e.g. interstitial nephritis), gastroenterologic (e.g. oesophageal 
dysmotility), cardiovascular (e.g. pericarditis) and neurologic (e.g. peripheral sensory 
neuropathy and central nervous involvement; acute and chronic myelopathies) (Kassan and 
Moutsopoulos, 2004). Among them the most common symptoms include numbness and 
tingling of the extremities, Raynaud’s phenomenon, malaise, lymphoadenopahy and 
gastrointestinal disturbances also fatigue was reported amongst the most common complaints 
(Vissink et al., 2012).  
Furthermore, cutaneous vasculitis is another skin manifestation that is considered as one of 
the most common extra-glandular features manifesting as palpable or non-palpable purpura. 
It is associated with the presence of hypergammaglobulinemia and related to a benign B-cell 
proliferation. On the other hand, cryoglobulinemic type of cutaneous vasculitis might occur, it 
is a systemic immune complex-mediated vasculitis with complement activation and can be 
used as a predictor of lymphoma; as it is considered as a prelymphomatous condition in SS 









Figure 1-2 Extra- and intra oral manifestations.  













 Accompanying autoimmune disease  
SS can be associated with organ specific autoimmune disease such as primary biliary 
cirrhosis, autoimmune thyroid or gastric disease. Furthermore, SS can develop secondary to 
another connective tissue autoimmune condition. In some patients, SS may precede the other 
disease by many years. It is sometimes difficult to determine whether a clinical manifestation 
is solely a consequence of SS or is due to other autoimmune disease. The combination does 
not modify the prognosis or outcome of the other autoimmune condition. About 60% of SS 
patients have the disease secondary to another autoimmune disorder such as RA, SLE or 
systemic sclerosis. On the other hand, almost 25% of patients with RA or SLE have histologic 
evidence of SS (Kassan and Moutsopoulos, 2004). Conversely, the distinction between 
primary and secondary forms of SS, which is usually based on an early detection of the 
disease, may be now out-dated. It has become known that some individuals with one 
autoimmune disease have increased susceptibility to develop another. Thus, it seems of little 
use and may cause confusion to distinguish one autoimmune disease as secondary to 
another. Consequently, the diagnosis of SS should be given to all who satisfy the classification 
criteria while also diagnosing any organ-specific or multiorgan autoimmune disease occurring 
with it, without distinguishing SS as primary or secondary (Shiboski et al., 2012). Table 1-2 
summarises those accompanying autoimmune diseases. 
Table 1-2 Accompanying autoimmune diseases in SS 
Adapted from Lazarus and Isenberg (2005) 
  
Additional autoimmune diseases found in SS  
Hypothyroidism  
Graves disease/thyrotoxicosis  
Scleroderma  
Pulmonary fibrosis  
Chronic active hepatitis  
Primary biliary cirrhosis  
Systemic lupus erythematosus 
Myositis  
Renal tubular acidosis   
Glomerulonephritis  
Idiopathic thrombocytopenia  





 Diagnosis of Sjögren’s syndrome  
Sjögren’s syndrome is one of the most clinically diverse autoimmune diseases. Owing to its 
heterogeneous presentation, clinical management of SS remains a great challenge. 
Therefore, there is a great need to diagnose it with the ability to assess the disease activity 
accurately (Patel and Shahane, 2014).  Early diagnosis of SS will prevent or ensure a timely 
treatment of many complications of the disease (Kassan and Moutsopoulos, 2004). It requires 
different areas of speciality practice. Due to the complex nature of the disease involving 
multiple sites, there is no single gold standard test for establishing the diagnosis of SS (Vitali 
et al., 2002). At present, the diagnosis usually depends on the combination of clinical and 
laboratory findings based on an expert opinion which will be discussed in the following section. 
Difficulty in diagnosing SS is explained in figure 1-4. The main differential diagnosis and 
exclusion criteria are summarized in tables 1-3 and 1-4. 
 
 





 Diagnostic tests 
Objective assessment of the ocular and oral features of SS is important to develop an accurate 
diagnosis:  
 Ocular tests 
Ocular tests are performed to evaluate the tear volume (e.g. Schirmer’s test), stability of tear 
film (e.g. tear break-up time) and the integrity of the ocular surface where selected semi- 
quantitative methods to assess the severity of KCS using vital dyes are used. Some of the 
modified tests lack validation and is not easily accessible also has low specificity, thus they 
are not accepted universally. However, Schirmer’s test and Van Bijsterveld’s ocular dye score 
(or any other dye) are part of the AECG criteria while ocular staining score (OSS) is part of 
the American college of rheumatology (ACR) criteria (Hernandez-Molina and Sanchez-
Hernandez, 2013). 
 Oral tests 
Oral tests are conducted to analyse the salivary gland function through sialometry and 
sialochemistry. The latter has an advantage over sialometry, which has the potential of 
showing these alterations in an early stage of the disease. It has been suggested as a 
diagnostic tool and the recent advances in mainly mass spectrometry systems have allowed 
several studies to identify several promising proteins and mRNA candidate biomarkers for SS 
(Al-Tarawneh et al., 2011). However, these markers need validation through further research 
(Hernandez-Molina and Sanchez-Hernandez, 2013).  
According to Aframian et al., (2013) some of these sialochemistry studies showed different 
conflicting results due to different saliva collection methods, which warrants the need for a 
standardized collection protocol. Among these studies, it was found that in patients with SS, 
some proteins such as proline rich enzymes and carbonic anhydrase were down- regulated 
while the inflammatory proteins such as β-2 microglobulin and immunoglobulin (Ig) κ light 
chain were up- regulated some of which were validated pre-clinically (Hu et al., 2010).  
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Furthermore, it was reported that Anti- Ro60 and Ro52 autoantibodies can be detected in the 
saliva of SS patients with high specificity, suggesting a practical alternative to serum and 
compatible with point-of-care testing in patients with SS (Ching et al., 2011). Therefore, more 
evidence that supports using saliva biochemistry tests as a diagnostic tool is needed.  
On the other hand, sialometry is easily performed and provides an objective assessment of 
the flow rate. Different sialometric tests were used; wafer test, Saxon test, oral Schirmer test, 
candy weight loss test, the palatal and specific glandular saliva flow, the capsaicin-stimulated 
salivary flow and the more traditional whole saliva flow with or without stimulus. The 
unstimulated whole flow rate test (WFR) is the only sialometric test that was included in the 
AECG criteria while none has been included in the ACR criteria, which found that WFR was 
unreliable diagnostic measure (Hernandez-Molina and Sanchez-Hernandez, 2013). It should 
be noted that glandular saliva can be more informative regarding disease progression and 
diagnosis (Pijpe et al., 2007, Vissink et al., 2012). 
The Challacombe scale was developed from research conducted at King’s College London 
Dental Institute, the Clinical Oral Dryness Score (CODS) uses a simple numeric system which 
enables the clinician to quantify the severity of the xerostomia and to decide if the condition 
needs treatment or not. This scale has been distributed to all general dental practitioners 
(Challacombe et al., 2015) (Appendix 1). Noting that earlier, Navazesh et al., (1992) has 
identified a set of 4 clinical parameters defining hyposalivation. 
 Oral and ocular symptoms scores 
Oral and ocular scores are subjective measurements that can be determined using 
questionnaires and indices; they can be either non-specific (e.g. Ocular surface disease index) 
or disease- specific; (e.g. Sicca symptoms inventory). The subjective assessment of the AECG 
criteria included two sets of questions regarding ocular and oral symptoms and the EULAR 




 Histopathology examination 
Histopathological examination of labial glands removed during a lower lip biopsy is a widely 
accepted diagnostic method where a focal lymphocytic sialadenitis (FLS) with a focus score 
of 1 or more is considered diagnostic for SS. Furthermore, the morphology contributes to the 
prediction of non-Hodgkin’s lymphoma (NHL) development if there are lymphoid germinal 
centres present in the glands. However, it is an area of controversy, some studies have 
suggested excluding biopsies if patients were fulfilling enough criteria; clinical sicca 
symptoms/signs and positive serology. While others reported that biopsies had the highest 
predictive value which depends on the criteria being used (Vissink et al., 2012). 
Shoboski et al., (2012) demonstrated that biopsy provides information about the extent and 
nature of the disease process. It has been criticized for being invasive and difficult to apply in 
all settings. However, being applied on nearly 1400 participants as part of their investigations 
would suggest otherwise. It is a minimally invasive 15-minute procedure, when it is skilfully 
and conservatively performed. Moreover, (Kapsogeorgou et al., 2013) found no change in 
repeated biopsies obtained over median period of 55 months indicating development of 
lymphoma in some patients with severe serological parameters. In addition, Carubbi et al., 
(2014) have identified an association between different histopathological patterns obtained via 
labial gland biopsies and different cytokine expression and clinical subsets. 
It is worth noting that limitations of this procedure include difficulty in asking the patients to 
repeat the biopsy frequently for an assessment of the disease progression, possible 
permanent dysaesthesia of the lip, negative focus scores in patients fulfilling the diagnostic 
criteria for SS, variability of the histological interpretation and being inconclusive on occasions 
(Colella et al., 2010). Moreover, the reliability of such procedure was recently tested by Costa 
et al., (2015) demonstrated that the focus scores might be overestimated despite having a 
good reliability due to differences in assessment methods, and even with their importance for 
SS prognosis, germinal centres are often inadequately assessed. 
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To overcome these limitations parotid gland biopsy was suggested as an alternative way to 
diagnose SS, predict and confirm lymphoma development with several advantages; 
applicability of repeated biopsies of the same parotid gland, the results can be related with 
other diagnostic results derived from the same gland (e.g. sialometry, sialochemistry and 
sialography) and less sensory loss of skin (Vissink et al., 2012).  Furthermore, measuring the 
effect of therapeutic intervention can be accomplished using sequential parotid biopsies. Pijpe 
et al., (2009) have demonstrated a histopathologic proof of glandular inflammation reduction. 
The importance of standardisation of laboratory techniques such as the cutting procedure via 
multiple cutting levels and an area of at least 4 mm2, noting the presence of non-specific 
sialadenitis, ectopic germinal centres and fibrosis have been reported (Fisher et al., 2015). 
 Serological findings   
Serological findings are used to diagnose SS and to assess its activity and progression as 
well as for prediction of lymphoma development, recognition of extra- glandular manifestation 
and evaluation of effectiveness of treatment. Hypergammaglobulinemia, several 
autoantibodies against non- organ specific antigen [rheumatoid factor (RF), antinuclear 
antibodies (ANA), extractable nuclear antigen (ENA) as SSA/Ro and SSB/La, rheumatoid 
arthritis-associated nuclear antigen] are common findings (Aframian et al., 2013).  
Anti-SSA ⁄ Ro (52 and 60 kDa) and anti-SSB ⁄ La (48 kDa) were the most characteristic 
autoantibodies of SS (30–60%) and is accepted as a criterion of the AECG criteria (Vitali et 
al., 2002, Aframian et al., 2013). While RF and ANA levels were suggested by the ACR as a 
criterion that can substitute for ENA (Shiboski et al., 2012). In a most recent review by Ferro 
et al., (2016) it was demonstrated that others were reconsidering the addition of positive anti-
SSB ⁄ La as SS diagnostic criterion where only 2 % of patients in a global cohort has positive 
anti-SSB ⁄ La and negative Anti-SSA ⁄ Ro. In addition, a number of other autoantibodies has 
been suggested as potential markers for SS diagnosis and severity, but they are more related 
to a specific extra-glandular manifestation of the disease (e.g. increased levels of carbonic 
anhydrase II Abs in patients with SS and distal renal tubular acidosis). Among them, two were 
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likely to have potential diagnostic value according to a review done by Aframian et al., (2013); 
Anti-muscarinic type 3 receptors (anti-M3R) Abs and α- fodrin Abs. Some reported a 
correlation between these Abs and disease severity and progression while others did not. 
They suggested screening for anti α- fodrin Abs with the routinely used anti-SSA⁄ Ro and anti-
SSB ⁄ La might be useful, particularly in those patients who are negative for anti-SSA⁄ Ro and 
anti-SSB ⁄ La. Further research is needed to determine their diagnostic value (Aframian et al., 
2013). Moreover, increased levels of IgG hypergammaglobulinemia, decreased complement 
levels C3 and cryoglobulinemia were amongst the predictive factors of lymphoma 
development and those aforementioned factors as well as anaemia, lymphopenia, 
thrombocytopenia and presence of monoclonal proteins were associated with extra-glandular 
manifestation such as splenomegaly, adenopathy and purpura. Regarding treatment effect, it 
was reported that RF levels were decreased following intervention as well as for B circulating 
cells. However, T regulatory cells have shown controversial results (Vissink et al., 2012).   
 Radiological tests 
Imaging of the salivary glands includes conventionally X-ray sialography, scintigraphy, salivary 
gland ultrasonography (SGUS), computed tomography and magnetic resonance imaging 
(MRI). The first 2 tests are part of the AECG criteria (Vitali et al., 2002). When using an imaging 
test, a person should consider the cost, the invasiveness, the ionising radiation dose, the 
clinical usefulness, the applicability and more importantly the diagnostic accuracy. Sialography 
for diagnosing SS significantly depends on the skills of the observer, indicating that it is not 
generally applicable as a diagnostic tool in SS and requires specific expertise with a fair (inter-
observer) agreement between trained and expert observers (Kalk et al., 2002b).  Moreover, 
other conditions might mimic SS showing similar glandular appearance even in normal 
subjects (Kalk et al., 1999). Also it can be considered as an invasive technique; with ionizing 
radiation exposure, pain and swelling following the procedure, but a study by Kalk et al., 
(2001b) has shown that it has good patient acceptance, low morbidity and that it was not as 
invasive as it was often thought. Also, given its high sensitivity and specificity in diagnosing 
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SS as well as its useful monitoring potential, sialography remains the best performing imaging 
tool, more accurate than US and MRI in SS diagnosis. On the other hand, scintigraphy was 
poor compared to sialography, MRI and US with no standardised quantitative indices despite 
being as part of the AECG criteria (Vissink et al., 2012).   SGUS or ultrasound score (USS) 
may offer a promising alternative as a valuable tool for detecting salivary gland abnormalities 
in SS; it is a feasible, easily accessible, inexpensive and non-irradiating imaging tool. Again, 
it requires an experienced clinician to interpret the images of SGUS thus it might not be easily 
applicable. It has been suggested to improve the diagnostic value of American-European 
Consensus Group (AECG) and American college of rheumatology (ACR) criteria. And it has 
been suggested as a first line of diagnosis by Salaffi et al.,(2008), showing a good correlation 
with sialography by Shimizu et al., (2006) and replacing scintigraphy (Milic et al., 2012). 
However, its reliability is still not clear yet and one of its limitations is difficulty of identifying the 
early stages of SS; inability to penetrate deep tissue as the sialography does. In order to 
enhance both the diagnostic and the monitoring potential of SGUS, it will require 
standardization and validation by comparing the SGUS scores of parotid and submandibular 
gland tissue with their flow rates in future studies (Vissink et al., 2012, Delli et al., 2015, 
Jousse-Joulin et al., 2016). A simplified scoring system (Appendix 2) was modified at King’s 
College London Dental Institute radiology department (Brown, 2010). It was used in the first 
study (chapter 3), based on a system proposed by Hočevar et al., (2005).  
Furthermore, other aspects of SS have been assessed, for example: - 
• Fatigue is measured via various scales and indices among them the Visual analogue 
scale (VAS) is one of the most frequently used tools. 
• Quality of life is evaluated via generic and some organ- specific measures. 
• Disease status incorporates measurements of the activity of the disease (e.g. SS 
Disease Activity Index) and measurements of organ damage (e.g. SS Disease 
Damage Index) (Hernandez-Molina and Sanchez-Hernandez, 2013). 
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 Classification criteria 
Classification criteria have been developed for trial purposes mainly in clinical studies to 
guarantee the standardization of diagnosis, and to enable the analysis and comparisons of 
results of patients between institutions. These classification criteria aim for 100% sensitivity 
and specificity. However, classification criteria are often high in specificity but low in sensitivity. 
Classification criteria are being used for diagnosing SS.  The criteria may not be reliable in the 
early stages of the disease where the characteristic features have not yet manifested. Thus, 
a certain proportion of patients may be misclassified. The heterogeneity of signs and 
symptoms has led to the development of multiple classification criteria. 
Over the years, several sets of criteria have been proposed worldwide. 11 classification criteria 
have been reported since 1965; none have been accepted or validated by the ACR or the 
European League Against Rheumatism (EULAR). The most accepted criteria, which have 
been used and referred to, is the AECG criteria. Diagnosis is based on the concurrent 
presence of various signs and symptoms of the disease as established by 6 diagnostic 
standards: oral symptoms, ocular symptoms, evidence of oral signs, evidence of ocular 
dryness, evidence of salivary gland involvement, positive Anti-Ro/La autoantibodies and a 
positive gland biopsy (Appendix 3) (Aframian et al., 2013). The AECG criteria yielded a 
sensitivity of 96.1% and a specificity of 94.2% in primary SS diagnosis and in secondary SS 
had a sensitivity and specificity of 97.2% and 90.2% respectively. The criteria became broadly 
used and referred to, ever since (Vitali et al., 2002). 
The ACR and EULAR criticized it for including subjective measures which can exclude 
asymptomatic patients, physiologic measures that lack specificity, and for alternating objective 
tests that differ in sensitivity and specificity.  To address these issues and to develop a new 
classification, the on-going Sjögren’s International Collaborative Clinical Alliance (SICCA) was 




According to the SICCA (ACR) criteria proposed in 2012, the diagnosis of SS requires at least 
2 of the following 3 findings: 
• Positive serum anti-SSA and/or anti-SSB antibodies or positive rheumatoid factor (RF) 
and antinuclear antibody (ANA) titre of at least 1:320. 
• Ocular staining score (OSS) of at least 3. 
 
• Presence of focal lymphocytic sialadenitis with a focus score of at least 1 focus/4 mm2 
in labial salivary gland biopsy samples (Shiboski et al., 2012). 
The level of agreement between the preliminary ACR criteria and the AECG criteria was high 
when all objective tests were included to define the AECG criteria (88%). However, it was low 
when subjective tests were allowed to replace the objective tests (Shiboski et al., 2012). 
According to Bowman and Fox, (2014), the high level of statistical agreement was due to the 
fact that recruitments to SICCA study included  patients from support groups who possibly 
originally diagnosed by the AECG criteria. Researchers emphasized the need for establishing 
new classification criteria to support etiologic, genetic and therapeutic research trials. These 
criteria should be easily performed, be clear, have higher sensitivity/specificity and consider 
the potentially serious adverse effects and comorbidities of the new immunomodulating 
agents. They should rely on well- established conventional objective tests that are strongly 
associated with the different features of the disease and to be able to alternate between those 
tests only if they were comparable diagnostically. In addition, it was suggested that it was 
preferable for the new classification criteria to be acknowledged by the (ACR) and (EULAR). 
This was indeed recently developed and will be discussed later. 
Vitali et al., (2013) reported some critical points about these criteria; firstly, that these new 
ACR criteria were not validated for secondary SS. Nevertheless, the new criteria were 
proposed as a valid tool to classify secondary SS according the SICCA study. Secondly, 
patients who fulfilled the AECG criteria might be misclassified due to the exclusion of 
subjective symptoms. Furthermore, the alternative use of ANA and RF instead of anti Ro and 
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anti La, which can be seen in another autoimmune disease and this warrants further studies. 
On the other hand, Vitali et al., (2002) suggested that the new ACR criteria which involve only 
3 might be favoured over the more complex  6 domains (including 13 items) in AECG criteria. 
However, they explained that the AECG criteria are readily accessible and easy to use.  The 
main criticism as mentioned before is alternating tests, which are not diagnostically equivalent. 
It has been suggested that there should be a blend of the ACR and the AECG criteria to 
include both sets with different classifications options which then can be accepted by the ACR 
and EULAR (Bowman and Fox, 2014). Furthermore, several amendments to AECG criteria 
have been suggested; such as adding salivary gland ultrasonography (SGUS) to the AECG 
criteria (Cornec et al., 2013).  Even though SGUS is a promising addition to AECG criteria not 
only for classification but also for diagnosis and monitoring the disease activity and 
progression nonetheless its role in the ACR classification criteria requires more research and 
should be tested in further studies  as mentioned earlier (Bootsma et al., 2013). 
At the ACR 2015 annual conference, C. Shiboski presented a new classification criteria which 
might replace the provisional ACR and AECG criteria and getting close to get accepted by the 
EULAR. This new criteria demonstrated great concordance with the AECG criteria (Ferro et 
al., 2016). The final classification criteria are based on the weighted sum of five items and a 
cut- off of 4 points would be considered SS: 
• Positive serum anti-SSA antibodies (3 points)  
• Ocular staining score (OSS) ≥ 5 or Van Bijsterveld score of ≥4 (1 point) 
• Schirmer’s test ≤5 in 5 min (1 point) 
• Salivary flow rate ≤0.1 ml/min (1 point) 
• Presence of focal lymphocytic sialadenitis with a focus score of at least 1 focus/4 




 Disease that may underlie dry mouth, dry eyes or parotid gland enlargement 
Table 1-3 Possible conditions leading to: 
 
   














(Mumps, Influenza, HCV,  
HIV) 
Amyloidosis Amyloidosis   Amyloidosis 
 




Blink abnormality  Metabolic diseases:  
 Diabetes mellitus 
 Chronic pancreatitis 











Diabetes mellitus Toxicity (burns or drugs) 
 










*antihypertensive, parasympatholytic, and psychotherapeutic agents. 
Modified from Kassan and Moutsopoulos, (2004).
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Table 1-4 Exclusion criteria according to the AECG and ACR criteria 
 
AECG; American-European Consensus Group (Vitali et al., 2002) 










Exclusion criteria                                                                  
(AECG)                                                           (ACR)                                                                                                  
Sarcoidosis                        
                  
Graft versus host disease    
             
Hepatitis C infection (HCV) 
 
Acquired Immunodeficiency Syndrome (AIDS) 
 
Head and neck radiation           
        
Pre-existing lymphoma 
 
Anticholinergic drugs  
(since a time shorter than 4-fold the half-life of drug)     
Sarcoidosis       
                                   
Graft versus host disease   
 




Head and neck radiation   






 Sialadenitis, nodal osteoarthritis and xerostomia (SNOX) as different disease 
entity 
In a study by Kassimos et al., (1997), patients from an Oral medicine clinic setting were 
diagnosed provisionally with SS but proven not to satisfy the criteria upon examination and 
following their investigations (serology, histopathology and flows). The distinguishing features 
were; diffuse non-specific sialadenitis in their biopsies, seronegative anti-SS-A, anti-SS-B and 
Rheumatoid factor results with the presence of nodal osteoarthritis (NOA). As far as for the 
flow rate was concerned, whole mouth flow rates were reduced compared to normal range 
similarly to other SS patients (who satisfied the criteria). However, parotid flow rates were only 
reduced in some of the SNOX patients. SNOX patients were not on any known xerogenic 
drugs and fewer showed any ocular dysfunction (proven by Schirmer’s test only).  
The other part of the study established SNOX as a disease entity by studying age and sex- 
matched controls within a Rheumatology outpatient setting showing a statistically significant 
increase in the number of patients with NOA and xerostomia. They also confirmed the 
presence of fewer cases of ocular dysfunction.  NOA is characterised by polyarticular 
osteoarthritis which is mainly inflammatory. Twenty-five per cent of NOA patients had SNOX 
features suggesting it as a distinct disease entity. Erosive osteoarthritis was linked to SS. 
However, it is clearly that SS patients can also have osteoarthritis but SNOX can be 
distinguished by the other features mentioned earlier. Another study has reported a positive 
correlation between the reduced flow rate and reduced mucosal wetness and with increased 
CODS seen in different dry mouth patients (including SNOX) (Osailan et al., 2011). A similar 
group of patients was described by another study and they termed these patients as having 
dry eyes and mouth syndrome (DEMS) (Price and Venables, 2002). SNOX was chosen as a 
disease control group for the following chapters in order to verify its presence among dry 
mouth patients while comparing it to SS patients.  
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 Pathogenesis   
Investigators have considered SS as an immune mediated salivary gland dysfunction prior to 
glandular destruction. Tissue loss due to apoptosis, fibrosis and atrophy of the salivary glands 
would signify the classical model of gland hypofunction in SS. A non-apoptotic model was 
introduced in which atrophy is a result of glandular hypofunction not a cause of it and this 
explains the presence of normal acinar cells in SS patients with glandular hypofunction 
(Dawson et al., 2006).  It is characterized by both T- cell lymphocytic infiltration of the exocrine 
glands and B-cell lymphocyte hyperactivity. However, the mechanism by which this action 
takes place is still unknown. Furthermore whether this hyperactivity is a primary cause or 
secondary effect in SS is not known either (Jonsson et al., 2011). 
 Generally, the development of SS may be divided into three stages: 
• Activation of autoimmunity by different aetiological factors. 
• Initiation of the immune system (innate and acquired) and an increase in the chronic 
autoimmune response. 
• Tissue damage (Pers et al., 2012).  
 Aetiological factors 
Although the pathogenesis of SS is still unclear, the following factors have been suggested: 
Environmental factors: it has been postulated that viral infections such as cytomegalovirus 
(CMV), Epsteine Barr virus (EBV), retroviral elements, human herpes virus type 6 (HHV6), 
human T lymphotropic virus type 1 (HTLV-1), human herpes virus type 8 (HHV-8) and recently, 
coxsackie viral sequences, play a role as triggering factors, still controversial results were 
found between studies (Tzioufas et al., 2012). 
 It is worth noting that infections with certain viruses as hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV) might lead to inflammation of the salivary glands mimicking that 
of SS without the production of autoantibodies (anti-SSA/SSB). 
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The genetic predisposition: it varies among ethnic groups in SS and studies have found 
higher incidence of SS in family members and a higher prevalence of serological autoimmune 
abnormalities than controls. As with other autoimmune diseases a strong association to 
specific major histocompatibility complex (MHC) alleles has been demonstrated as well as the 
presence of genetic polymorphism (Tzioufas et al., 2012). Studies on the role of epigenetics 
have been extensively growing; it was found that in SS patients a global DNA methylation is 
reduced in the epithelial cells of salivary gland also microRNA expression profile is altered in 
SS patients compared to controls (Cornec et al., 2014). 
Hormonal factors: the strong female predominance observed in SS, suggests an influence 
of sex hormones but their role in the pathogenesis of SS remains unknown, however it seems 
that estrogenic deficiency predisposes to SS, thus might explain the development of the 
disease during the peri-menopausal period of life of females (Tzioufas et al., 2012). 
 Immunopathology  
 Cellular pathways   
It is assumed that infection as a trigger (most commonly viral) and other factors (mentioned 
above) caused the disorganisation of epithelial cells (ECs). Once triggered damaged or/and 
dead, EC will have a significant role in the pathophysiology as a regulators of the inflammatory 
process (aberrant homing of auto reactive B-cells and T- cells), it was speculated to be 
involved in the initial steps of the pathogenesis hence the name autoimmune epitheliatis was 
suggested as an etiological name of the disease (Tzioufas et al., 2012). 
 These triggered EC activate the HLA-independent innate immune system whereby they 
release triggering auto-antigens (e.g. SS-A protein and SS-B) to Toll-like receptors (TLR), 
which recognize pathogen-associated patterns (present in several microorganisms and 
apoptotic products) and they act as antigen presenting cells together with the adjacent T- cells 
and begin producing pro-inflammatory cytokines that up-regulate chemokines, and adhesion 
molecules production in the gland.  These changes will direct lymphoid migration into the gland 
where the HLA-dependent acquired immunity takes place which involves lymphoid cell 
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recruitment, homing, activation, differentiation and proliferation, as well as the expansion and 
organization of lymphoid infiltrate. (The following graph explains it in full detail) 
After migration of the lymphocytes and other cells such as dendritic cells (DCs) into the gland 
in response to chemokines and adhesion to specific adhesion molecules, they interact with 
each other and with the ECs. It is noteworthy that DCs have gained more interest in recent 
years, having a potential role in the pathogenesis. Immune complexes will be formed and will 
bind to the plasmocytoid (p)DCs through TLR, activating it and this will lead to production of 
Interferon (IFN)-α which is type-I IFN cytokine . This powerful modulator will further activate 
the epithelial cells and other immune cells (e.g. further homing and activation of lymphocytes). 
Studies have found an increased expression of IFN-regulated genes in SS patients (glands 
and bloods) compared to controls (Pers et al., 2012). This is so called the interferon signature 
that links both innate and acquired immunities. This was confirmed later by the presence of 
DCs in salivary glands as part of the inflammatory foci (Jonsson et al., 2011). 
Then B lymphocyte migration, interaction with T cells and activation in the gland occurs under 
the influence of Th cells and cytokine B-cell activating factor (BAFF) that is produced in 
abundance by myeloid (m)DC which is modulated by the IFN-α thus causing aberrant B-cell 
maturation leading to the emergence of self-reactive B-cells serving as an antigen-presenting 
cells to T cells, and locally produce autoantibodies and rheumatoid factors.  The on-going 
antigen stimulation can promote clonal expansion of B cells in the glands and blood, which 
might become malignant later. The presence of Ro/SS-A antibodies is correlated with longer 
periods of SS, greater damage of the glands and extra-glandular manifestation as mentioned 
previously (Maslinska et al., 2015). Some of the other signs and indicators of B-cell 
hyperactivity are presence of germinal centre-like structures in the glands, elevated glandular 
levels of B- cell associated cytokines (IL-6/ IL-21, BAFF/ a proliferation-inducing ligand 
(APRIL)) and chemokines (stromal cell- derived factor- 1 (SDF-1 or CXCL12), and B cell-
attracting chemokine 1 (BCA-1 or CXCL13) as well as in saliva, tears and serum. Elevated 
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levels of soluble (s)CD27 in tissue while reduced number of memory B-cells in peripheral blood 
was reported amongst the indicators of B-cell hyperactivity (Kroese et al., 2014). 
Analysis of infiltrates of salivary glands revealed majority of T cells surrounding the ductal 
epithelial cells with 80% CD4 cells and 10% CD8 (cytotoxic) while the remaining are B cells, 
DCs, macrophages and plasma cells. Their presence varies according to the severity of the 
disease. In mild lesions, the T cells are the majority while B cells are in advanced lesions. As 
the lesion increases in severity, the number of macrophages increases while the DCs 
decrease. The T cells are decreased in advanced lesions, but the cells that are affected are 
the CD4 while CD8 remain stable (Pers et al., 2012). 
 Cytokine production 
Cytokines are produced by a broad range of cells and a given cytokine can be produced by 
more than one cell type with a pleiotropic effect, an example of some cells is provided: 
Activated T lymphocytes (CD4 mainly) with high expression of HLA class II molecules and 
with the presence of co-stimulatory molecules, will differentiate into T helper (Th) 1 that 
produces IL-2, -3, IFN-γ and TNF-α promoting cell mediated response and to Th2 that produce 
IL-4, IL-5, IL-6, IL-10 and IL-13 which is engaged in humoral response. Th1/Th2 cross regulate 
(balance) each other by their cytokines secretions (Pers et al., 2012). Conflicting studies 
describing the role of regulatory T cells in the pathogenesis of SS in animals and patients were 
reported. Several studies have indicated that even though Th1 responses are thought to 
predominate in SS autoimmune lesions, evidence suggest that Th2 are the leading cytokines 
in mild lesions and re-emerging later in advanced lesions. In addition, with the discovery of 
IL23, identification of a new subset of Th cells which is Th 17 (secrets IL-17, IL-22 and other 
pro-inflammatory cytokines) in patients’ salivary glands and bloods was done indicating a high 
correlation with SS pathogenesis and warranting further investigation.  Activated B- cells may 
differentiate to produce similar Th1 and Th2 cytokines as well; Be1 and Be2. These cytokines 
maybe classified to pro-inflammatory, immunosuppressive cytokines and hematopoitic growth 
factors in addition to BAFF production (Pers et al., 2012). 
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Macrophages are one of the important components of SS histological lesions; they produce 
IL-18 that was found associated with higher risk of lymphoma development. While IL-12 was 
found associated with lower risk of lymphoma development, both of them are produced by DC 
cells as well (Manoussakis et al., 2007). Other cells include epithelial cells as mentioned 
previously and various stromal cells. 
When dividing the cytokines into Th1 Th2 or any other cells one must bear in mind that 
although mentioned above as being produced from and exhibiting a certain function, they 
might be produced from other sources with different function; an example of which is IL-6 pro-
inflammatory cytokine produced by different cells as monocytes/macrophages and DCs, and 
by T cells in chronic inflammatory conditions enhancing lymphocytes B growth and maturation. 
Also, it seems to be important for resolving acute inflammation, by inducing mechanisms that 
will shift innate to adaptive responses (anti-inflammatory). Lastly, IL-6 has also been shown to 
be involved in Th17 cell activation (Sverremark-Ekstrom, 2010). This necessitates reporting 
the cytokine sources and functions with caution.  Also, it must be not forgotten that chemokines 
are the motivating force of the lymphocyte recruitment. Initially pro-inflammatory chemokines 
such as CXCL10 (IP-10; IFN-gamma-inducible protein) are involved, while at advance stages 
the homeostatic chemokines CXCL12, CXCL13, macrophage inflammatory protein-3- β (MIP-
3- β); (CCL19) and secondary lymphoid-tissue chemokine (SLC); (CCL21) play an important 
role in inflammatory infiltrate maintenance and progression (Bombardieri and Pitzalis, 2012, 
Kroese et al., 2014, Barone et al., 2008). Tables 1-5 and 1-6 summarise most of the important 








Table 1-5 Cytokines and their functions 
 
    
Family 
 
Cytokines  Producer cells Function 
 













T cells, NK cells, neutrophils, 
intraepithelial lymphocytes 
Antiviral, Increased MHC class 1 
expression 
 
Antiviral, Increased MHC class 1 
expression 
 
Macrophages activation, increased 
expression of MHC molecules and antigen 
processing components, Ig class switching 
and supress Th17 Th2 





































Macrophages and epithelial 
cells 
 







T cells, thymic epithelial and 
stromal cells 
 
T cells and Mast cells 
 
 
T cells and Mast cells 
 
 
T and B cells macrophages  
and endothelial cells 
 
 
T and B cells macrophages 
and dendritic cells 
 
 







T cell and macrophages activation and 
fever 
 
T cell and macrophages activation and 
fever 
 
T cell proliferation and differentiation, T reg 
maintenance and function (T cell growth 
factor) 
 
Synergistic action in early hematopoisis 
 
 
B cell activation, IgE switch, induce 
differentiation into Th2 cells  
 
Eosinophil growth and differentiation 
 
 
T and B cell growth and differentiation, 
acute phase protein production and fever 
 
 
Potent suppressor of macrophages function 
(cytokine synthesis inhibitory factor) 
 
 
Activates NK cells, induces CD4 T cell 





B cell growth and differentiation, inhibit 
macrophage inflammatory cytokine 






MHC; major histocompatibility complex, TNF; tumour necrosis factor, APRIL; a proliferation-
inducing ligand, BAFF; B-cell activating factor, NK; natural killer cells, T fh; follicular T helper 
cells. 






    
Family 
 



























Activated macrophages and  
kupffer cells 
 
Th2 cells, T cell and primarily 
T fh cells 
 




Dendritic and macrophages 
 
 
High endothelial venules, 
smooth muscle and epithelial 
cells 
Induce cytokine and antimicrobial peptide 
production by epithelia, endothelia and 
fibroblast (pro-inflammatory) 
 
Induce IFN- γ production by T cells and NK 
cells and promotes Th1 induction 
 
Germinal centre maintained, induce 
proliferation of T, B and NK cells 
 
Induce cytokine and antimicrobial peptide 
production, induce liver acute phase 




Induce proliferation of Th17 memory T cells 
increase IFN- γ production 
 
 








Macrophages, NK and T cells 
 
 
Activated T cells 
 
B cells pDC 
Promotes inflammations, and endothelial 
activation 
 
B cell proliferation 
 
B cell proliferation 
 
Table 1-5 (Continued) 
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Chemokines  
 
Name  Target cells 






































































Neutrophil, basophil CD8 subset and endothelial cell 
 
 








CD34 bone marrow cell, thymocyte, monocyte/macrophages, naïve 









monocyte/macrophages, T cells (Th1> Th2), NK cell, basophils, immature 
dendritic cell, Eosinophil, neutrophil, astrocyte, fibroblast and osteoclast 
 
 
monocyte/macrophages, T cells (Th1> Th2), NK cell, basophils, immature 
dendritic cell, Eosinophil, B cell 
 
 
monocyte/macrophages, T cells (memory T cell> T cell; Th1> Th2), NK 




NK; natural killer cells, IP-10; IFN-gamma-inducible protein 10, I-TAC; Interferon-inducible T-cell 
alpha chemoattractant, SDF-1; stromal cell-derived factor- 1, MCP-1; monocyte chemoattractant 
protein-1, MIP-1 α; macrophage inflammatory protein 1-alpha, RANTS; regulated on activation, 
normal T cell expressed and secreted, SLC; secondary lymphoid-tissue chemokine. 











   
Chemokines  
 

























T cells (Th1> Th2), monocytes eosinophil, basophils, immature dendritic 
cell and NK cells 
 
 
Naïve T cells, mature dendritic cell and B cells 
 
 
T cells (memory T cells, Th17 cells) blood mononuclear cells, immature 
dendritic cells, activated B cells NKT cells GALT development 
 
 
Naïve T cells, B cells, thymocytes NK cells and mature dendritic cell and 
 
 
Table 1-6 (Continued) 
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Cytokines in general contribute to the pathogenesis of SS in various ways; play a vital role in 
the initiation and continuation of inflammation in the secretory glands, may have a direct effect 
on epithelial cells, linked to systemic complications of SS and may play a role in 
lymphomagenesis as well. While the pathogenesis of SS remains unclear, evidence suggests 
that cytokines play a central role in SS; 
• Elevated mRNA expressions of inflammatory cytokines have been consistently shown 
in affected tissues (minor and major glands). 
• Cellular studies have verified that cytokine-induced apoptosis of secretory epithelial 
cells leading to secretory dysfunction.  
• Studies on cytokine gene animal models have stated that both Th-1and Th-2 cytokines 
are important for SS development. 
•  Studies reporting over expression of cytokines in serum, saliva and even tear of SS 
patients compared to controls (Roescher et al., 2009).  
Roescher et al., (2009) provided a substantial review on the commonly identified cytokines in 
SS, some of the studies are summarised in (Appendix 20-24) while a summary is provided in 
(Appendix 25) as part of the review of the literature which is used as part of the methodology 
applied for chapter 5 with the addition of recently reported studies. 
The aetiology and pathogenesis of SS are still far from being understood. Despite continued 
extensive studies, several issues are yet to be addressed. Given the important role of 
cytokines in SS, they were investigated in (chapter 5). Obviously, more studies are needed to 
understand the complexity of such disease. An overview of the pathogenesis of SS is present 
































(Innate) immune system 
Alteration of glandular 
 vascular endothelium 
(chemokines/receptors) 
 
Infiltration of gland by lymphocytes 
of HLA-dependent (acquired) 
immune system 
 
Activation of lymphocytes within 
the gland leading to production of 
cytokines, autoantibodies and 
metalloproteinases-->apoptosis 
and cell destruction 
 
Hyposecretion due to glandular 
destruction 
Disruption of the glandular 
secretory process as a result of 
interaction between B, T cells, 
macrophages and acinar cells 
 
Early hyposecretion due to 
glandular disruption (cytokine 
effect) 
 
Apoptosis (cell destruction) 
 
Non- apoptotic 
model of glandular 
hypofunction                  
in SS 
Classical (apoptotic) 
model of glandular 
hypofunction                   
in SS 
Environmental, hormonal and 
genetic factors 




 Prognosis of Sjögren’s syndrome 
In most cases SS has a good prognosis in respect to mortality as it is a chronic slowly 
progressing disease characterised by sicca symptoms with a generalised pain and fatigue. 
Some patients may exhibit extra-glandular manifestation which might be life threatening and 
may exhibit some of the considered risk factors of lymphoma development which is one of the 
most serious manifestations in SS. Median time for development of lymphoma after the 
diagnosis of SS has been reported to be about 7.5 years and a median age of 58 (Voulgarelis 
et al., 2012). While more recently a median age of 55 with a median time of 5.3 years from 
time of diagnosis was reported (Papageorgiou et al., 2015b). 
The suggested three stages of SS progression are: 
• Initial glandular infiltration of CD4+ Th cells and then B cells with the presence of serum 
autoantibodies.  
• Infiltration of lymphocytes into the extra-glandular tissue and the development of 
pseudolymphoma and hypergammaglobulinaemia. 
• Progression to B cell lymphoma, possibly attended by hypogammaglobulinaemia and 
immunodeficiency; hence, it has been suggested that SS is a lymphoproliferative 
disorder (Moriyama et al., 2012). 











  Development of mucosa associated lymphoid tissue lymphoma 
(MALT-L) in Sjögren’s syndrome 
  Background 
 Historical perspective of MALT-L  
The association between SS and the subsequent development of malignant lymphoma was 
first described in 1963 (Bunim and talal, 1963). 20 years later, the concept of mucosa 
associated lymphoid tissue lymphoma was introduced by Isaacson and Wright,  (1983) where 
they described 2 cases of gastrointestinal lymphoma with a histology resembling that of MALT 
rather than lymph nodes, a year later a description of lymphoma in extra-intestinal sites with 
a  similar histology  was reported (Isaacson and Wright, 1984).  
Following on from this, MALT lymphomas became recognised as a distinct subtype of NHL; 
several classifications have been proposed, first recognition of MALT lymphoma as a discrete 
entity was in 1994 by The Revised European- American Lymphoma (REAL) classification, it 
was classified under the group of marginal zone B- cell lymphoma (MZLs) (Harris et al., 1994). 
Three subtypes of MZLs were identified in the more recent criteria by the World Health 
Organisation (WHO) for lymphoma, (established in 2001 and updated in 2008); nodal, extra-
nodal (MALT-L) and splenic type. This classification has shown to be more precise than any 
of the previous classifications and it has since become used by most pathologists and 









Generally, MALT-L can develop nearly in every organ and it is divided to either gastric (most 
common) or non- gastric MALT-L; head and neck region is the second most common site 
where tonsil and salivary gland are commonly involved amongst others.  Salivary gland MALT-
L is almost always associated with SS; if there is a prolonged antigen-driven stimulation 
triggering subsequent lymphoid proliferation a malignant clone can emerge and a MALT-L can 
develop. MALT-L are low grade lymphomas and can occur in any of the salivary glands, but 
the parotid gland is most commonly involved in addition to other MALT sites that might be 
involved. According to the WHO classification the official name used to be extra-nodal 
marginal zone B- cell lymphoma, the only modification done later in 2008 was removing the 
term B-cell (Cohen et al., 2006). There were other types of lymphomas that have been 
reported with SS, but MALT-L followed with diffuse large B-cell lymphoma (DLBCL) are by far 
the most common types associated with SS (Anderson et al., 2009).  
 Epidemiology 
Today, it has been known that patients with certain autoimmune and inflammatory disorders 
such as SS have an increased risk of developing malignant lymphoma. The risk varies 
between studies due to the heterogeneity of the sample sizes. Initially the risk was 
overestimated. Subsequently the standardised incidence ratio (SIR) was estimated at 20 and 
15 according to Zintzaras et al., (2005) and Theander et al., (2006) respectively. While in a 
more recent study a lower ratio was estimated (SIR =7) (Weng et al., 2012). Furthermore, a 
study by Fallah et al., (2014) reported a standardised incidence ratio of 4.9. According to 
Nishishinyaetal.,  (2015), the risk was 4, 10 and 18% during the first 5, 15 and 20 years 
respectively. Parotid gland is the most commonly affected site displaying a 1000 fold increased 
risk (Zintzaras et al., 2005). It has usually a good prognosis with a 90.9 % overall survival rate 
(OS) (Papageorgiou et al., 2015b). 81% OS was reported in another study but lifelong follow-
up is needed due to a high recurrence rate that reaches up to 35% over five years according 
to Anacak et al., (2012). 
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 Pathological features and Histology  
Clinically, salivary MALT lymphomas are localised (as an enlargement of the gland often 
unilateral and hard) and clinically it would be difficult to differentiate it from benign hyperplasia. 
No B symptoms are observed with rare involvement of the bone marrow. They exhibit a very 
indolent course with an extended progression time and a generally excellent prognosis, even 
without treatment. Some cases develop disseminated disease, usually to other MALT sites 
(ocular adnexa, stomach) or to lymph nodes. A few may transform to aggressive diffuse large 
B- cell lymphoma (Nocturne and Mariette, 2015). Para-neoplastic manifestations can include; 
vasculitis and neuropathy amongst others which might be extra-glandular manifestation of SS 
and used as predictive factors for lymphoma development as well which makes it difficult to 
differentiate between these 2 causes, and due to its indolent nature it is usually difficult to 
detect them (until later stages) (Risselada et al., 2013). 
Histologically, most salivary gland MALT lymphomas occur on a background of myoepithelial 
sialadenitis (MESA); benign lymphoepithelial lesion. It is a key feature consisting of atrophic 
acinar tissue infiltrated by small lymphocytes and plasma cells, often with reactive lymphoid 
follicles. Typically, there are numerous epimyoepithelial islands; which are often seen in major 
glands and might be seen in minor glands but not often and might be difficult to recognize 
because the glands are destroyed. The lymphoid tissue part consists of ectopic germinal 
centres while the epithelial islands consist of basal epithelial cells and modified myoepithelial 
cells with few ductal cells (figure 1-6). More advanced MALT lymphomas are characterised 
by a damaging, proliferations of neoplastic marginal zone B cells, ‘‘cavitating’’ lymphoepithelial 
lesions with a gradual replacement of reactive follicles. The neoplastic lymphoid cells are a 
distinctive and constant; these are centrocyte-like cells, in some cases and they might 
resemble monocytoid cells. Furthermore, scattered transformed blasts (large cells) and 
plasma cells are present as well (Bacon et al., 2007). It is difficult to differentiate between 
reactive follicle and neoplastic cells; but larger infiltrate, clear evidence of cytological atypia 




Figure 1-6 MALT- lymphoma of the parotid gland  
Arrow indicates the germinal centres while asterisks indicate lymphoepithelial lesion. 













 Lymphomagenesis of MALT-L 
Emerging data connecting autoimmune disease to lymphoma development has been 
described (Mandal et al., 2014, Baecklund et al., 2013). Yet the exact mechanism is still far 
from being understood. The following is a short description of the transition from SS to 
lymphoma. 
Continuing from the pathogenesis of SS and as mentioned previous; B- cell hyperactivity 
appears to be a hallmark of SS with transition of MESA to lymphoma in a multi-stage manner; 
with continuous stimulation and increased focal stimulation, ectopic, dysregulated germinal 
centres (GC) are likely to occur which are representing the lymphoepithelial lesions. The auto- 
reactive B- cells in these sites are associated with follicular DC networks resulting in the 
formation of memory B- cells at these sites. With sustained survival of B- cells and continuous 
production of autoantibodies, it would promote the expansion of unusual B-cell clones and 
produce the outgrowth of monoclonal aggregates of B cells. Increased B- cells clonal 
expansion in salivary glands of SS patients compared to controls was discussed in a review 
(Kroese et al., 2014). Neoplastic transformations of these clones are implicated for lymphoma 
development. It is still unclear what has driven the B- cells into clonal proliferation. Both ectopic 
GC and clonal expansion are associated with the risk of lymphoma development though the 
latter showed no absolute correlation (Jonsson et al., 2007). Yet there is a debate in the 
literature whether monoclonality can reliably diagnose MALT-L and differentiate it from MESA 
as it is difficult to differentiate between these entities histologically (Vega et al., 2005) 








 Possible mechanisms underlying the development of lymphomas 
The following section is based on a review done by Dong et al., (2013). As it is an autoimmune 
disease with characteristic infiltrations of T and B lymphocytes, the following mechanisms or 
causes were suggested demonstrating the importance of interactions among T cells, B cells 
and epithelial cells:-   
  T cell dysregulation  
T cells can: 
• Stimulate B cells via the CD40-CD40L interaction with the action of various cytokines 
and chemokines.  
•  Stimulate the production of BAFF; may contribute to the lymphoma development.  
• Allow clonal B lymphoid cells to escape immunological surveillance and elimination by 
inhibiting the protective T cell polyclonal lymphocytic infiltration into mucosal and 
exocrine tissues through regulatory T cells.   
• Regulate and participate in the autoimmune pathogenic process (T follicular helper) 
cells. 
Proliferation and differentiation of T cells are regulated by regulatory B cells which in turn if 
become dysregulated will affect the T cells dysregulating them as well. All of which may 
enhance the tendency toward lymphoma development. 
 Abnormal B cell biology 
B cell accumulation is seen mainly in the later stages of SS supported by the following: -   
• Reduction of circulating CD 27+ memory B cells while increased in inflamed tissue. 
• Disturbed distributions of peripheral blood B cells classification which may enhance 
lymphoma development. 
• Over expression of both BAFF and APRIL contributing to sustained survival of auto-
reactive B cells which consequently lead to lymphoma development.  




• Stimulation of RF-producing clones via immunoglobulins which are important in the 
development and expansion of MESA-associated clones as well. 
• Expression of hyper-mutated immunoglobulins with RF properties. 
• Clonally expanded B cells in salivary glands may be at high risk of lymphoma 
development. 
 Cytokines  
• Both Th1 and Th2 cytokines are implicated in SS development with shift toward the 
Th1 in the later stages then re-emergenace of Th2 in lymphoma development. 
• BAFF over expression is controlled by type I IFN leading to lymphoma development. 
• Increased Levels of Fms-like tyrosine kinase 3 ligand (FLT3L) which were correlated 
with advanced lesions and lymphoma development. 
• Expression of chemokines CXCL13 and CCL21 in lymphoepeithelial lesions while 
CXCL12 in lymphoma lesions indicating its importance. 
• Involvement of IL-6 in rearrangement in immunoglobulin V region genes during B-cell 
proliferation. 
Refer to Appendices 20-25 for the relevant references. 
 Viruses 
Several viruses have been linked to SS as mentioned before and it was hypothesized that 
they are not only implicated in initiating the immune response but act as a sustained antigen 
leading to sustained B cell proliferation and consequently to lymphoma development. One 
study found no relation between lymphoma development and EBV, CMV, HIV and H. Pylori 
infection even though they were linked with other MALT lymphomas (Solans-Laque et al., 
2011). Some studies have found an association with HCV, a lymphotropic virus that mainly 
affects B cells. However, this association remains uncertain. Furthermore, another link to 
Human herpes virus infection was reported in a review. 
Moreover, several oncogenic events, translocations and genetic polymorphisms have been 
reported to facilitate lymphoma development (Dong et al., 2013). 
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 Cellular and molecular pathways summary 
 
 
Figure 1-7 Cellular and molecular pathways implicated in lymphomagenesis in SS 
Under certain conditions with the involvement of several factors, salivary gland epithelial 
cells are believed to start activated and deregulated initiating the inflammatory process 
and recruiting the lymphocytic infiltrate; with the production of pro-inflammatory cytokines 
they are further activated. Accordingly, apoptotic or/and necrotic epithelial cells will 
develop due to the immune attack releasing autoantigens or non- apoptotic cell will 
release exosomes containing these autoantigens complexes. These complexes will 
activate the plasmacytoid dendritic cells (pDC) through TLR producing INF-α which in 
turn facilitate the production of BAFF by the myeloid dendritic cells (mDC). Over 
production of BAFF will lead to aberrant B cell maturation with the production of 
autoreactive B cells that produce autoantibodies and rheumatoid factors and this long-
lasting activation of innate and adaptive immunity will lead to immunologic exhaustion 
whereby the polyclonal expansions is switched to oligoclonal then finally to monoclonal 
cells with surface immunoglobulins displaying RF-like activity and a malignant clone may 
emerge that might ultimately lead to lymphoma development.  
BAFF; B-cell activating factor, BAFFR; BAFF receptor, IFN-α; interferon-α. 






 Predictive risk factors 
Despite efforts to identify risk factors for lymphoma development, neither the onset of its 
development can be identified efficiently nor which patient will develop lymphoma. Some 
predictors have been repeatedly reported by a number of studies with no clear explanation as 
to why they are linked to lymphoma development, however they share the same biological 
rationale, being a multistep disease that has antigen- driven stimulation, and so it will transform 
polyclonal B cells to neoplastic cells through a benign B cell clone.  According to a recent 
review by Papageorgiou et al., (2015a) and a meta-analysis (18 published studies) by  
Nishishinya et al., (2015), a number of local and systemic disease related risk factors have 
been stated, some were well established while others were recently introduced table 1-7. 
Among the clinical predictors are parotid gland enlargement and skin vasculitides (specifically 
cryoglobulinemic type). Although the former failed to reach significance in some articles while 
the latter showed significance in few studies (Nishishinya et al., 2015). Nevertheless  they 
were the most commonly reported predictors (Papageorgiou et al., 2015a).  
Lymphadenopathy was reported as significant predictive marker and lesser commonly stated 
predictors were splenomegaly, neuropathy and glomerulonephritis (Papageorgiou et al., 
2015a, Nishishinya et al., 2015). 
Regarding the serological predictors, the role of CD4 T cell lymphocytopenia has been 
confirmed as predictors and linked to lymphoma development in a number of studies, as well 
as a lower CD4/CD8 ratio. Few have regarded neutropenia as an independent risk factor. 
Several studies have reported mixed monoclonal cryoglobulinemia as a strong indicator of 
lymphoma, and one of them has associated it with advanced stages of MESA. While another 
study correlated MALT-L development with lower complement C4 levels which is another 
strong predictor stated by others as well, whereas C3 levels was found associated in some 
studies (n=3) but not in others (n=4). Hypergammaglobulinemia, β2 microglobulin, anti- Ro 
/anti- La, and serum-free light chains levels have been linked with high disease activity but not 
lymphoma (Papageorgiou et al., 2015a, Nishishinya et al., 2015). Male-sex, anaemia, positive 
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ANAs and RF were not associated with lymphoma development (Nishishinya et al., 2015). A 
recent study demonstrated the link between peripheral neuropathy and lymphoma with low 
vitamin D levels. In addition, the role of soluble biomarkers like (s) CD22, (s) CD27 are yet to 
be investigated. However disturbance in the peripheral B cell subpopulations was linked to 
lymphoma with reduction of memory B cells in the peripheral blood and increased (s) CD27 
(Papageorgiou et al., 2015a). Furthermore, high serum BAFF levels and FLT3 ligand levels 
were associated with lymphoma development and high disease activity (Papageorgiou et al., 
2015a, Nishishinya et al., 2015)  
With regards to histological predictors a lymphocytic focus score of 3 or more was correlated 
with lymphoma development. Also, the detection of ectopic GC-like structures was reported. 
Although they are still ill defined, and little is known about the mechanisms initiating their 
formation and potential subsequent lymphomagenesis, they are still considered one of the 
strongest risk factors as they are not linked to lymphoma only but with the disease activity as 
well.  (Papageorgiou et al., 2015a). Given their importance, there is a need for consensus 
guidelines to standardise the evaluation of ectopic lymphoid infiltrates and GCs in salivary 
gland tissue of patients with SS (Delli et al., 2016). Regarding the evidence of monoclonality 
in tissues controversial studies were reported (Vega et al., 2005). Certain chemokines and 
cytokines were linked to lymphoma development as mentioned previously; CXCL12 
expression was found in malignant lesions whereas CXCL13 and CCL21 were found in the 
reactive follicles (Barone et al., 2008). Expression of IL-12 and IL-18 were negatively and 
positively correlated with lymphoma development (Manoussakis et al., 2007). Also, several 
genetic factors were linked to lymphoma development such as the p53 mutation, BAFF and 
A20 genetic variations (Papageorgiou et al., 2015a). Furthermore, we have considered USS 
scores with the presence of hypoechoic foci as one of the risk factors as well and this will be 































BAFF; B-cell activating factor, FLT3 ligand; Fms-related tyrosine kinase 3 ligand.  
* commonly reported.  
Modified from Papageorgiou et al.,  (2015a) and Nishishinyaet al., (2015). 
 
 
Risk factors  
Clinical 
Recurrent or constant swelling of parotid glands * 
Glomerulonephritis 
Peripheral neuropathy 




Low complement factor C4 * 
Mixed monoclonal cryoglobulineamia* 
 




CD4 T cell lymphocytopenia 
 
Serum BAFF levels 
 
Serum FLT3 ligand levels 
 
Peripheral B cell subpopulation disturbance 
 
Histological 
High focus score ≥3 
 




IL-18/IL-12 expression, dendritic cells infiltration rate 
 
Genetic 
A20 genetic variation 
 






 Outcome and management 
MALT- lymphoma prognosis is closely related to its diagnosis, the histological type of lesion 
and the stage of it; better prognosis for low grade lymphomas in comparison to high grade. 
No standardised protocols for lymphoma screening and follow up of patients with SS have 
been described and no ideal therapeutic strategy is defined yet. Treatment for each patient 
should be tailored depending on the severity of the disease. Currently, SS treatment mainly 
relies on symptomatic relief; analngesics, tears and saliva substitutes, sialogogues such as 
pilocarpine and cevimeline. Immunosuppressant and systemic steroids are prescribed for 
patients with extra-glandular manifestations however, their efficacy is yet to be determined. 
Among the B cell targeted therapy; rituximab was the most studied, though its efficacy is not 
enough to allow prescribing it in a large population (Cornec et al., 2014). 
SS patients with known risk factors for lymphoma development (table 1-7) should be closely 
monitored. Patients with localised lymphoma can be managed by local radiotherapy or surgery 
and in the past the latter was preferred mostly. In addition, a more conservative watch and 
wait strategy for those localised lymphomas has been used by some centres since it has 
shown that treated and untreated patients have comparable favourable survival rates (87-
95%) (Pollard et al., 2011). Advanced stage lymphoma may be treated with combination 
chemotherapy. A number of new promising drug candidates were introduced for the treatment 
of SS and lymphoma and some biological treatments have proven ineffective to control the 
disease. Furthermore no treatment will prevent its recurrence thus periodic local and systemic 










Saliva is produced by salivary glands that exhibit similar functional anatomy across all gland 
types with myoepithelial cells covering the acinar cells and a ductal system allowing saliva to 
pass to the oral cavity. The secretory end pieces or acini are composed of either major mucous 
(mucin) or serous (non-mucin) secreting acinar cells or a mixture of the two (muco-serous)  
(Tandler, 1993, Proctor, 2016). 
 Saliva composition 
Saliva in humans is a dynamic fluid. It retains several important functions for maintaining oral 
health and homeostasis. The average composition of a sample of whole saliva is usually 99% 
water and less than 1% solids (macromolecules) (inorganic and organic components). The 
relative contribution of each gland is approximately 65%, 23%, 8%, 4% for submandibular, 
parotid, minor salivary glands and sublingual glands respectively in case of unstimulated 
saliva. While parotid glands contribute the most in case of stimulated saliva. Parotid glands 
are the source of serous saliva while the rest contains mix serous and mucous being the 
source of mucins. Also, it has non- glandular components from oropharyngeal mucosae. It 
may contain gingival crevicular fluid (GCF), food debris and blood derived compounds such 
as plasmatic proteins, erythrocytes and leukocytes (Chiappin et al., 2007). The inorganic 
components are ions (Na+, Cl-, K+, Mg2+, Ca 2+, HCO3-, HPO3-) present at different 
concentrations than in plasma. Furthermore secretions from different glands have different 
ionic levels (Chiappin et al., 2007).  The organic components include: - 
 a) Non- protein components  which include DNA, RNA and small amounts of uric acid, 
billirubin, amino acids, cholesterol, fatty acids and glucose (Chiappin et al., 2007).  
b) Proteins: such as amylase, cystatins, calgranulin, mucins and others, there are 2340 
proteins identified (salivary or systemic origin) (Aframian et al., 2013).  Protein secretion 
depends on the stimulation condition of the salivary gland with most proteins secreted by 
acinar cells. Among those for example are mucins (Muc5b and Muc7 gene products) secreted 
by the submandibular and sublingual glands as well as most minor glands but are not secreted 
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by the parotid and von Ebner’s glands (Carpenter, 2013). The concentration of salivary 
components is flow rate dependent noting that they may originate entirely from the salivary 
glands or may be derived from the blood by passive diffusion or active transport. In the case 
of salivary cytokines, concentrations were reported to be higher in whole mouth saliva than in 
major glands having GCF as a primary source (Ruhl et al., 2004). However, the main sources 
in glandular tissue would be infiltrating cells, epithelial cells, endothelial cells amongst others. 
 Salivary gland physiology 
Normal secretion of saliva requires an intact acinar and ductal anatomical structure with 
normal functioning acinar and ductal cells, intact neural stimulation to these cells as well as 
an intact vascular supply. Any factors interfering with these structures might lead to 
hyposalivation. Salivary secretion starts with an initial secretion of isotonic fluid by acinar cells 
which is then modified by the ductal system producing a hypotonic fluid which enters the oral 
cavity. Major salivary glands receive both parasympathetic and sympathetic nerve supplies, 
where the secretion is mainly controlled by the parasympathetic stimulation and to a lesser 
degree by sympathetic stimulation which differs in its intensity between the glands.  It was 
reported that the parotid glands are supplied with fewer sympathetic nerves than the 
submandibular glands, and the labial minor glands are thought to lack a sympathetic secretory 
innervation.   The salivary reflex is influenced by impulses from the higher centres of the central 
nervous system acting on the salivary centres in the medulla. The blood supply to the parotid 
gland is from branches of the external carotid artery (superficial temporal and maxillary 
arteries) and the venous drainage is via the retromandibular veins. Submental and sublingual 
arteries supply both submandibular and sublingual glands and the facial artery supplies the 
submandibular gland while the venous drainage is via anterior facial vein.  The location of 
minor salivary glands in the oral cavity region itself determines the blood supply and venous 
drainage, reviewed by  Proctor (2016). 
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 Salivary flow 
The average salivary flow varies between 0.5-1.5L per day at a rate of 0.4mL/min and 
approximately 50% is unstimulated flow, while the stimulated saliva contributes around 40% 
of the average daily production. The accepted normal range of unstimulated salivary flow is 
0.1- 0.5 mL/min. Stimulated flow rate is almost 2 mL/min (Sreebny and Vissink, 2010). 
Unstimulated parotid saliva range is 0.03-0.05 mL/min while the submandibular is 0.04-0.06 
mL/min. The stimulated glandular saliva usually is 3 times the unstimulated secretion that can 
reach up to 7 mL/min for parotid saliva and less than 0.2 mL/min is considered hyposalivation 
(Mandel, 1980). Nevertheless, general agreement about these cut-off values does not exist. 
Several factors can influence flow rate and composition (e.g. circadian rhythms, degree of 
hydration, body position and others) (Edgar et al., 2004) (Dawes, 1987). 
 Functions of saliva 
 
Figure 1-8 Main functions of saliva and its components 
(Amerongen and Veerman, 2002)  
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 Saliva as a diagnostic tool  
Saliva is gaining attention as an attractive alternative diagnostic tool, and is increasing in 
popularity. Collection of saliva is a non-invasive, safe, feasible, it doesn’t require special 
training unless it is collected from a specific gland, and is a relatively easy process (Aframian 
et al., 2013). When collecting saliva samples, one should consider the effect of variability of 
flow rate for example intra- variation measurement error on repetition of 25% (Vissink et al., 
2012). Also, have a standardised collection time and site, while unstimulated saliva collection 
is the preferable method but low volumes might be obtained especially with SS patients. A 
collection device is the best method for glandular specific saliva such as a parotid saliva 
sample. Sample storage conditions should also be optimised (on ice packs and frozen as soon 
as collected), samples should be handled consistently e.g. centrifugation and mucins effect 
on cytokines (Salimetrics)(discussed elsewhere).  
Saliva can contribute significantly to disease screening, intervention evaluation, recurrence 
prediction, risk assessment, and other prognostic outcome measures. Its potential use as a 
diagnostic fluid depends on the ability to detect and stability of a named substance. For 
example, cytokines and chemokines might be inhibited differently by different types of saliva 
(being higher in whole mouth saliva than a specific gland sample). Also, it seems that the 
detection of immunoglobulins are not affected by the inhibitory effect of saliva and that might 
be explained by their volume difference (150 vs. 8-25 kDa) (Wozniak et al., 2002).  
In the past decade, advances in mass spectrometric technologies led us to a new era in 
biomarker discovery. Salivary proteomics can enhance the sensitivity and specificity of 
disease detection, as the proteomics technologies continue to mature and expand allowing a 
possible identification of minute details; lower volume proteins such as cytokines. Detection of 
salivary biomarkers and the on-going progress of diagnostic technologies have addressed its 
diagnostic value for clinical uses. 
Compared to blood, saliva may express more sensitive and specific markers for certain local 
oral diseases. Also, many blood components are reflected in saliva, which indicates that saliva 
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may offer a promising diagnostic tool for systemic disease. These components, if successfully 
found and validated they may serve as biomarkers, thus a non- invasive tool for diagnosis will 
be developed (Zhang et al., 2013). However, with respect to salivary composition, there is a 
wide range of variation, low concentration of diagnostic components and the possibility of 
blood contamination. This makes it difficult to develop standardized analytical techniques and 
this has prevented salivary diagnostics from being clinically practical, making blood sampling 
preferable. Also, one must bear in mind when analysing whole mouth saliva that it is 
influenced by the proportion of parotid to submandibular secretions as well as the effect of 
the non-salivary elements. In studies quantitating antigens, immunoglobulins, or any proteins 
which are not produced by the salivary glands, extreme care must be taken in examining 
whole saliva to eliminate gingival fluid especially if a whole saliva sample is collected with a 
masticatory stimulus (Mandel, 1980). 
Saliva has been used mainly in dentistry as a tool for caries risk assessment (buffering 
capacity and bacterial count), periodontal disease assessment and for investigating systemic 
diseases which influence the oral cavity e.g. Behçet's disease and oral cancer. Some of the 
proposed diagnostic applications of saliva were; monitoring steroid hormone levels, detection 
of drug abuse and monitoring of some medications. It has been particularly useful for 
qualitative diagnosis (presence or absence of markers) such as viral infection detection (HIV, 
HCV and EBV diagnosis). Several studies have tried to find a link to oral, breast and pancreatic 
cancer using saliva; other studies have tried to use saliva for early detection of diabetes 
mellitus (Chiappin et al., 2007). In  the case of SS and dry mouth in general, saliva has been 
used a part of  routine diagnostic investigation, sialochemistry and proteomics have been done 
for SS. Cytokines linked with the inflammation in the gland could serve as saliva biomarkers 
in the diagnosis of SS and salivary gland lymphoma (Katsiougiannis and Wong, 2016). (This 




 When probing to identify disease-associated proteins, investigators tend to embrace a 
discovery approach (unravelling the whole proteome) and/or a targeted approach, whereby a 
selected number of proteins are further validated in a clinical setting. Each approach has its 
own merits and drawbacks. However, if proven beneficial, a saliva test could be a valuable 
supplement to established diagnostic methods. Due to the potential advantages of salivary 
analysis, more studies are needed. Consequently, we are likely to see it being used more 
often as a diagnostic tool and more people will be involved in the process of diagnosing a 
variety of disorders. What is becoming increasingly clear is that composition of saliva is much 






















 Thesis aims 
To enable a better understanding of disease activity and progression the following aims were 
undertaken:  
1. Investigate the potential use of the salivary gland assessment tests in discriminating 
SS and non- SS sicca patients as well as to differentiate between the different 
subgroups of SS.  
2. Determine the diagnostic accuracy of USS.  
3. Complete a longitudinal study on dry mouth patients at 5 and 10-year time-points.  
In chapter 3 records and assessment of the clinical parameters of salivary gland function was 
done.   Some are commonly used in diagnosing Sjögren’s syndrome patients such as whole 
and parotid flow rates while clinical oral dryness score is used as a supplementary test 
enabling clinicians to visualise the extent of hyposalivation. In addition, the ultrasound score 
has gained a considerable attention in the literature as an ideal non- invasive test thus 
determining its diagnostic accuracy was of great importance. The ability of the clinical 
parameters to stratify different subgroups of SS (SS at risk and SS with MALT-L) was looked 
at and their long-term outcome was considered. This is of particular relevance as salivary 
gland dysfunction is one of the main clinical features of SS, with its subsequent complications 
and its well-known effect on the person’s quality of life thus monitoring an actual oral dryness 
is of significant importance. Furthermore, it was intriguing to compare between different 
subgroups of SS to identify whether these parameters can detect the differences between 
them with a special interest in ultrasound scores. 
4. Identify salivary markers of disease activity and progression in SS; MALT-L risk and 
MALT-L subgroups. 
In chapter 4 the proteomic profile of representative parotid saliva samples was determined 
and this was followed by a candidate marker selection and verification via ELISA where even 
matched whole mouth saliva was compared as well. The different subgroups will be included 
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together with SNOX and age, sex- matched healthy controls thus providing a new insight into 
the potential use of the candidate protein as a biomarker. 
In chapter 5 cytokines were studied due to their significant role in several aspects of SS 
pathogenesis; their relevance in literature was recognized and gradual screening of cytokines 
was performed with a purpose of identification of their salivary levels via semi-quantitative 
tests. Then a more sensitive test (performance assay) was followed to further confirm their 
presence and their salivary levels. The same patients’ groups (from chapter 4) were included 
to assess their ability in differentiating between these groups and their levels in whole mouth 
saliva were determined as well and compared. Finally, whether a relationship exists between 
selected salivary components (chapter 4 and 5 and the clinical parameters of salivary gland 
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2 Materials and methods 
 Clinical 
 Ethical approval  
The protocol for this study was reviewed and approved by the National Research Ethics 
Service (NRES) Committee London-Brent since October 2011, reference number: 
11/LO/1121.  All the participants signed an informed written consent form. 
 Study group  
Patients with symptomatic dry mouth, attending clinics at Guy’s and St. Thomas’s Hospital 
Oral Medicine department (GSTT NHS Foundation Trust), were placed in the following 
diagnostic groups:  
• SS with or without another autoimmune disease (AID). 
• Sialadenitis, nodal osteoarthritis & xerostomia (SNOX). 
• Drug induced hyposalivation (DIH). 
• Not otherwise specified (NS) for patients who did not fit any of the above groups. 
SS classification was based on the most widely accepted criteria that was proposed by the 
American-European Consensus Group in 2002 (Vitali et al., 2002). Early SS was not 
commonly included while patients with confirmed or suspected lymphoma attending Oral 
Medicine clinics and lymphoma clinics (Department of clinical oncology) were sub grouped 
accordingly to: 
• SS at risk of developing MALT lymphoma; further categorised into high and low 
risk patients. 
• SS /confirmed MALT lymphoma with no treatment 
• SS /confirmed MALT lymphoma post-treatment 
The diagnosis of lymphoma was histologically proven in all cases either following excision of 
the parotids, via fine needle aspiration (FNA), parotid or labial gland biopsy. 
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Healthy age and sex-matched controls were recruited from Oral Medicine, Oral Surgery, 
Undergraduate Care Planning clinics and amongst staff. Their salivary samples were used for 
chapters 4 and 5. 
For chapter 3 all disease control sicca patients mentioned above were included while only 
SNOX was selected for further salivary analysis in order to verify its presence among dry 
mouth patients while comparing it to SS patients with a purpose of not adding variable groups 
in the disease control patients and focusing on the variability within the SS subgroups. 
Furthermore, considering the cost of including other samples it was decided to include only 
one group which was not previously been tested. 
 Exclusion criteria 
• Salivary gland disease secondary to Hepatitis, HIV infection or other disease (Vitali et 
al., 2002). 
• Infected gland with pus discharge which might interfere with analysis results. 
• Patients with a provisional diagnosis of SS, who did not have their biopsies done and/or 
their autoantibodies levels measured were excluded. 
It was made clear to all subjects that participation will be anonymised. Participants were given 









 Data collection  
Electronic patient records (EPR) and case files of patients were reviewed. Patient’s 
demographics, dates of initial and last visits as well as their diagnosis were recorded. Clinical 
parameters including: Clinical Oral Dryness Score (CODS), Ultrasound Scores (USS), 
Salivary Flow Rates (parotid and whole mouth), labial Salivary Gland Biopsy results (LSG), 
and autoantibody levels (ANAs, ENAs and Rheumatoid factor) were all recorded and the 
information was entered into organized data sheets. 
CODS also referred to as The Challacombe Scale enabling clinicians to visually identify and 
semi-quantify the amount of dryness with a score of 1-10 where 1-3 indicate mild dryness, 4-
6 moderate and 7-10 indicate severe dryness (Challacombe et al., 2015) (Appendix 1). 
To evaluate salivary gland changes on ultrasound imaging, Dr Jacqueline Brown Consultant 
Radiologist and calibrated team at Guy’s and St. Thomas’s Hospital, developed a simplified 
scoring system (Brown, 2010). It is based on a system proposed by Hočevar et al., (2005). 
The radiologists were calibrated and worked to an agreed pictorially-based and verbally 
descriptive scoring template. The score of 1 is the least involved while 9 is the severely 
involved. Patients with a score of >4 and bilateral glandular involvement were considered SS 
patients (Appendix 2).  
 Focal lymphocytic sialadenitis (FLS) is the characteristic pattern of inflammatory infiltrate 
seen in the glandular biopsies of SS patients and it is scored according to Chisholm and Mason 
Score.  Focus Score= Number of lymphocytic aggregates (≥50 cells) per 4 mm2 ≥1 (Chisholm 
and Mason, 1968). 
Data were recorded for the cross- sectional study where the 4 main parameters (whole and 
parotid flow rates), CODS and USS were compared between SS subgroups (SS, SS at risk of 
developing MALT-L and those with MALT-L) as well as the disease control group (DCT). 
Concurrently correlation between those parameters was done while correlating focus score 
and USS only. For the longitudinal study, 80 patients were followed over a period of 5 years 
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and the same 4 parameters were compared at baseline and 5-year time points. Sixteen 
patients were followed over 10 years and again their parameters were compared.  
Simultaneously, Clinical and laboratory predictors of lymphoma described earlier by Nocturne 
and Mariette,  (2015) were recorded when found.  For this study, patients were considered at 
risk of developing lymphoma if they had at least three of these factors with a tendency towards 
a higher risk with the presence of parotid gland swelling, purpura, low serum C4 complement, 
cryoglobulinemia, high focus score and germinal centre in their biopsy. In addition, higher 
ultrasound scores with the presence of the hypo-echoic foci were also considered as one of 
the predictive factors and their role in predicting lymphoma will be studied. 
Furthermore, data regarding patients with confirmed lymphoma was recorded as well and it 
included: type and site of the lymphoma and type of treatment received. 
To address the realistic issue of missing data potentially emerging from the retrospective 
nature of this study, frequent communication (whenever applicable) was made with the 
patients themselves, to gather more information and to invite them to participate and their 










 Saliva collection 
As a part of the routine clinical assessment only unstimulated whole mouth saliva (UWMS) 
and stimulated parotid saliva (SPS) were collected. The former was collected by asking 
subjects to passively drool into a 20 mL universal sterile plastic tube for 10 minutes. While 
SPS was collected into another universal tube for 10 minutes. The collection was done using 
a Lashley cup (Lashley, Dec 1916) (figure 2-1) and stimulation of secretion with a 2% Citric 
acid solution. The tubes were pre-weighed and then weighed again after collection in order to 
calculate the salivary flow rates (detailed clinical protocol is found in Appendix 4 & 5). 
Samples were immediately placed on ice and transferred to the lab where they were 
processed by centrifugation at 10.000 rpm for 10 minutes (whole saliva). Parotid saliva was 
left without centrifugation at first, but subsequent experiments (e.g. Luminex assays) identified 
the importance of centrifugation for at least 5 minutes. Samples were split into a number of 
aliquots and stored at -80 °C until required. None of the aliquots were used more than once 
per assay. (Start date for collection August 2013. End date March 2016).  
 
Figure 2-1 The Lashley cup for the collection of parotid saliva 
(A) The cup consists of inner and outer circular chambers (rings). (B) The inner ring is placed 
over the orifice of Stensen’s duct and connected to a plastic tube for the collection of saliva. 
(C) The outer ring is used for suction and is connected to a syringe which is used to create a 




























 Laboratory analyses 
 Total protein concentration 
The total protein concentration of samples (parotid and whole saliva) was determined using 
Bicinchoninic Acid assay (BCA assay) (Thermo Scientific, Rockford, Illinois, USA), according 
to manufacturer’s instructions. A standard curve of absorbance vs. protein concentration was 
generated using Bovine serum albumin which was serially diluted. Samples were diluted 1:10 
in ultra-high-quality water (UHQ.H2O) and both standards and samples were run in duplicate 
and absorbance at 450 nm was measured using a Dynex Revelation® 4.24 
spectrophotometer. The final total protein concentrations of the samples were determined 
considering the dilution factor and expressed as mg/mL. 
 Sample preparation and Gel Electrophoresis  
Samples were analysed for protein content using Sodium Dodecyl Sulphate Polyacrylamide 
gel electrophoresis (SDS-PAGE). Precast NuPAGE® Novex® 4-12% Bis-Tris Protein gels 
cassettes (Invitrogen) placed in XCell vertical electrophoresis unit (Invitrogen), were used to 
separate proteins under reducing conditions according to molecular weight. Samples were 
prepared as recommended by addition of NuPAGE® lithium dodecyle sulphate sample buffer 
(LDS, Invitrogen), 10% 0.5M dithiothreitol (DTT,x 10 stock) followed by heating at 100 oC for 
three minutes. A final sample volume of 20 µl was prepared. SDS- Running buffer was 
prepared y diluting it with 25 mL of NuPAGE® MES SDS running buffer and 475 mL UHQ.H2O.  
Ten µL of the prepared sample and 5 µL of SeeBlue® Plus Pre-stained marker (Invitrogen) 
were loaded into the wells.  Electrophoresis was performed at 125 mA and 200 volts constant 





 Coomassie Brilliant Blue, total protein stain 
Separated protein bands were visualised by incubating gels with ready-made Coomassie 
Brilliant Blue R 250 (sigma) diluted in acetic acid (10 mL of stain with 15 mL of acetic acid) for 
30 minutes, with gentle agitation followed by distaining of background with 10% (v/v) acetic 
acid in UHQ.H2O overnight. Gels were scanned on a transmission bed scanner (Amersham, 
Biosciences) where their digital records were taken. 
 Liquid chromatography tandem mass spectrometry (LC-MS/MS) and database 
searching  
Following SDS- PAGE of parotid saliva samples collected from age and sex match patients 
and controls, the sample lanes were divided into four sections prior to reduction, alkylation 
and digestion with trypsin (Roche Diagnostics GmbH, Mannheim, Germany) at 37 oC for two 
hours then overnight at room temperature. Digests (peptides) were extracted from the gel 
pieces and dried to completion by speed vac (Thermo Fisher Scientific). The lyophilised 
peptide mixture was resuspended in 50 mM ammonium bicarbonate (Sigma Chemicals) prior 
to loading onto a nano-LCII chromatography system (Thermo Fisher Scientific). Peptides were 
separated by reversed-phase chromatography, firstly by trapping column (C18-A1, 5mm, 2cm 
packing) then by analytical column (C18-A2, 3mm, 10cm packing; both Thermo Fisher 
Scientifc) at a flow rate of 300 nl/min using a three-step gradient (5-40% Acetonitrile 
(ACN)/0.1% formic acid (FA); 40%-95% ACN/0.1% FA; 95%-5% ACN/0.1% FA) for 120 
minutes. 
Peptides were ionised by electrospray ionisation using an Orbitrap Velos Pro mass 
spectrometer (Thermo Fisher Scientific) operating under Xcalibur v2.2. The instrument was 
programmed to acquire in automated data-dependent switching mode, selecting precursor 
ions based on their intensity, for sequencing by collision-induced dissociation using a Top 20 
method. The MS/MS analyses were conducted using collision energy profiles that were 
chosen based on the mass-to-charge (m/z) and the charge state of the peptide. Raw mass 




All LC-MS/MS data were searched using the MASCOT database search algorithm (Matrix 
Science, London, UK) against the human portion of the Uniprot protein database 
(uniprot_sprot_130220_database) to obtain peptide and protein identifications. MASCOT 
results were imported into Scaffold v2.2.06 (Proteome Software, Portland, OR, USA) and 
viewed. 
 Enzyme linked immunosorbent assay (ELISA) 
Commercially available pre-coated plates (Quantikine ELISA Kit, R&D Systems, Minneapolis, 
MN), (cat. no. DS8900) for S100A8/S100A9 Heterodimer (calprotectin) were used for both 
whole (n=56) and parotid saliva (n=83). The samples were thawed and diluted at an optimised 
dilution factor of (1/500) (serial dilution D1=1:50, D2=1:10) for whole saliva and (1/200) (serial 
dilution D1=1:10, D2=1:20) for parotid saliva. Standards and samples were loaded in 
duplicate. Incubations were done at room temperature on a horizontal orbital microplate 
shaker. All materials were supplied with the kit and the manufacturer’s instructions were 
followed. 
Generally, the samples and standards were added to the plate and any analyte present will 
bind to the antibody (capture antibody). The plate was then washed to remove unbound 
proteins. A second horse radish peroxidase (HRP)-labelled antibody (detection antibody) was 
added, incubated and washed to remove any unbound materials. This was followed by the 
addition of Tetramethylbenzidine (TMB) substrate solution and a blue colour changes in 
proportion to the amount of analyte present in the sample (figure 2-2). Colour development 
was stopped and measured at 540nm with a 450nm reference absorbance (Dynex 
Revelation® 4.24; see Appendix 6 for detailed protocols). 
The accuracy of the results was tested separately. To check for matrix interference the 
samples were spiked with a known concentration equivalent to the first standard (40ng/mL) 
(1:2). Three samples were spiked, 1 whole saliva sample and 2 parotid saliva samples (all 
positive with a concentration comparable to the highest standard). The samples were tested 
in duplicates in 4 dilutions (neat spiked sample, 1:2, 1:4, 1:8).   
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A four-point standard curve was generated with the same dilutions and compared to spiked 
samples. Optical density was measured at 540 nm and 450 nm as mentioned previously. 
Recovery and linearity were then calculated. 
Intra-assay precision was assessed using 3 samples of known concentration each tested 5 
times on one plate. Inter-assay precision was assessed using 2 samples tested in 6 separate 































 Proteome Profiler Array  
The Human XL Cytokine Array (R&D Systems, Minneapolis, MN), (cat. no. ARY022) is a 
membrane-based sandwich immunoassay that enables the relative detection of 102 cytokines 
and chemokines simultaneously.  The kit was used according to the manufacturer's protocol. 
All steps were carried out in a 4-well multi dish provided in the kit and the incubations were 
performed on a rocking platform shaker. In brief, all reagents and parotid saliva samples 
collected from subjects (four samples per kit) (n=12) were brought to room temperature. A 
suggested 100 μL of saliva (range 50-200 μL) was diluted with the array buffer (supplied with 
the kit) to a final volume of 1.5 mL. Then added to the membranes and incubated overnight at 
4°C. These nitrocellulose membranes (used as a substrate rather than a plate in a traditional 
ELISA) are spotted with capture and control antibodies in duplicate, each pair of these spots 
represents a different analyte. The membranes were washed to remove unbound material 
followed by incubation with a cocktail of biotinylated detection antibodies. Streptavidin-horse 
radish peroxidase (HRP) and chemiluminescent detection reagents were then added, and a 
signal was produced at each capture spot equivalent to the amount of cytokine bound (figure 
2-3). The chemiluminescence of the membrane was measured using the ChemiDoc (Bio-Rad, 
Hemel Hempstead, UK) then quantified by band densitometry using ImageJ software 
(downloaded from National Institute of Health, https://imagej.nih.gov/ij/). (Detailed steps are 
found in Appendix 7). 
 






 Luminex® xMAP Assays  
Bead- based multiplexed immunoassays (R&D Systems, Minneapolis, MN) allow the detection 
of multiple analytes in one assay and the main advantage of Luminex technology lies within 
its significant reductions in time and cost compared with ELISA, especially when many 
immunological markers needed to be measured and sample volumes are limited (Arellano-
Garcia et al., 2008). 
The principle of the assay is similar to ELISA: after the addition of samples and standards to 
the mixture of colour coded beads which are pre-coated with specific capture antibodies, the 
analyte of interest was bound to them. Biotinylated detection antibody cocktail was added and 
binds to the captured analytes, this is followed by the addition of Phycoerythrin (PE)-
conjugated streptavidin which binds to the detection antibody cocktail. The assay was run on 
a 96-well plate format, followed by reading on a Luminex ® 100/200TM instrument (Bio-
Plex®200). A magnet captures and holds the magnetic beads in a monolayer, while two 
spectrally separate light-emitting diodes (LEDs) lighten the beads. One LED recognizes the 
analyte that is being detected and, the second LED controls the amount of the PE-derived 
signal (figure 2-4). Images of the wells were taken with a CCD camera. Samples were 
assayed for analytes according to established protocols and incorporating standard curves, 
blank, controls (if present). The assays were completed in a minimum of 4 hours depending 
on the viscosity of the samples. Once readings were completed the results were exported to 
Excel spreadsheet. Account was taken of outlying sample results; present sample 
fluorescence –background (blank), standard deviation, coefficient of variance (%CV), recovery 
of analyte in sample, dilution, bead Count (minimum of 37) and sampling errors. Magnetic 
beads were selected and the screening assays were used at first in order to have more 
flexibility in creating the panel with a broader selection of analytes which can be up to 100 
analytes simultaneously. Performance assays were performed subsequently on selected 
analytes for maximum assay precision and developing more accurate results and it can be up 
to 22 analytes per panel.   
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 Magnetic Screening Luminex Assay 
Twenty cytokines were selected and their levels were measured in parotid saliva of 76 subjects 
(detailed description of the groups is provided in the relevant chapter). The cytokines assayed 
included: IFN-γ, TNF-α, IL-1α, -1β, -2, -3, -4, -5, -6, -8, -10, -12p70, -17A, -22, -23, -33, IP10, 
MCP-1, MCP-3 and ST2. 
The selection was based partially on the results obtained earlier from the proteome profiler 
analysis where substantial differences were observed between the groups. The remaining 
were cytokines in saliva (mainly whole) that were selected after conducting a thorough review 
of the literature which involved searching through the database for cytokines, SS and 
lymphoma (this will be addressed in chapter 5).   Commercial kits for luminex assays optimized 
for detection of cytokines in serum, plasma and cell culture supernates were used following 
the manufacturer’s instructions.  Sample preparation and optimization was tested at first on a 
trial kit with a single panel with just two analytes (IL-17A and -23) where the minimum required 
dilution was determined by analysing multiple representative samples from each group at 
different dilutions (neat, 1:2, 1:4 and 1:8). Neat samples yielded the highest readings within 
the assay range thus no dilution was required. Also, the effect of centrifugation was assessed 
where it was noticed that lower bead count or bead aggregation occurred as a result of the 
viscous nature of the uncentrifuged samples. This was eliminated in most of the samples after 
centrifugation for few minutes. The analytes were provided in two customised panels (kits). 
One included IL-3 and ST2 (R&D Systems, Minneapolis, MN) (cat. no. LXSAHM-3), while the 
rest were included in the other panel (R&D Systems, Minneapolis, MN) (cat. no. LXSAHM-
19). Standards and neat samples were added in duplicates and the steps were followed as 
described in the protocol (Appendix 8). Initially the standard curve was extended to <1pg/mL 
to further assess the sensitivity and the assay range. Points were excluded from the standard 
curve if the CV<25% and accuracy outside of 75-125% were not obtained, starting from the 
lowest standard. Samples still showing bead aggregation or bead count less than 37 were 
excluded (Staples et al., 2013). 
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 Magnetic Performance Luminex Assay 
Selected cytokines (IL-1α, -1β, -4, -6, -8 and MCP1) were measured in parotid saliva samples 
(n= 82) and whole saliva samples (n=57). The assays depend on panel-optimized diluents 
that provide maximum performance. 
 Again, a trial kit with a single panel (IL17, -23) was used in order to verify the minimum 
required volume of reagents to produce accurate results with ≥37 beads. Parotid samples that 
showed high levels of certain cytokines in the screening test were diluted (1:2), while whole 
mouth saliva were diluted (1:4) according to previous collaborative experiments by colleagues 
(S.Alsahaf thesis, KCL, 2015). A Single customised panel (cat. no. FCSTM03) was used to 
measure all of the six cytokines, using a similar protocol to the screening assay (Appendix 
8).  
 










 Data analysis 
The results were exported to Windows 7 Excel 2007 spreadsheet. The statistical analyses 
were carried out via IBM SPSS v21 and GraphPad Prism® 6 (GraphPad Software Inc., 
California, USA) was used for graphical presentation. All analyses were done on data obtained 
until April of 2016. All data were tested for normality (using Shapiro-Wilk test) to establish the 
type of analysis (parametric/nonparametric). For the cross-sectional data, Mann–Whitney U 
test and kruskal-Wallis test followed by Dunn’s post hoc test were used for non- parametric 
data while t- test and one-way ANOVA followed by Scheffe post hoc test were used for the 
normally distributed data. For the longitudinal study, the same tests were applied to determine 
the differences between the time points of the groups.  Statistical significance was defined as 
a p-value of less than 0.05. For diagnostic evaluation, receiver operating characteristic (ROC) 
analysis was applied. The predictive power of USS was tested using chi square test. 
Spearman's rank correlation coefficient was used to assess the associations. Regarding the 
data obtained from the proteomic analysis, assessment was done using a cut- off of a 
logarithmic transformed fold change ratio of ≥2. Data acquired from the proteome profiler 
arrays was tested using two methods which were the fold change cut-off of ≥2 and one- way 
ANOVA followed by Tukey HSD post hoc test. The data were plotted as fold change (log2 fold 
change ratio) and significance (-log10 p-value) in a volcano plot.  A kruskal-Wallis test followed 
by Dunn’s post hoc test were used to determine the differences between groups regarding all 
the Luminex results (screening and performance) and ELISA data. The sample size 
calculation for Luminex and ELISA assays was based on one-way Analysis of Variance 
(ANOVA) for comparing the average amount of a particular protein/cytokine present in the 
salivary sample between 5 different groups of participants. A study with 80% power and an 
effect size of 0.42 will require a total sample of 75 (15 per group) for comparing the protein 
levels at 5% level of significant using a two-tailed test. The power calculation was carried out 
using G-power version 3.1.5 software. Mean and SEM will be usually expressed in text and 
median and IQR will be expressed in figures unless otherwise stated. 
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3  Prognostic value of clinical parameters in Sjögren’s syndrome  
 Introduction  
Other than mucosa associated lymphoid tissue lymphoma (MALT-L) development, the course 
of Sjögren’s syndrome (SS) is generally assumed to be characterized by mild differences in 
disease symptoms with very slow deterioration. It is a heterogeneous multi-systemic disease 
diagnosed by certain criteria requiring multiple clinical and laboratory parameters (Vitali et al., 
2002, Shiboski et al., 2012). The prognostic value of these parameters has been reported 
worldwide where different studies have investigated the long-term outcome of some of them 
in SS patients such as ocular disease parameters, serological parameters and clinical 
parameters; in Denmark (Kriegbaum et al., 1989), the Netherlands  (Kruize et al., 1996) 
(Kruize et al., 1997), Japan (Cui et al., 1997), Poland (Chwalinska-Sadowska et al., 1998), 
Greece (Skopouli et al., 2000), Italy (Botsios et al., 2001), Finland (Pertovaara et al., 1999, 
Pertovaara et al., 2001), China (Lin et al., 2010), USA (Malladi et al., 2012) and in Hungary 
(Horvath et al., 2014). 
Other studies have assessed autoantibody patterns and followed SS patients with lung 
disease (Linstow et al., 1990, Kelly et al., 1991, Davidson et al., 1999, Davidson et al., 2000, 
Pertovaara et al., 2004, Mandl et al., 2012).  Also, the SS damage index was used to evaluate 
the long-term outcome in the form of growing damage in SS patients where they have reported 
2 fold increase in total score damage in 10 years in 55% of patients. Unfortunately, they did 
not report the oral domain as it was not reliably recorded (Krylova and Isenberg, 2010). Clinical 
complications were addressed by another longer outcome study, demonstrating higher 
malignancy rate and additional autoimmune and haematological disorders over a period of 25 
years  (Abrol et al., 2014) .  
Although the previously mentioned studies have focused more on other clinical and serological 
parameters, there are number of studies that have assessed the long-term course of salivary 
gland function (oral parameters) mainly in terms of salivary flow rates such as Jonsson et al., 
(1993) which was the first study to report the impact of progression of salivary gland 
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inflammation on salivary flow rate. Theander et al., (2005) have assessed the oral signs as 
part of the outcome measures and were the first to demonstrate a predictive value of 
laboratory tests for exocrine function in SS. Furthermore, salivary flow rate follow- up was 
reported by different studies (Gannot et al., 2000, Haga, 2002, Pijpe et al., 2007, Haldorsen 
et al., 2008). Very slow deterioration was mainly observed in studies with patients with a longer 
disease duration. 
Salivary gland dysfunction is one of the main clinical features of SS, manifested by xerostomia 
with its subsequent complications and its well-known effect on the person’s quality of life, 
though it should be noted that the complaint of xerostomia might not be correlated with actual 
hyposalivation. Thus, monitoring an actual oral dryness is of significant importance. Indeed, 
salivary gland assessments are routinely used as part of the objective diagnostic criteria (oral 
parameters) of SS specifically unstimulated whole flow rate (WFR) with a cut- off of 0.1 ml/min 
(Vitali et al., 2002). In addition, individual glandular flow rate tests may demonstrate 
consecutive involvement of a particular gland providing more information regarding the 
disease progression and variances of different stages of SS. Even though 
submandibular/sublingual flow rates might be useful in the early phases of SS reported by  
others such as Pijpe et al.,(2007), parotid flow rate (PFR) might be more informative in patients 
with longer disease duration where parotid glands are involved especially in SS patients at 
risk of or already having developed lymphoma (MALT-L). 
Additionally, evaluation of salivary gland changes can be done using ultrasonography, despite 
not being part of the diagnostic criteria, it has proven its value as a diagnostic instrument in 
SS in a lot of studies. A simplified ultrasound scoring system was developed (Brown, 2010). It 
is based on a system proposed by Hočevar et al., (2005) and it  was used in this study. In 
spite of being not informative in early phases of SS it might be beneficial in later stages for the 




One of the methods of assessing oral dryness is The Challacombe scale or Clinical Oral 
Dryness Score (CODS) which uses a simple numeric system enabling a clinician to semi-
quantify the severity of the xerostomia and to decide if the condition needs treatment or not.  
Also, it might provide a means of monitoring the progress of oral dryness over time 
(Challacombe et al., 2015).  
Loss of salivary gland function can be noticeable in early onset of SS and progression of this 
functional loss seems to be even of a lower extent after a longer period of disease duration. 
Mostly cross-sectional and only a few longitudinal studies on the prognosis of salivary gland 
function in SS have been performed. This study has assessed salivary gland parameters and 
clinical data in SS patients with a focus on whole and parotid flow rates, CODS and USS; 
cross- sectional associations between each other and USS with histopathology were 
undertaken for the following group: disease control (DCT) dry mouth group which involves; 
not otherwise specified (NS), sialadenitis, nodal osteoarthritis & xerostomia (SNOX) and drug 
induced hyposalivation (DIH). For SS groups, they were SS with or without other autoimmune 
disease, SS at risk of developing MALT-L and those who developed MALT-L. Moreover those 
4 oral parameters were followed in a cohort of patients over 5 and 10 years and their 
progression was noted. Description of the classical predictors of lymphoma in SS patients was 













 Aims and objectives 
Salivary gland assessments are commonly used in diagnosing Sjögren’s syndrome (SS) 
patients and it is of great significance to evaluate their ability to stratify different subgroups of 
SS and to consider their long-term outcome. Our hypothesis was that measurements of 
salivary gland involvement; whole mouth and parotid flow rates, clinical oral dryness and 
ultrasound scores can differentiate between SS subgroups and other dry mouth patients. The 
secondary hypothesis was that SS does show on-going salivary function loss over time. 
To enable better understanding of the disease activity and progress the following aims were 
pursued: 
1. Unravel whether the measurements of salivary gland involvement can help classify SS 
patients into the different subgroups (SS, SS at risk of developing MALT-L and SS with 
MALT-L) and whether they can differentiate them from other dry mouth patients (NS, 
SNOX and DIH). 
2. Establish whether there is an overall association between the above-mentioned 
parameters. 
3. Correlate the ultrasound scores with diagnostic focus scores as well as measuring their 
levels of agreement. 
4. Evaluate the diagnostic accuracy of the ultrasound scores. 
Also in this study, a cohort of patients was followed- up and the following specific aim was 
undertaken: 
5. Complete a longitudinal study on dry mouth patients at 5 and 10-year time-points to 





 Materials and methods 
 Study group  
Patients with symptomatic dry mouth attending Guy’s and St. Thomas’s Hospital Oral 
Medicine department (GSTT NHS Foundation Trust) were included. Patients who fulfilled the 
American-European Consensus Group (AECG) criteria (Vitali et al., 2002) were included as 
SS patients while others were considered as disease control subjects according to their 
relevant findings; drug induced hyposalivation (DIH), Sialadenitis, nodal osteoarthritis and 
xerostomia (SNOX) and Not otherwise specified (NS). Dry mouth patients were selected from 
the patients’ records where few patients were considered as newly diagnosed patients. Further 
subgrouping of SS patients involved presence of another autoimmune disease (e.g. 
rheumatoid arthritis, systemic lupus erythematosus, scleroderma and primary biliary cirrhosis). 
Patients with lymphoma (MALT-L) were also recorded whenever found. SS patients were 
considered at risk of developing MALT-L if they had at least three of any of the commonly 
reported risk factors (Nocturne and Mariette, 2015), the markers of severe SS (e.g., parotid 
enlargement, hypocomplementemia, palpable purpura, cryoglobulinemia, high focus score,  
germinal centre in their biopsy and previous lymphoma) are associated with a more 
pronounced risk of NHL, hence they were subgrouped as high risk patients while the low risk 
group were associated with other generalised inflammatory factors such as raised β2 
microglobulin levels, lymphopenia and hypergammaglobulinemia . In addition, higher 
ultrasound scores with the presence of the hypo-echoic foci were also considered as one of 








 Data collection  
Electronic patient records (EPR) of 366 patients during the years of 2005 to early 2016 were 
initially examined; medical notes of patients were used to follow subjects who attended for 
earlier durations. All patients had been or are currently being followed at clinics. Clinical 
parameters; whole and parotid flow rates, ultrasound and dry mouth scores (USS and CODS) 
were recorded for all the patients when present. Date from first visit and last visits were logged 
in order to subgroup the patients into their relevant categories; follow- up of 3 years or less 
was considered for the cross- sectional study while 10± 2 and 5± 1 year follow-up for the 
longitudinal study, also patients’ data at baseline was included in the cross- sectional analysis. 
Furthermore, patients who were due for a 5 or 10-year follow- up visit, who appeared to satisfy 
the MALT-L risk diagnosis or with confirmed MALT-L were invited to clinics for this study; 
altogether, 129 patients consented to a new clinical and laboratory investigation (samples 
were used for the subsequent chapters 4 and 5). These investigations included whole and 
parotid flow rates recordings while measurement performed by (AJ) and some of the clinical 
staff so as for CODS and USS was performed by specialist radiologist. Patients with full 
records at baseline and follow-up were considered for the longitudinal analysis while those 
with one complete set of data at one time were for cross- sectional analysis; those with 
incomplete data of the 4 parameters at a single time or still with a provisional diagnosis were 
excluded. Cross- sectional comparisons at baseline were done between the different groups 







 Data analyses  
For the cross- sectional analysis, comparison between 2 groups (disease controls vs. overall 
SS groups) was done via Mann–Whitney U tests then Kruskal-Wallis test followed by Dunn’s 
post- hoc tests to determine the differences between the multiple groups (SS subdivisions) for 
parameters that were not normally distributed (PFR, WFR and USS). CODS were normally 
distributed thus one- way ANOVA followed by Scheffe post hoc test were used for multiple 
comparisons and independent sample t- tests for comparing 2 groups (disease controls vs. al 
SS groups). Spearman's rank correlation coefficient (Spearman's rho) was used to determine 
the association of these 4 parameters. Discriminant validity was assessed via Receiver 
Operator Characteristic (ROC) curves to determine the ability of USS to differentiate between 
SS subgroups and non- SS group. Negative and positive predictive values as well as odds 
ratios were calculated from contingency tables. Cohen’s kappa coefficient was used to 
measure the level of agreement between biopsy focus scores and USS while Spearman's 
rank correlation coefficient (Spearman's rho) was used to assess their relationship. For the 
longitudinal study, the same tests were applied to determine the differences between the time 
points of each parameter of the groups. The median and quartiles were used as estimates of 
central tendency and dispersion of non -parametric data while means and standard error of 









 Results  
  Cross- sectional study (Study group) 
Out of 366 patients, 122 were excluded due to insufficient data. The remaining 244 patients 
were included in a cross- sectional analysis and of them 80 patients were followed over a 5- 
year period while only 16 could be followed over a 10- year period with complete records of 
all 4 parameters. The remaining patients (n=148) were either considered recently diagnosed 
patients, had ≤3 years follow up (n= 117) or were patients with only one complete set of 
records at a time point (baseline) bot not at follow-up (n=31). The 244 patients consisted of 
non- SS patients (n=70) (25 DIH, 20 NS, and 25 SNOX) and SS patients (n=174; 119 without 
and 55 with another autoimmune disease). Thirty of the SS patients were at risk of MALT-L 
and 26 had MALT-L. A summary of the different diagnostic groups for the cross- sectional 
study is shown in table 3-1. A schematic work flow of data collection is shown in figure 3-1.  
 
Figure 3-1 Study identification and selection flow chart.  
Records of 366 patients have 
been documented
122 excluded (incomplete data)
80 for 5 year follow-up
244 for the cross- sectional study 
Among them 30 patients were found to be at risk 
of MALT-L and 26 have already developed it 
16 for 10 year follow-up
148 recently diagnosed 
WFR; unstimulated whole flow rate, PFR; stimulated parotid flow rate, USS; ultrasound score, 










Table 3-1 Demographics and clinical characteristics of the SS patients and disease control subjects included in the cross-sectional 
analysis (n=244)    









SS               SS at risk     
 
SS/ MALT-L   
 
Overall SS  
Number (%) 
 
 25 (36)  25 (36)  20 (28)  118 (68)  30 (17)  26 (15)  174 (100) 
 
 
      
SS                
SS+ 
80 (68)                             
38 (32) 
 
22 (73)                          
8 (27) 
 
17 (65)                      
9 (35) 
 
119 (68)             
55 (32) 


















Gender, n (%) F                  
M 
23 (92)           
2 (8) 
 
21 (84)            
4 (16) 
 
18 (90)       
2 (10) 
 
109 (92)                             
9 (8) 
 
30 (100)                         
0 
 
26 (100)                   
0 
 
165 (95)             
9 (5)   
Anti SSA/SSB 








78 (67)                              
34 only SSA 
 
28 (93)                          
3 only SSA 
 
23 (88)                      









































0   
[non-specific]                       
6 ND 
0   




[normal]                        
4 ND 
105 (89)                   
12 [non-specific]        
1 [normal] 
29 (97)                                                
1 [non-specific] 
 




SNOX; sialadenitis, nodal osteoarthritis & xerostomia, DIH; drug induced hyposalivation, NS; not otherwise specified, SS; Sjogren’s syndrome, 
MALT-L; mucosa associated lymphoid tissue lymphoma, SS at risk; SS at risk of developing MALT-L, SS+; SS with other autoimmune disease, RF; 
Rheumatoid factor biopsy positive; positive for focal sialadenitis, [non- specific sialadenitis], ND; not done. 
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 SNOX as part of the disease control group 
Of the 70 disease control patients 7 were followed over 5 year while one only was followed 
over 10 years, 25 patients (36%) appear to fulfil the description of SNOX (17 in the recently 
diagnosed group and 7 in the 5- year follow up while 1 is in the 10- year); none were on 
xerostomic drugs and 19 (76%) of them had a diagnosis of non- specific sialadenitis according 
to their biopsy results while the other 6 patients have not had biopsies yet but they had the 
rest of the features of osteoarthritis, xerostomia, negative anti SSA/SSB. Three (12%) were 
positive for Rheumatoid factor. There was a female predominance (23 vs. 2) and they were of 
an older age group (62 vs. 51). Although they complained of xerostomia but their WFR (0.14 
±0.03 ml/min; mean ±SEM) were not below the accepted cut-off nor were their parotid flow 
rates (0.3± 0.08 ml/min). Their CODS were 4 ±0.5. Only 5 patients had an average USS of 3 
and 4 patients with an average of 4 while the remaining patients had scores of zero.  These 
patients are clearly distinguishable from SS patients and almost half of them were chosen for 
the laboratory analysis in the next chapters.  
 SS sub group 
Of the 118, 45 were followed over 5 years and 6 over 10 years. SS patients included in this 
study, 80 were diagnosed as having SS and 38 as having SS with other autoimmune disease. 
Sixty-seven % were ENA positive while 50% were ANA positive, 69 % RF positive and 89% 
biopsy positive having a focus score of one or more while 12 patients had evidence of non-
specific sialadenitis and one patient showed normal gland histology. Forty-three parotid saliva 
samples (and whole if present) were collected and half of them were used for the following 
chapters. Interestingly some parotid saliva samples (n=7) were mucus like secretions of 
patients who had longer SS duration (3 in the 10-year follow –up group, 3 in the 5- year group 





 MALT-L risk sub group 
From the cohort of 30 patients at risk of developing MALT-L, 13 were recently diagnosed (≤ 3 
years or new patients), 13 patients were in the 5-year follow- up category and 4 patients were 
in the 10- year category and all of them are still current patients. Demographics and clinical 
characteristics for each group are shown in tables 3-1, -2 and -3. Further subgrouping has 
revealed that patients that were classified as low risk of developing lymphoma (n=7) were 
mostly in the recently diagnosed group. 5/13 patients (38%) vs. 2/13 patients (15%) in the 5- 
year category and none in the 10 year. This group had at least three of the following; 
consistently raised β2 microglobulin levels, lymphopenia and hypergammaglobulinemia or 
raised ultrasound scores. Twenty-three patients were classified as high risk; 8/13 patients 
(62%) of the newly diagnosed group, 11/13 (85%) of the 5-year group and all 4 (100%) of the 
10-year group. Of the 23, 14 patients (61%) had raised β2 microglobulin levels, 15 (65%) had 
either consistent or recurrent parotid swelling.  Fifteen (65%) had hypergammaglobulinemia, 
15 (65%) with high focus score of 4 and above and germinal centres were present in 4 of 
them. Fourteen (61%) had lymphopenia, 12 (52%) had high ultra sound scores with hypo-
echoic foci (scores of 8 and 9) while another 10 (43%) patients had scores of 5-7 with the 
presence of the foci, 10 (43%) with hypocomplementemia, 5 (22%) with lymphadenopathy, 4 
(17%) with vasculitis, 2 (10%) with cryoglobulinemia, 2 (10%) with polyclonal expansion and 
1 (4%) with glomerulonephritis. One patient had a chest lymphoma and another 3 had gastric, 
Hodgkin’s and plasmacytic lymphoma respectively. One patient had a confirmation of MALT-
L during the period of follow-up. In addition, other types of cancer were noted in some of the 
patients (e.g., melanoma, thymoma, ovarian and breast cancer). Twenty-seven parotid saliva 
samples (and whole saliva if present) were collected while 3 were not collected and 18 
samples were used for the subsequent studies (chapters 4 and 5) while 9 samples were not 
used; mucus like secretions (plugs) which were difficult to analyse. Fourteen (52%) patients 
were either treated with steroids or hydroxychloroquine by time of sample collection.  
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 MALT-L sub group 
From the cohort of 26 patients that developed MALT-L, 6 were recently diagnosed (≤ 3 years 
or new patients), 15 patients were in the 5- year follow- up category and 5 patients were in the 
10-year category. Demographics and clinical characteristics for each group are found in tables 
3-1, 3-2 and 3-3. All patients are still currently seen at clinics while one patient died in the 
course of the disease due to interstitial lung disease. Six patients (23%) had bilateral parotid 
involvement. Ten (38%) were in left parotids and one of them had mediastinal MALT-L as well, 
while the right side was noted in 5 patients (19%) and one of them had gastric MALT-L as 
well. Left submandibular gland involvement was found in one patient (4%) and another 2 (8%) 
were confirmed via buccal and labial biopsy respectively. Interestingly one patient had nasal 
involvement while another was at risk group but confirmed upon biopsy of the parotid. Four of 
them (15%) had monoclonal expansion. 17 patients (65%) were SS patients only while the 
rest 9 (35%) were SS with other autoimmune disease. One patient had a recurrent lymphoma 
following partial paridectomy 4 years later.  
An attempt was made to collect 24 parotid saliva samples (and whole mouth saliva if present) 
Two patients did not produce any saliva (parotid or whole) while six samples were collected 
with sufficient volume but the volumes of the remaining samples were too low to calculate a 
flow rate (used only for subsequent chapters 4 and 5). Eight of these parotid saliva samples 
were mucus (plug) like secretions. Treatment was commenced following MALT-L diagnosis 
and it was surgical excision (partial or full) (mostly done in the past) for 13/26 patients (50%) 
followed by chemotherapy or radiotherapy in some cases. For the rest of the other 13 patients 
a watch and wait policy (observation) was adopted for 6 (23%) patients. Three patients (13%) 
had radiotherapy (4 Gy in two fractions) (low intensity radiation) while three had chemotherapy 






 Clinical parameters outcome  
 WFR  
The overall median (Q1-Q3) unstimulated whole flow rate for the SS group 0.04 (0- 0.16) was 
significantly reduced when compared to the disease control group 0.12 (0.1- 0.24) (p <0.0001). 
Subgrouping of SS has revealed reduction of flow rates of the MALT-L risk group 0.01 (0- 0.1) 
and MALT-L group 0.002 (0- 0.06) when compared to control group (p <0.0001 for both) as 
well as when they were compared to SS subgroup 0.08 (0- 0.24) (p=0.039 and 0.049 
respectively). No differences were detected between the SS subgroup and disease control 
group (figure 3-2). 
 PFR 
Median (Q1-Q3) stimulated parotid flow rate of the overall SS group 0.14 (0- 0.3) was 
statistically lower than the disease control group 0.28 (0.16- 0.44) (p <0.0001) while when it 
was subgrouped; at risk 0.01 (0- 0.25) and MALT- L 0 (0-0.13) groups were reduced when 
compared with disease control group (p=0.005 and <0.0001correspondingly) whereas only 
MALT-L group was reduced compared to the SS subgroup 0. 22(0- 0.33) (p=0.022). SS sub 
group was not reduced in comparison to the disease control group (figure 3-3). 
 USS 
Median (Q1-Q3) ultrasound score of the overall SS group 5 (4-7) was significantly higher than 
the disease control group 0 (0-0) (p <0.0001) while subgrouping SS has shown an increased 
means of all the SS subgroups; SS 5 (3-5), at risk 6.5 (5-8) and MALT-L 7.5 (6-9) when 
compared to disease control (p <0.0001 in all). In addition, both at risk and MALT-L were 









Median (Q1-Q3) dry mouth score of the overall SS group 5 (3-7) was higher than the disease 
control group 3 (1-5) (p< 0.0001) as were the subgroups; SS 5 (2-7) at risk 5 (3-7) and MALT-
L 7.5 (5-8) (p=0.013, 0.005 and <0.0001 respectively). Amongst the subgroups, MALT-L was 
higher than SS subgroup (p=0.006) (figure 3-5). 
All parameters (WFR, PFR, USS and CODS) showed no differences between SS with and 
without another autoimmune disease. In addition, no differences were detected between 
patients at high and low risk of developing MALT-L except for USS where patients at high risk 
had an increased median score (Q1-Q3) of 7 (6-9) compared to the low risk group 5 (3-6) 
(p=0.029) (figure 3-6). 
 Associations  
All the SS disease measures (clinical parameters) correlated well with each other in cross-
sectional analyses at baseline (n=244), notably whole flow rate with parotid flow rate and dry 
mouth score. Ultrasound scores showed a reasonable correlation with all the measures as 
shown in table 3-2. 
 









Spearman's rho     
 WFR PFR USS CODS 
WFR 1    
PFR .604** 1   
USS -.39** -.37** 1  
CODS -.59** -.503** .39** 1 
WFR; whole flow rate, PFR; parotid flow rate, USS; ultrasound score, CODS; clinical 










Figure 3-2 Whole mouth saliva flow rates of different groups (cross-sectional) (A) SS 
groups are combined (B) SS subgroups. n= (244) 
DCT; disease controls which are not otherwise specified (NS), sialadenitis, nodal 
osteoarthritis & xerostomia (SNOX) and drug induced hyposalivation (DIH), SS; Sjögren’s 
syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, SS at risk; SS at risk of 
MALT-L. Data are reported as median ± (IQR) and expressed as mL/min.  






























Figure 3-3 Parotid saliva flow rates of different groups (cross- sectional) (A) SS 
groups are combined (B) SS subgroups. n= (244) 
DCT; disease controls which are not otherwise specified (NS), sialadenitis, nodal 
osteoarthritis & xerostomia (SNOX) and drug induced hyposalivation (DIH), SS; Sjögren’s 
syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, SS at risk; SS at risk of 
MALT-L.  Data are reported as median ± (IQR) and expressed as mL/min.  































Figure 3-4 Ultrasound scores of different groups (cross- sectional) (A) SS groups are 
combined (B) SS subgroups. n= (244) 
DCT; disease controls which are not otherwise specified (NS), sialadenitis, nodal 
osteoarthritis & xerostomia (SNOX) and drug induced hyposalivation (DIH), SS; Sjögren’s 
syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, SS at risk; SS at risk of 
MALT-L.  Data are reported as median ± (IQR).  































Figure 3-5 Clinical oral dryness score (CODS) of different groups (cross-sectional) (A) 
SS groups are combined (B) SS subgroups. n= (244) 
DCT; disease controls which are not otherwise specified (NS), sialadenitis, nodal 
osteoarthritis & xerostomia (SNOX) and drug induced hyposalivation (DIH), SS; Sjögren’s 
syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, SS at risk; SS at risk of 
MALT-L. Data are reported as mean ± (SEM).  



























Figure 3-6 Ultrasound score of SS patients at low and high risk of developing mucosa 
associated lymphoid tissue lymphoma (MALT-L) 
Classified as igh risk patients (n=23) and low risk patients (n=7). Data are reported as 































 Diagnostic accuracy of USS 
 Receiver operator characteristic (ROC) curve  
From the optimal cut off points that were computed based on optimum separation via ROC 
curves, USS ≥4 was selected and it displayed 81.03% sensitivity (95% CI: 74.41- 86.57) and 
94.29% specificity (95% CI: 86.01- 98.42). Area under the curve (AUC) was 0.92 (95%CI; 0.89 
to 0.96) and p<0.0001 with a likelihood ratio of 7.543 (figure 3-7). Further points based on the 
maximum sum of sensitivity and specificity were selected and ROC curves were tested further 







Figure 3-7 ROC curve of ultrasound score in identifying patients with SS 









Table 3-3 ROC curve of ultrasound score in identifying patients with SS subgroups 
Optimal cut- off scores of ultrasound scores, DCT; disease controls, SS; Sjögren’s syndrome, 
SS/MALT-L; SS with mucosa associated lymphoid tissue lymphoma, SS at risk; at risk of 
MALT-L, AUC; area under the curve. 
 
 










AUC  P value 
 
DCT vs. SS 4 74.58 


















DCT vs. SS/MALT-L 5 84 









SS vs. SS at risk 6 70  









SS vs.  SS/MALT-L 6 84  













68         
(46.5- 85.05) 





 Positive and negative predictive values (PPV and NPV) 
The above selected cut- offs were used to generate a 2X2 contingency tables in order to 
estimate the  positive predictive value (PPV), negative predictive value (NPV) and odds ratio 
where chi square tests were used. An example of the comparison between the disease 
controls and overall SS groups is provided whilst the rest are summarised in table 3-4. 
X2 analysis of 244 patients 
Data analysed Overall Sjögren’s syndrome Disease controls Total 
USS + (> OR =4) (True positives) 141 (False positives) 4 145 
USS - (<4) (False negatives) 33    (True negatives) 66 99 
Total                             174                               70 244 
(Chi square=10.84; p<0.0001)                                       PPV=97.24% (95%CI; 93.12- 98.92)              
Odds ratio= 70.5% (95%CI; 24.16- 187.3)                   NPV=66.67% (95%CI; 56.91- 75.18) 
 
 
Table 3-4 Summary of chi square results on SS subgroups 
DCT; disease controls, SS; Sjögren’s syndrome, MALT-L; mucosa associated lymphoid tissue 
lymphoma, at risk; at risk of MALT-L, NPV; negative predictive value, PPV; positive predictive 
value, NS; not significant. 
















DCT vs. SS 4 95.6 


















DCT vs. SS/MALT-L 5 95.45 
(78.2- 99.77)  
 
94.52       
 (86.74- 97.85) 
 
362  <0.0001 
 
SS vs. SS at risk 6 40.38  








SS vs. SS/MALT-L 6 40.38  
(28.16- 53.93)  
 







At risk vs. SS/MALT-L 7 46.88       
(30.87-63.55) 





 Association with focus scores 
The pathology results of labial gland biopsies from a total of 62/174 SS patients were recorded; 
there were 43 patients in the SS subgroup with a mean score ± SEM of 3.7± 0.04, 11 MALT-
L risk patients with a mean score of 5.2± 0.6 and 8 MALT-L patients with a mean score of 6.6± 
0.6. The scores for 57/70 disease control patients were scored 0 as their pathology results 
were either normal gland or non- specific sialadenitis.  Biopsies were not done for the rest of 
controls while the remaining SS patients were done but not scored. A significant positive 
correlation was noted between the USS and focus score of the overall group (spearman r= 
0.7, n=119, p <0.0001) and a considerable correlation in the SS groups (spearman r=0.3, 
n=62, p <0.0001).  
 
 Measurement of agreement 
An ultrasound score of ≥4 was considered positive for SS patients and was used to sort them 
accordingly to positive and negative disease groups. The focus score of ≥ 1 per 4 mm2 was 
considered positive for SS and patients were sorted as well. Cohen's kappa (κ) was performed 
in order to determine if there was agreement between the two methods, there was a good 
agreement, κ = 0.748 ± (SEM) 0.061, p < .0001.  The overall agreement was calculated as 
87.3% and the USS results had a PPV of 88.1% and a NPV of 89.6% of the biopsy results; 
out of the 60 patients with negative biopsy results, 8 were positive for ultrasound while out of 









 Longitudinal study (Study group) 
Eighty patients were followed over 5 years (7 non- SS patients and 73 SS patients; 45 SS, 13 
SS at risk and 15 already developed MALT-L) while only 16 SS patients were followed for 10 
years (6 SS, 4 at risk and 5 with MALT-L) and only one of them was a SNOX patient. Detailed 
demographics and clinical characteristics are found in tables 3-6 and 3-7. 
 Five-year follow- up  
The mean follow-up period (mean± SEM) was 5.5 ± 1.6 years with a range from 4 to 7 years 
for the 80 patients. During the follow-up period, WFR levels were found to not change between 
all of the groups of patients (DCT vs. overall SS) (p=0.33) and (DCT vs. SS subgroups) 
(p=0.5), as well as for the PFR values (DCT vs. overall SS) (p=0.87) and (DCT vs. SS 
subgroups) (p=0.8). 
No statistically significant changes were seen between the mean values of dry mouth scores 
(CODS) at baseline and follow-up between all the tested groups (DCT vs. overall SS) (p=0.54) 
and (DCT vs. SS subgroups) (p=0.57). 
Mean values of USS did not change at baseline and follow- up period between all of the tested 
groups (DCT vs. overall SS) (0.78) and (DCT vs. SS subgroups) (p=0.5). We observed no 
differences between SS patients with and without other autoimmune disease, or between 










 Ten-year follow- up 
Sixteen patients were included with a mean follow-up period (mean± SEM) of 11.3 ± 2.4 years 
and a range from 8 to 13 years. Only one disease control patient (SNOX) was included. WFR 
of the overall SS remained at their already very low level starting with a very low reading and 
continued having zero reading at later timepoints afterwards. PFR of the overall SS remained 
the same during the follow- ups. While USS of the overall SS showed only a slight non-
significant deterioration during the second follow - up. CODS for the overall SS groups was 
increased insignificantly during the second follow-up and remained stable afterwards. None of 
the above-mentioned parameters showed a significant change (table 3-5).  
Table 3-5 SPSS analysis of the clinical parameters in the 10- year follow- up analysis  
WFR; whole flow rate, PFR; parotid flow rate, USS; ultrasound score, DMS=CODS; clinical oral dryness 
score. The first four groups (comparisons) were done when SS was combined while the second 4 groups 
were done when SS was subgrouped. 
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Table 3-6 Demographics and clinical characteristics of the SS patients and disease control subjects included in the 5-year 
longitudinal analysis (n=80) 
   Disease controls (n=7) SS patients (n=73)      
Diagnosis   SNOX  
Overall SS    
(n=73)  
SS              
(n=45)          
SS at risk    
(n=13)  




6 SNOX (86)                                               
1 DIH     (14)                                             
SS                            
SS+
44 (60)                               
29 (40) 
28 (62)                                        
17 (38) 
10 (77)                           
03(23) 
6 (60)                                 
9 (40) 
 
Age, mean (SEM)             58.3 (4.4) 51.4 (1.3)  50.7 (1.6)  51.2 (2.6) 52.9 (3.9)  
 
Gender, n (%) 
 
F                  
M 
23 (92)                                                                    
02 (8)  
68 (93)                                 
05 (7) 
40 (89)                                           
05 (11) 
13 (100)                                  
00 




               Median (Q1-Q3) Median (Q1-Q3)  Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) 
WFR at baseline   0.2 (0.09- 0.42)   0.03 (0- 0.11)  0.07 (0- 0.16)   0 (0- 0.1)  0 (0- 0.03)  
WFR at follow-up  0.1 (0.05- 0.15)   0 (0- 0.14)  0.05 (0- 0.16)  0 (0)  0 (0)  
             
PFR at baseline  0.4 (0.34- 0.5)   0.12 (0- 0.3)  0.2 (0- 0.5)  0 (0- 0.3)  0 (0- 0.1)  
PFR at follow-up 
 
0.4 (0.15- 0.6) 
   
0.1 (0- 0.3) 
  
0.2 (0- 0.5) 
  
0 (0- 0.2) 
  
0 (0- 0.13) 
  
  Mean (SEM)   Mean (SEM)  Mean (SEM)  Mean (SEM)  Mean (SEM)  
USS at baseline  0.7 (0.7) 
 
  5 (3.5)  4.6(0.3)  6.6 (0.5)  7.5(0.4)  
USS at follow-up 
 
 0.6 (0.6)    5 (1)  4.8 (0.2)  6.3 (0.4)  6.9(0.5) 
 
CODS at baseline  3 (1.2) 
 
  5.4 (0.3)  4.7 (0.4)  5.9 (0.7)  7.2(0.5)  
CODS at follow-up   2.6 (1.1)       6 (0.3)   5.5 (0.4)   6.7 (0.5)   7.4 (0.5)   
SNOX; sialadenitis, nodal osteoarthritis & xerostomia, DIH; drug induced hyposalivation, SS; Sjogren’s syndrome, +; with another autoimmune disease,       
MALT-L; mucosa associated lymphoid     tissue lymphoma. WFR; whole flow rate, PFR; parotid flow rate, USS ultrasound score, DMS; dry mouth score                                                                                  





Table 3-7 Demographics and clinical characteristics of the SS patients and one disease control patient included in the 10-year 
longitudinal analysis (n=16)




SNOX   
  
Overall SS    
(n=15)  
SS       
(n=6)           
SS at risk    
(n=4)  




1  SS                            12 (80)                         5(83)                                       4 (100)   3 (60)                                
    SS+ 3 (20) 
 
1(17)  0 
 
 2 (40) 
 




 At first visit  64 
  44.9 (3.4) 53 (3.2)  37.5 (6.7)   41.2 (6.4) 
 
 At last visit  88 
  60.1 (2.8) 66.5 (1.3)  53 (7.5)  
 
58.2 (5.2)  
                
 
 
  Median (IQR) 
 Median (Q1-Q3) Median (Q1-Q3)  Median (Q1-Q3)  Median (Q1-Q3) 
WFR at baseline   0 
 
 0.05 (0- 0.12)  0.2 (0.03- 0.4) 
 0 (0- 0.1)   0 (0-  0.1)  
WFR at follow-up 1  0   0 (0- 0.04)  0.03 (0- 0.06)  0 (0- 0.2)   0.05 (0- 0.06)  




           
PFR at baseline  0   0 (0- 0.3)  0.11 (0- 0.3)  0 (0- 0.11)   0.13 (0- 0.4)  
PFR at follow-up 1  0  
 
0 (0- 0.1)  0 (0- 0.2) 
 0 (0- 0.12)   0 (0)  
PFR at follow-up 2  0  0 (0- 0.14) 0 (0- 0.3)  0 (0- 0.4)   0 (0- 0.1)  
             
 USS at baseline  0 
 
 7 (5- 8)  4.5 (3- 5.25) 
 7 (6.25- 8.5)   8 (7- 8.5)  
USS at follow-up 1  0 
  
6 (5- 8) 
 
5 (3.25- 6.25)  7 (5.25- 9.5)   7 (5- 8.5)  
USS at follow-up 2  0 6 (5- 7) 5 (3.75- 6)  6.5 (6- 8.5)   7 (5.5- 8.5)  
            
 CODS at baseline  4 
 
 5 (2- 8)  5 (3.5- 6)  6 (2.5- 8)   7 (1- 8.5)  
CODS at follow-up 1  10 
 
 7 (5- 8)   7 (4.75- 8)  8 (5.75- 8.75)   5(4- 8.5)   
CODS at follow-up 2   5     6 (5- 8)   7 (3.75- 9.25)   7 (5.5- 7.75)     6 (4.5- 7.5)   
SNOX; sialadenitis, nodal osteoarthritis & xerostomia, SS; Sjogren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, 
+; with another autoimmune disease, WFR; whole flow rate, PFR; parotid flow rate, USS ultrasound score, CODS; clinical oral dryness 







  Discussion 
In addressing the aims of this study, we hoped to gain answers to a number of questions. Can 
a marker differentiate between the different subgroups of SS and show a difference to other 
disease control groups? Can ultrasound scores predict development of MALT-L? 
Furthermore, is there a clinical parameter (marker) that is able to monitor the progression of 
Sjögren’s syndrome over time and does SS show loss of glandular function over time? 
 Cross- sectional analysis 
Xeostomia is one of the main clinical manifestations seen in SS patients. However, this 
subjective complaint may not be necessarily reflecting an actual hyposalivation and loss of 
salivary gland function (Billings et al., 2016). The loss of glandular function can be measured 
via overall or specific glandular flow rates, (CODS) or implied from glandular structure (USS). 
Histology would be the most suited test demonstrating the actual loss of normal tissue that 
results in functional loss but other than the difficulty of obtaining repeated samples (ethically) 
we have mentioned previously that functional loss might not be a result of tissue loss and 
patients with normal glands might manifest signs of functional loss. Thus, it was decided to 
select applicable tests that can be repeated easily while correlating selected measures with 
histology.   
SNOX patients were enrolled in this study and the subsequent studies (chapters 4 and 5) as 
a non-SS sicca (disease) control group because the disease is often confused with SS and 
shares some symptoms; fatigue, dryness complains and signs; inflammation of the salivary 
glands (non-specific vs. focal in SS groups). SNOX was little tested by other studies since its 
first description by Kassimos et al., (1997) and the following Price and Venables, (2002), it 
was interesting to follow this disease group further. 
Regarding the MALT-L risk patients, a number of risk factors have been documented from 
large cohort studies (Papageorgiou et al., 2015a, Nishishinya et al., 2015). However, a clear 
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explanation as to why these factors should facilitate lymphoma development has not been 
clarified yet, besides they might be as a result of an advanced disease rather than a possible 
risk factors. For this study, in order to have more stringent selection with specified patients 
who are considered at risk, a group of at least 3 factors was chosen as a selection criterion, 
and patients were further sub grouped to high or low risk depending on the severity of the 
manifestations (factors). In chapter 1 subsection 1.6.4 the commonly reported factors were 
linked to high risk patients and those less reported (including the USS which is not commonly 
reported by others) were linked to low risk patients. Patients in this study demonstrated at 
least 4risk factors. 
The MALT-L patients group included in this study was confirmed via biopsies of either parotid 
gland in most of the patients or minor salivary glands in 2 patients, while one patient had 
submandibular lymphoma. They were included for further verification where comparisons 













 Clinical parameters 
The cross-sectional analysis part of this study has revealed a significant reduction of WFR in 
the overall SS group when compared to the disease control group. This is mostly attributed to 
the subgroups of MALT-L risk and MALT-L as they were the ones showing the greatest 
reduction when compared to the disease controls as well as to the SS subgroup (figure 3-2). 
Whole flow rate could not differentiate between SS subgroups and the other forms of dryness 
and this is supported by a number of studies (Billings et al., 2016, van den Berg et al., 2007, 
Osailan et al., 2012, Ohyama et al., 2015) although the last study demonstrated higher values 
but showed a similar trend . Normal healthy subjects were not included for this study due to a 
difficulty in finding healthy subjects data but a small group (n=20) were collected and included 
for the subsequent studies (chapters 4 and 5) and their flow rates were evaluated and 
compared to the rest of the present groups (disease controls and SS subgroups). Most studies 
have reported that reduced whole flow rates were frequently found in SS patients compared 
to healthy controls (Mandel and Baurmash, 1976, Skopouli et al., 1989, Sreebny and Zhu, 
1996, Carpenter et al., 2000, Kalk et al., 2002a, Vissink et al., 2003, Helenius et al., 2005, 
Billings et al., 2016). In fact, it is one of AECG criteria (Vitali et al., 2002). 
Similar findings were found regarding the PFR where the mean flow rate was reduced in 
comparison to the disease controls yet again it was mainly because of the MALT-L risk and 
MALT-L subgroups since no differences were found between the SS subgroup and the 
disease control and only the MALT-L group was reduced compared to the SS subgroup 
(figure 3-3). Again other similar findings were reported previously with similar values in 
disease control and SS subgroup (Kalk et al., 2001a, Kalk et al., 2002c, van den Berg et al., 
2007, Osailan et al., 2012). Once more the differences between SS and other groups involved 
comparisons with healthy controls more frequently. This supported our findings from the next 
chapter (chapter 4) where we have included healthy controls as well. In a way, it also 
supported the findings from this chapter since a lot of our patients were considered to be at 
later stages of SS (with the inclusion of all of the at risk and MALT-L groups) showing reduced 
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parotid flow rates. Also, this was supported by others where they have reported reduced SS 
flows (Stuchell et al., 1984 , Kalk et al., 2001a, Kalk et al., 2002c, Pedersen et al., 2005).  
Concerning CODS, the mean value of the overall SS group was greater than the disease 
control group and each of the subgroups was higher than the disease control while MALT-L 
was increased compared to the SS subgroup (figure 3-5). Similarly, Osailanet al., (2012) 
reported an increased CODS of SS patients when compared to SNOX and NOS while DIH 
was insignificantly lower than the SS scores (Challacombe et al., 2015).  
The USS mean values of the overall SS group and the SS subgroups were significantly 
increased when compared to the disease control group. Furthermore, both MALT-L risk and 
MALT-L were higher than SS subgroup. USS was the only parameter that showed a difference 














Cross- sectional association (table 3-2) has identified a strong negative correlation between 
both salivary flow rates (whole and parotid) and CODS most notable with the whole flow rate. 
A study has identified a similar finding supporting the present results. CODS was the highest 
in the group of patients demonstrating the lowest flows (irrespective of their diagnosis) 
(Osailan et al., 2011, Osailan et al., 2012, Challacombe et al., 2015). 
Both WFR and PFR showed a strong correlation (r=0.6, p<0.0001) in concordance to Kalk et 
al., (2002a) and Vissink et al., (2003) (r=0.75, p<0.001). Although studies reporting the 
involvement of parotid glands in later stages of SS suggest that there is no correlation between 
whole mouth and parotid flow rates and that the reduction of whole saliva is attributed to the 
significant decrease in the submandibular/sublingual flows (Vissink et al., 1993, Kalk et al., 
2001a, Kalk et al., 2002c, van den Berg et al., 2007, Pijpe et al., 2007) but patients involved 
in this study are considered at their later stages specially those who are at risk or developed 
lymphoma and this was evident when the correlation was done for the subgroups individually 
where it was (r=0.5, p<0.0001) for SS while it was (r=0.9, p<0.0001) for MALT-L. Regarding 
the USS, again a significant negative correlation was found with salivary flow rates and a 
positive correlation with the CODS so a more severe case (reflected by low flows and high 
CODS) will tend to have a high USS, although the association is considered moderate and it 
will be discussed further in the following section. 
It is well known that measurement of salivary flow (Jorkjend et al., 2004, Burlage et al., 2005) 
and presumably CODS may show variations in the same individual and between other 
individuals although this has not been verified in this study but it should be noted for further 
investigation. Such variation needs to be studied in USS as well; inter- and intra- individual 




 Diagnostic accuracy of USS 
The sensitivity of the USS ≥ 4 yielded 81.03% with a specificity of 94.3% and odds ratio of 
70.5% in this study (figure 3-7). Two systematic reviews reported comparable results, one 
reported a lower sensitivity yet comparable specificity values. Delli et al., (2015) stated a 
pooled sensitivity of 69% (95%CI: 0.67–0.71), specificity of 92% (95%CI: 0.91–0.93), and 
diagnostic odds ratio of 33.89 (95%CI: 20.75–55.35) in their recent meta- analysis. Also, in 
their systematic review, Jousse-Joulin et al., (2016) have reported up to date studies 
evaluating the usefulness of ultrasound in which a number of them showed  good sensitivity 
and specificity in 4 out of 11 studies with a range of (45.8 to 91.6%) sensitivity and (73 to 
98.1%) specificity. Some studies has suggested adding USS to the objective measures of the 
AECG criteria as it showed an increased sensitivity up to 87% while retaining its specificity 
(Cornec et al., 2013). Others such as Bootsma et al, (2013) have recommended correlating it 
with flow rates of parotid and submandibular glands. Although the latter was not done in our 
study we can comment on the ultrasound score relation to the parotid flow rates. In our results 
both whole and parotid flow rate were correlated with USS (spearman r= -0.4, p value <0.0001) 
confirming its importance as a diagnostic test (table 3-2). The same paper also pointed out 
the potential of USS in identifying MALT-L, and this was done in our study where its ability to 
differentiate between different subgroups of SS as well as between other non- SS sicca 
patients was tested via roc curve analysis establishing the optimal cut off score that provided 
the maximum sum of sensitivity and specificity followed by calculating the negative and 
positive predictive values via contingency tables (table 3-4). The diagnostic odds ratio was 
calculated to measure the effectiveness of ultrasound as a diagnostic test enhancing its 
reliability which is also confirmed in our study via the significant correlation between the 
histology focus scores and ultrasound scores of the overall subjects (spearman r= 0.7, p value 
<0.0001) and a considerable association in the SS groups (spearman r=0.3, p value <0.0001) 
thus suggesting a uniform disease process  and supporting their other suggestion of using 
ultrasound as a first measure (Bootsma et al., 2013).  Therefore, theoretically a positive result 
of an ultrasound (score of 4 or more) complemented by other tests such as ocular, serology 
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and flows would replace the need for performing a biopsy unless otherwise indicated, for 
example; in case of MALT-L suspicion. 
The use of USS as a diagnostic test was confirmed by Astorri et al., (2016) reporting an 
agreement of 91% (κ=0.82) showing that USS had a positive predictive value of 85% and a 
negative predicative value of 96% of the histology results. In contrast to our results the level 
of agreement was lower showing 87.3% concordance between USS and focus score with a 
slightly higher (88.1%) positive predictive value but lower negative predictive value (89.6%) of 
the biopsy results. 
However, one must bear in mind that although focus score is considered a gold standard test, 
it does not mean that it has 100% sensitivity and specificity as it might misclassify some 
patients introducing false positive and false negatives. Thus, the predictive values in the 
present study were calculated based on a given confirmatory diagnosis and there was a lower 
negative predictive value (66%) while the positive predictive value was higher (97%) than the 
values calculated in relation to histology results. So, although the number of false negatives 
was high (thus the lower NPV) we should note that some patients possibly in earlier stages of 
SS with score of 3 or less were considered as negatives but on the other hand it limited the 
number of false positives making it therefore a simple test to exclude patients without SS.  
We report lower USS performance when differentiating between SS subgroups (table 3-3); 
sensitivity (range 70- 84%), specificity (range 74-98%), PPV (range 40-95%) and NPV (range 
68-95%) being lower especially in the later subgroups with higher cut- offs that provided the 
maximum sum of sensitivity and specificity in each comparison. The lowest positive predictive 
values of 40% in case of cut- off ≥6 to differentiate between SS and SS at risk or with MALT-
L are due to the presence of a high number of false positives which could for example be a 
patient with low risk showing no hypo-echoic foci shown by USS or in case of patient with 
MALT-L post- surgery who is scored accordingly with a lower USS but on the other hand the 
high NPV makes it difficult to include false negatives.   USS could not differentiate between 
the MALT-L risk and MALT-L. Despite having high specificity values in discriminating SS from 
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other forms of dryness (NOS, SNOX and DIH), which generally presumed that they do not 
have that much of an effect on the structure of the glandular parenchyma.   In this study 70 
DCT patients were given an USS value and only 9 gave a score greater than zero while the 
rest were zero scored; only 4 of the 9 patients had scores of 4 or 5 making them false positives 
while the rest of the 9 patients had an average score of 3 as opposed to the advanced 
glandular involvement in SS.   It should be considered that other conditions  might cause a 
similar ultrasound picture and this needs further attention. Furthermore, it should be noted that 
the above- mentioned studies have reported different USS scoring systems, thus Jousse-
Joulin et al., (2016) have highlighted the importance of developing a consensual scoring 
system with consistent procedures and appropriate training in achieving reproducible results. 
Moreover, similar to other researchers they have suggested that USS can be an early 
diagnostic test in SS diagnosis as it usually involves all of the glands opposing to sialogram 
that only gives information regarding a single gland. Although we have successfully attempted 
to correlate histology with ultrasound, one must not forget that the former deals with minor 
glands while the latter is related to major glands and it would be more appropriate to correlate 
it with major gland histology or vice versa (ultrasound of minor glands correlation with the 
focus scores) and that warrants further investigation.  
Additionally, although it is not our main focus in this study but it is worth stating that the mean 
focus scores of the SS subgroups differed significantly from the control group being mostly 0 
in the latter while the SS subgroups were showing a gradual increase in their focus score 
being 3.7, 5 and 6 in SS, at risk and MALT-L respectively. 
The correlation between USS and flow rates indicates the association between the severity of 
sialadenitis seen as increased USS and functional incapacity of salivary glands, although it 




From the cross-sectional study the following conclusions can be drawn; regarding whole and 
parotid flow rates, the overall SS group showed a significant difference when compared to the 
non- SS sicca disease controls. It could be due to the significant difference observed in both 
MALT-L risk and MALT-L groups since SS subgroup did not differ from the disease control 
group. As for the CODS score and the ultrasound scores differences can be seen between 
the overall SS as well as the SS subgroup when compared to DCT. The two advanced groups 
(at risk and MALT-L) showed a significant difference when compared to SS subgroup as well, 
indicating the necessity of identifying and monitoring them. 
USS would be the ideal non-invasive test to differentiate and monitor SS patients in general 
as proven in this study (81% sensitivity and 94% specificity) and supported by previous studies 
replacing sialography/ scintigraphy and showing a good correlation as well as agreement with 
focus scores, thus providing more evidence on its reliability. An optimum cut- off ultrasound 
score of 4 could differentiate SS from non- SS patients while higher scores are used for the 
later subgroups with a reduction in both sensitivity and specificity. However, this can be used 
















  Follow- up studies 
The longitudinal follow-up part of this study (either 5 or 10 year) has shown that SS patients 
did not change significantly regarding WFR, PFR, USS and CODS indicating a stable and 
rather a mild course of SS disease where the duration has not influenced the salivary gland 
function (tables 3-5 and 3-7). There are many possible factors that might affect the exocrine 
function as mentioned before in chapter 1 subsection 1.4.1 but in this present study we have 
not focused on them since our primary outcome was investigating the effect of time on salivary 
function. 
 Five-year follow- up 
Few studies have investigated the long-term course of SS and similar findings were reported 
by some of them as well; 39 SS patients were followed prospectively by Jonsson et al.,  (1993) 
over a period of 3.25 years (39 months) where histology focus scores and WFR (stimulated) 
were re-evaluated. They have reported no statistically significant changes in the salivary flow 
values while their focus scores were increased. 
Theander et al., (2005) reported non- significant deterioration of WFR in their cohort of SS 
patients (n=58) over 5 years (prospective follow- up), stating that 40% of their patients were 
either 0 or 0.1 mL/ 15 min at baseline thus having this low volume will not become any further 
reduced. This supported our results; 40% had 0 WFR and 32% had reduced WFR 
(<0.1mL/min) and this was due to the inclusion of SS at risk and MALT-L groups. Furthermore, 
in the present study, patients with 0 WFR remained the same while those with reduced WFR 
became 0 and only some of them (n=6) were improved showing WFR >0.1 mL/min. The rest 
of the patients who had normal flow rates at baseline remained stable except for reduction in 
3 patients. According to Theander et al., (2005) 7% of the patients had improved while 33% 
had worsened. Despite those similarities, our means were lower than their reported means 
(0.8 mL/min at baseline and became 0.7 mL/ min) reported by them while ours was 0.1 mL/min 
and became 0.07 mL/min, this is due to the fact that in our cohort, patients at risk or with 
MALT-L were included as well. They have used a visual analogue scale (VAS) for oral dryness 
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and reported deterioration in some of the patients and improvement in others (Theander et al., 
2005). Whereas CODS in our cohort showed a non- significant reduction where 22% of 
patients with low CODS became worse while the rest did not (few were improved and some 
were stable).  Most of the patients with high CODS remained stable as well.  
Pijpe et al., (2007) followed 60 SS patients prospectively recording patients’ whole and 
glandular saliva flow rates at baseline and follow- up along with sialochemistry analysis. 
Similarly, unstimulated WFR (as well as unstimulated glandular flow rates) remained at their 
rather low readings while glandular saliva (stimulated PFR) was correlated with disease 
duration; decreased flows at follow- up, thus indicating that there is a loss of stimulated 
glandular function over time which contrasted our findings. Pijpe et al., (2007) found that this 
reduction is even more prominent in submandibular/sublingual flow rates especially in the 
early phases of SS.  Furthermore, they reported no difference between SS patients with or 
without another autoimmune disease, nor between the VAS of oral dryness at baseline and 
follow- up which are similar findings to ours. Another follow- up study was done on SS patients 
(n=43) and reported similar findings (change in flows at later visit) (Bouma et al., 2003). A 
possible explanation for the controversy regarding the PFR is the inclusion of SS patients with 
an early onset disease in their study vs. late stages in ours. 
Yet again, (Haldorsen et al., 2008) reported similar findings supporting our results; a median 
5- year retrospective follow- up of 141 patients has revealed a non- significant change in the 
median WFR stating a reduction in 29.8% of patients and increase in 31.9%. 
In our study, out of the 73 patients 29 had an initial PFR of 0 which didn’t change in most of 
them (5 only were improved), 6 patients had flows of ≤ 0.2 mL/min, 4 became worse, one did 
not change and one was improved. While in patients with ≥ 0.2 mL/min, 15 showed worsening 
of their flows and only 3 were improved while the rest did not change. 
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 Ten- year follow- up 
Regarding the 10-year follow- up, similar findings were found; these preliminary results 
indicate no change in salivary function over time and they are in accordance with the results 
of a Japanese study which investigated signs and symptoms of 43 SS patients reporting no 
progression of sicca symptoms over 10-20 years period (Cui et al., 1997). 
Relative stability of SS patient’s signs and symptoms as well as for their serological markers 
was stated over a 5 to 10-year period - up, reporting the development of extra- glandular 
manifestations in some of their patients (Gannot et al., 2000). The stimulated PFR of most of 
the patients remained the same with some elevation. Although the results might be misleading 
as some of the patients did not show salivary function on their initial visit and thus it cannot 
become any worse. However, other patients’ flow rates did not change overtime as seen in 
the previous studies as well as in ours indicating that a compromised salivary function can be 
relatively stable over years. 
Haga et al., (2002) have studied the association between low WFR  and different clinical and 
immunological markers including SS duration (mean 13.5 years) reporting no significant 
correlation between them. This was explained by the inclusion of a relatively high number of 
patients with long disease duration. However it was noted  that the WFR of almost half of his 








  Other considerations in follow-up studies 
Finding records of a 5- year follow- up of SNOX patients was challenging while 10-year follow- 
up was impossible (one patient) since they were normally discharged following confirmation 
of their diagnosis or followed for few years. When they were re-invited, we had to consider 
their age which hindered them from coming, thus it was difficult to confirm the stability of this 
disease over the 10-year period. However, no change was noted over 5 years among all the 
measured parameters confirming the stability and low progressing nature of it. The one patient 
included in the 10-year study showed no salivary flows despite showing normal glands on the 
ultrasound and her CODS was considered moderate at her first and last and severe in 
between visits. 
Other points worth mentioning are: 
1. Some patients were recorded since their date of experiencing dryness symptoms not 
per their diagnosis which was confirmed a few years later following their initial visit 
while some were referred following their diagnosis from other hospitals. 
2. Regarding SS patients with MALT-L the data suggests that a larger group of patients 
were in the 5- year category.  However, many of the others who were recently 
diagnosed (or seen), would have already attended different clinics (rheumatology 
clinics for example) and been diagnosed by others earlier and then referred to Oral 
Medicine clinics later.  
3. The medical records of number of patients were up to 20 years old but USS were only 
introduced in 2007 which limited our search up to only 10 years and only 16 patients 
with full records were included. In addition, digital ultrasound images were not found 
in order to score them retrospectively (only few were done when found). 
4. Despite the high variability of the groups it can be concluded that there is no significant 
decline in exocrine gland function over time regarding WFR, PFR, USS and CODS 
while individual patients may display flare ups and remissions as in any other 
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rheumatic diseases. The small number of patients involved in the 10-year follow- up 
study precludes definitive conclusions but it was in accordance with other studies. 
5. The subjective complaint of xerostomia is not always associated with an actual 
decreased flow as demonstrated in this chapter especially in the disease control group 
and SS subgroup where the median whole flow rate was 0.1 mL/min and almost 0.1 
mL/min respectively while median parotid flow rate was 0.3 mL/min and 0.2 mL/min in 
the cross- sectional part of this study. Xerostomia might be associated with 
compositional changes of saliva (Carpenter et al., 2000, Kalk et al., 2001a, Kalk et al., 
2002c, Helenius et al., 2005, Pedersen et al., 2005, Billings et al., 2016). Thus, the 
next 2 chapters we will be focusing on the compositional changes of saliva stating their 
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4 Salivary proteomic biomarkers in Sjögren’s syndrome 
 Introduction 
The identification of the protein profile of body fluids, such as saliva, is considered one of the 
promising strategies for the discovery of new biomarkers. There is a well-recognized need for 
the identification and validation of biomarkers to possibly be used in diagnosis, prognostic 
assessments, as a research tool and probably to identify novel targets for therapeutic 
intervention. Saliva can be non-invasively collected, thus providing an attractive alternative 
approach that harbours a wide range of components. Changes in these components are 
assumed to reflect the pathogenesis of Sjögren’s syndrome (SS), because salivary glands are 
the major site of autoimmune destruction, saliva may represent the most appropriate body 
fluid for biomarkers identification.  
In addition, there is a 1000-fold increased risk of lymphoma development in parotid glands 
from SS patients compared to other NHL subtypes (Ekstrom Smedby et al., 2008). This makes 
parotid saliva a valuable substrate that might be able to differentiate between the different 
subgroups of SS patients (SS, SS at risk of developing lymphoma and those with lymphoma). 
Several proteomic studies have shown differential protein expression in the saliva of SS 
patients and healthy control subjects (Fleissig et al., 2009, Ryu et al., 2006, Hu et al., 2007b, 
Ambatipudi et al., 2012, Deutsch et al., 2015, Giusti et al., 2007, Baldini et al., 2011b). Some 
studies have validated their candidate markers (Hu et al., 2010). While few have performed 
proteomic analysis of samples from lymphoma patients (Baldini et al., 2011a, Hu et al., 2009). 
In this study, proteomic analysis of parotid saliva samples from healthy subjects, SS patients 
and SS patients at risk of developing lymphoma was done. This was followed by selecting a 
candidate marker and validating it via ELISA on a larger group of samples including disease 
control (SNOX) patients and SS patients who have developed lymphoma. The marker was 




 Aims and objectives 
It is of great importance to assess whether saliva proteomic biomarkers can be used for the 
stratification of patients with Sjögren’s syndrome (SS). 
In this study, it was hypothesized that SS related proteins exist in human saliva and could be 
used to discriminate SS patients from healthy control subjects. Furthermore, identified salivary 
biomarkers could be useful in identifying a subgroup of SS who may progress to lymphoma. 
To address this, the following aims were under taken: 
1. Analyse newly collected saliva samples from SS patients to determine salivary 
biomarkers of disease activity. 
2. Analyse newly collected saliva samples from SS patients who are at risk of developing 
lymphoma to determine salivary biomarkers associated with development of 
lymphoma. 
Selection of a candidate protein for initial biomarker verification is followed and evaluation of 
its predictive value for the detection of SS, SS at risk of developing MALT-L and MALT-L was 
commenced. 
The specific aims were as follows:  
3. Investigate the potential use of the candidate protein as a diagnostic biomarker in 
discriminating SS with different subgroups. 
a) Compare the levels of this protein in SS patients to levels in healthy and diseased 
control patients (SNOX). 
b) Establish whether there is an association between the candidate biomarker with the 




 Materials and methods 
 Study group 
Six, age- and sex- matched subjects (2 healthy controls, 2 SS and 2 SS at risk of developing 
MALT-L) were included in the proteomic analysis.  
For further analysis via ELISA, their samples were then added to a larger group of subjects 
with a total number of 83. Diagnosis breakdown for subjects was healthy controls, diseased 
controls (SNOX), SS groups combined and separated (SS, SS at risk of developing MALT-L 
and those with MALT-L).  
 Saliva sample collection 
Stimulated parotid saliva (n=83) and unstimulated whole mouth saliva samples (n=56) were 
collected and stored as outlined in chapter 2, subsection 2.1.4. A minimum of 1 hour fasting 
preceded all sample collections. Their flows and total protein concentration were measured 
as described in (Appendix 4 & 5) and chapter 2, subsection 2.2.1. 
Figure 4-1Schematic representation work flow of the protein identification for parotid 




 LC-MS/MS equipment 
Trypsin digestion 
Mascot, Uniprot database and 
Scaffold (version 2.2.06), Proteome 
Software 
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 Laboratory analyses 
 Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
 SDS-gel electrophoresis and total protein stain 
Two sets of parotid saliva samples (gels) (n=3 each) were sent for proteomic analysis 
separately in different occasions (different runs), they were prepared under reducing 
conditions and subjected to gel electrophoresis then stained as described earlier in chapter 2, 
subsections 2.2.2 and 2.2.3. 
 LC-MS/MS and database searching  
The two sets of gels (each with 3 bands representing the different groups) were excised to 
four sections and treated as described in chapter 2, subsection 2.2.4. The section with the 
high abundant protein amylase was taken and analysed at the end, to enhance the detection 
of the low abundant proteins (figure 4-1). All LC-MS/MS data were searched using the 
MASCOT database search algorithm as mentioned previously. The results were then 
analysed separately and introduced as the first proteomic analysis (run) and the second run.   
 ELISA 
Commercially available pre-coated plates (Quantikine ELISA Kit, R&D Systems, Minneapolis, 
MN), (cat. no. DS8900) for S100A8/S100A9 Heterodimer were used for both parotid saliva 
(n=83) and whole saliva (n=57). Detailed protocols are found in chapter 2, subsection 2.2.5 
and (Appendix 6). 
 Statistical analysis 
All results were exported to Windows® Excel 2007 spread sheet.  Proteomics data were 
compared using fold change ratios and fold change while the statistical analyses for ELISA 
data, were carried out via SPSS. GraphPad Prism® 6 (GraphPad Software Inc., California, 









Figure 4-2 Representative two SDS-PAGE gels of parotid saliva samples from healthy 
controls and Sjögren’s syndrome patients.  
1; healthy controls, 2; SS, 3; SS at risk of developing mucosa associated lymphoid tissue 





 Study group 
Table 4-1 Demographics of patients included in the salivary proteomic analysis 




   
Parotid saliva analysis First run Second run  
Age* 
 







1 SS  
1 SS at risk  
1 CT 
1 SS 
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1      2       3 
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 LC-MS/MS database searching  
A total of 1324 proteins were identified overall from the first run (at lowest stringency; when 
parameters (filters) were set to their minimum values), while 818 proteins were detected from 
the second run. These proteins were filtered with these parameters; minimum number of 3 
peptides, meeting or exceeding protein threshold values for 95% confidence level and 80% 
peptide threshold, resulting in 161 proteins and 144 proteins respectively for each run. The 
identified proteins were sorted into functional categories based on their annotations in the 
Uniprot database and Gene Ontology searching (figure 4-4). Both were further filtered by 
choosing the immune system process category, which resulted in 53 proteins in the first run 
and 45 in the second as marked on (figure 4-4). The relative expression levels (fold change 
ratio) of these proteins were compared between control samples and SS at risk of developing 
MALT-L samples at first then between control samples against SS samples. A secondary 
comparison of proteins was done after logarithmic transformation of the raw ratios (log2). A 
final comparison between both runs was performed following their individual analysis where 
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Figure 4-3 Schematic presentation of LC-MS/MS database searching of both runs  
Fold change ratio 
Then log2 ratio Common 
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Figure 4-4 Gene ontology (GO) functional categories of the proteins identified by the 
network analysis 
(A) The first run where the immune system process proteins were selected (n=53) 




















Starting with an arbitrary fold change ratio cut- off of ≥2, the proteins were further reduced to 
45 and 17 proteins in the 1st and 2nd run correspondingly. An example of the Scaffold list of 
identified proteins of the second run and their peptide count is shown in (figure 4-5). After 
comparing both runs, the preliminary list of common proteins of interest were selected (n=11) 
as shown on (figure 4-5). Appendix 9 & 10 demonstrate these proteins with their total ion 
currents (TIC) and their fold change ratio between sample groups calculated by TIC for the 
first and second runs. In addition, 6 of them showed up-regulation in SS samples when 
compared to controls in both runs. 
For the first run, some proteins were present only in the SS at risk of developing MALT 
lymphoma patient but neither in the healthy control nor the SS patients (e.g. Matrilysin). 
Proteins not identified in healthy control but present in both diseased patients were 14-3-3 
protein zeta/delta, Thioredoxin and Protein S100-A9. The remaining proteins had an increased 
fold change in both diseased patients compared to the healthy control. Among them, Annexin 
A1, Actin cytoplasmic 2, Ig γ-1 chain C region and S100-A8 showed the highest fold changes.  
Similarly, the same eleven proteins were expressed differently between the samples in the 
second run. Some proteins were not present in the control sample but present in both samples 
from the disease groups (e.g. 14-3-3 protein zeta/delta and Matrilysin. The rest again had high 
fold change values in samples from disease groups. 
The list of proteins was further narrowed; the ratios between SS at risk of MALT-L to healthy 
controls were transformed to log2 values to have more stringent selection with a cut- off set to 
2. Likewise, the differences between the control samples and SS samples were detected. The 
final selection was done based on having ≥2 fold increase in both diseased samples (SS and 
SS at risk of MALT-L) as well. Thus, four proteins; Actin cytoplasmic 2, Ig γ-1chain C region, 
S100-A8, and S100- A9 were finally selected (figure 4-6). One of which was not present in 
healthy sample of the first run.  A final comparison was done between both disease samples 




Figure 4-5 Scaffold list of identified proteins and their peptide count of the second run 
  SS at risk of lymphoma development was compared to healthy control using arbitrary fold change ratio cut- off of ≥2, the proteins were selected as determined 
by the blue line (n=17). Further to comparison with the first run, the common proteins were identified as marked on this graph; Yellow starred are the proteins 
not present in the control sample but present in both disease samples. Blue starred are the proteins increased fold change in the diseased samples compared 























Figure 4-6 Final proteins selected using additional fold change (log2) cut-off of 2 or more 
when compared to controls.  
(A) Three proteins in the first run, protein S100-A9 was not detected in the control sample. 
(B) Four proteins in the second run.  
SS; Sjögren’s syndrome, MALT-L risk; SS patients at risk of developing mucosa associated 





       SS; Sjögren’s syndrome, MALT-L risk; SS patients at risk of developing mucosa associated 
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Fold change ratio Fold change 
Log2 
Actin, cytoplasmic 2 2.4 1.3 1 0 
 
Ig γ-1 chain C region  
 
5 2.3 1.004 0.01 
 
Protein S100-A8  
 




2.1 1.1 12.1 3.6 
Table 4-2 Final proteins with their fold change ratio and fold change when SS patients at 
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Figure 4-7  Overall schematic presentation of LC-MS/MS database searching and analysis of 
both runs  
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 Preclinical validation by immunoassay (ELISA) 
 Study group 
A total of 83 subjects’ parotid saliva samples were included for this study, summary of patients’ 
demographics and clinical data is shown in table 4-3. As part of their routine clinical assessment, 
parotid and whole mouth saliva flow rates were collected and recorded. 
 Salivary flow rates and the total protein concentration  
Whole mouth saliva (WMS) was collected from 56/83 (68%), insufficient samples were mostly from the 
patients group; SS 11/19 (57%), SS at risk of developing cancer 8/18 (44%), SS who developed the 
cancer (SS/MALT-L) 7/14 (50%) and SNOX 12/14 (85%). Total protein concentrations were assayed 
for all, except for one WMS sample and one parotid saliva sample. 
 Whole flow rate (WFR) was significantly lower in SS patients (overall cohort) compared to controls 
(p<0.0001). While it was lower in SS patients at risk of lymphoma development and those who had 
already developed it (p=0.001and p=0.01, respectively) in comparison to controls (figure 4-8). 
Stimulated parotid flow rate (PFR) was significantly lower in SS/ MALT-L patients compared to healthy 
controls (p=0.024) even though the overall SS group did not differ significantly (figure 4-9). Total protein 
concentration for whole saliva was higher in the overall SS patients compared to the disease control 
group (p=0.016) and it was higher for only the patients who developed the lymphoma in comparison to 
the disease controls (p=0.026). On the other hand, the total parotid protein concentration did not differ 
significantly between the groups (figures 4-10 and 4-11). 
A negative correlation was found between whole mouth saliva flow rate and total protein concentration 
(Spearman r=-0.34, p=0.012) while the parotid flow rate and total protein concentration were not 
correlated. No association was found between whole mouth saliva and parotid flow rates nor between 
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n  Groups p value  
Age (years)    50.7±2.6 19   62.7±2.6 15   51.5 ±2.7 20   51.9± 3 18   53.7± 2.6 14   52.3±1.6 52       
sex    F 18     15     19     18     14     51    
      M  1      0      1      0       0      1       
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 (n=56)  
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CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; Sjogren’s syndrome, MALT-L; mucosa associated lymphoid 
tissue lymphoma, at risk of developing MALT-L, WFR; whole flow rate, PFR; parotid flow rate. Data are reported as Median and Q1; first quartile, 



























Figure 4-8 Whole mouth saliva flow rates of different groups (A) SS groups are combined 
(B) SS subgroups. (n=56)  
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjogren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, at risk; at risk 
of MALT-L.  Data are reported as median ± (IQR) and expressed as mL/min.  


















































Figure 4-9 Parotid saliva flow rates of different groups (A)SS groups are combined (B) 
SS subgroups. (n=83) 
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjogren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, at risk; at risk 
of MALT-L. Data are reported as median ± (IQR) and expressed as mL/min.  

















































Figure 4-10 Total whole protein concentration of different groups (A) SS groups are combined 
(B) SS subgroups. (n=55) 
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjogren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, at risk; at risk 
of MALT-L. Data are reported as median ± (IQR) and expressed as mg/mL.  























































Figure 4-11 Total parotid protein concentration of different groups (A) SS groups are 
combined (B) SS subgroups. (n=82) 
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjogren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, at risk; at risk 
of MALT-L. Data are reported as median ± (IQR) and expressed as mg/mL.  




























 Association of the flow rates and total protein concentration 
Table 4-4 Spearman correlation between flow rate and total protein concentration of 







 Salivary S100A8/A9 levels  
Table 4-5 Additional clinical characteristics of SS patients 
n*; overall number of group, SS; Sjogren’s syndrome, MALT-L; mucosa associated lymphoid 
tissue lymphoma, RA; Rheumatoid arthritis, SLE; systemic lupus erythematous, PBC; 




Spearman's rho     
 WFR PFR TWPC TPPC 
WFR 1    
PFR 0.1 1   
TWPC -.34* -0.06 1  




subgroups    
n/n* (%) 
SS    
n/n* (%) 
SS at risk of 
MALT-L 
n/n* (%) 







































WFR; whole flow rate, PFR; parotid flow rate, TWPC; total whole protein concentration,                     





 Parotid saliva 
The median concentration (Q1-Q3) of S100A8/A9 in parotid saliva from overall SS patients 
was 743.1 (91- 3526) ng/mL while the healthy and disease controls were 31.9 (0- 273.2) and 
208.9(0- 265.3) ng/mL respectively (figure 4-12 (A)).  Significant differences were found in 
S100A8/A9 levels of the overall SS patients group compared to healthy and diseased controls 
groups (p=0.001 and 0.031) correspondingly.  
When comparing the subgroups of SS patients; median concentration of S100A8/A9 in SS 
patients was 506 (84.6- 1031) whereas it was 666.8 (131.2- 5642) and 937.4 (90- 4566) for 
SS patients at risk and those who already developed the cancer respectively. Both later groups 
showed a significant difference when compared to the healthy control group; (p=0.014) for the 
patients who already developed the cancer and (p=0.019) for those who are at risk of 
developing it while insignificant increase was noted in SS subgroup (figure 4-12 (B)). Visible 
differences were noted during the ELISA (figure 4-13). 
 Whole mouth saliva  
Although higher median level was detected in the overall SS group 16628 (3165- 20184), it 
was not statistically different from the healthy and disease groups 8457(687.3- 17154) and 
3857 (2418- 8697) (figure 4-14 (A)). 
However, SS subgroups did show significant higher levels; median concentration of patients 
who already developed lymphoma 22545 (16032- 28096) was higher than the healthy control 
group (p=0.046), SNOX group (p=0.009) and even the SS group 5244 (1550- 17225) 
(p=0.049). SS patients who are at risk of developing lymphoma had high levels 18841 (4034- 
19872) but not statistically significant (figure 4-14 (B)).  
All of the variables were statistically analysed using Kruskal-Wallis One-Way Analysis Of 
Variance (ANOVA) followed by post-hoc Dunn’s test for multiple comparisons. An example of 




































Figure 4-12 Concentration of S100A8/A9 in parotid saliva from different groups (A) 
SS groups are combined (B) SS subgroups. (n=83). 
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjogren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, at risk; at 
risk of MALT-L, -/+ with or without, AID; autoimmune disease.  
Data are reported as median ± (IQR) and expressed as ng/mL.  
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Figure 4-13 TMB substrate colour development of parotid saliva assay 
(A) Before stop solution 
(B) After stop solution 
Obvious colour intensification is noticed towards the SS groups (lanes 7-12) specially the 













































Figure 4-14 Concentration of S100A8/A9 in whole saliva from different groups (A) SS 
groups are combined (B) SS subgroups. (n=56) 
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjogren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, at risk; at risk 
of MALT-L, -/+ with or without, AID; autoimmune disease.  
Data are reported as median ± (IQR) and expressed as ng/mL.  
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In both parotid and whole saliva, there was no statistically significant difference detected 
between patients with (red) or without (blue) another autoimmune disease (AID) (figures 4-
12 and 4-14 (A)) nor between treated/ untreated patients as well (refer to Appendix 13). No 
differences were detected between patients at high (orange) and low risk (green) of developing 
lymphoma (figures 4-12 and 4-14 (B)) (Mann–Whitney U test). 
Twenty- one samples (potential outliers) were repeated due to their questionable values; as 
zero (9 samples; 8 parotid samples and 1 whole sample) or high values (12 samples; 5 whole 
and 7 parotid samples), out of the 9 samples 5 remained zero while 4 gave a reading although 
not high, while all of the high readings gave similar values upon repetition. 
The mean concentration of S100A8/A9 was compared between the right and left parotid 
glands of the same patient (n=2). Patients at risk of developing the cancer were selected 
where one gland shown with swelling while the other did not. Higher levels were detected in 
the swollen side for both patients (table 4-6). The higher levels were re-assayed as mentioned 
earlier and they gave similar results, therefore their means were taken and compared.  
 







Concentration (ng/mL)   
 






Swollen parotid gland 
 
9093.3     1103 





 Sensitivity of S100A8/ A9 immunoassay  
The accuracy of the ELISA was tested for whole and parotid saliva by spiking samples with a 
known concentration of S100A8/A9. A four-point standard curve was generated with 4 
dilutions (neat, 1:2, 1:4, 1:8) and compared to them (refer to chapter 2, subsection 2.2.5). The 
spiking test was done to check whether any salivary components such as mucins were 
inhibiting or interfering with the analyte detection. The results showed that the technique 
remained sensitive with the presence of saliva as there was no difference between the 
samples and the standard curve (all three lines representing the various conditions overlap) 
(figure 4-15). The mean recovery (accuracy) of the three samples was 107.7% ranged 
between 80.5 and 142.9%. The linearity was reported by the manufacturer (spiked whole 





Figure 4-15 Observed concentration S100A8/A9 in spiked saliva samples (n=3) 
Whole and 2 parotid saliva samples spiked 1:2 with highest calibrator and serially diluted. 
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 Assay reproducibility  
The reproducibility (intra-assay precision) of the ELISA was determined as the mean 
coefficient of variation (CV) of 5 replicates of 3 samples (positive parotid saliva) in one assay 
table 4-7. While the inter-assay precision was 8.2 % using two samples tested on 6 separate 
plates, these were comparable to the values reported by the manufacturer (2.7- 4.5% for the 
intra assay CV and 3.2- 5.8% for the inter assay CV). 




















5 5 5 - 
Mean (ng/ml) 
 
3550.3 7268.9 2034.4 4284.5 
Standard deviation 
 
124.6 313.9 59.6 166.03 
CV (%) 
 
3.5 4.3 2.9 3.9 
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 Associations of S100A8/A9 levels 
 Whole and parotid saliva levels 
There was a positive correlation between the salivary levels of S100A8/A9 in parotid and 
whole saliva of the overall subjects group (n=56) (spearman r=0.268, 0=0.046) (figure 4-16). 
Correlation was found when SS subgroups were only included (n=26) (Spearman r=0.496, 
p=0.01). No association was found regarding the control group (n=18) (Spearman r=0.106, 
p=0.67). 
 
Figure 4-16 Spearman rank correlations of S100A8/A9 levels from parotid and whole 











 In relation to clinical parameters 
Correlation was examined between S100A8/A9 levels and 3 clinical parameters which are 
whole and parotid saliva flow rates and ultrasound scores. No correlation was noted between 
the parameters except for the parotid flow rate and calprotectin levels in parotid saliva as 
shown in table 4-8. 
Table 4-8 Correlation between S100A8/A9 levels and different clinical parameters  




























 Coefficient (r) 
P value  
 
Parotid    
PFR vs. S100A8/A9 levels 83 -0.256* 0.02 
USS vs. S100A8/A9 levels 51 0.23 0.09 
Whole    
WFR vs.  S100A8/A9 levels 56 -0.138 0.309 
USS vs.  S100A8/A9  levels 26 0.14 0.495 
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 Receiver operator characteristic (ROC) curve of S100A8/A9 levels 
ROC curves were constructed and showed that S100A8/A9 in parotid saliva was able to 
differentiate between control subjects and the overall SS patients with 82.35 % sensitivity 
(95%CI; 69.13- 91.6) and 56.25% specificity (95%CI; 37.66- 73.64) at a cut-off salivary 
concentration of ≥ 80.6 ng/ml (AUC=0.75 (95%CI; 0.65-0.85), p=0.0001). While in whole saliva 
the cut- off was ≥ 50766 ng/ml with 73.08% sensitivity (95%CI; 52.21- 88.43) and 50% 
specificity (95%CI; 31.3- 68.7) (AUC=0.73, (95%CI; 0.53- 0.82), p=0.02). 
When comparing SS subgroups vs. controls only whole saliva levels could differentiate 
between SS with MALT-L and controls with a cut- off of ≥15748 and 85.71 % sensitivity 
(95%CI; 42.13% to 99.64%) and 80% specificity (95%CI; 61.43- 92.29) (AUC=0.89, (95%CI; 
0.75- 1.026), p=0.002).   
Whereas whole mouth saliva levels cut- off of ≥15449 ng/ml was able to differentiate between 
SS patients and SS patients who developed MALT-L with a 85.71 % sensitivity (95%CI; 42.13- 












  Proteomic analysis 
This study examined whether differentially expressed parotid salivary proteins might serve as 
biomarkers of disease activity and be used for the stratification of patients with SS. The 
proteomics data generated by LC-MS/MS analysis suggested that a range of proteins 
including Actin cytoplasmic 2, Ig γ-1 chain C region, S100-A8, and S100- A9 have 
considerable potential as biomarkers and two of these proteins were selected for further 
validation via ELISA (figure 4-6) .  
Ideally three patients per group should have been selected and analysed by LC-MS/MS at the 
same time for a proper comparison utilizing sound statistical methods (p- values). This was 
not achieved due to number of factors. Most importantly was the limited number of samples 
at the beginning of the study since MALT-L and MALT-L risk patients were initially difficult to 
identify with certainty.  Secondly, since proteomics requires significant resources it was 
decided to use proteomic analysis as a guide to plan for a further validation experiment utilizing 
high throughput immunoassay to be done on a larger group of patients.  
Two sets of samples each with 3 samples; 1 healthy, 1 SS and 1 SS at risk of MALT-L were 
analysed on different occasions due to their availability by time of analysis and their results 
were therefore not combined due to potential technical variations between runs. 
Fold change ratio was calculated based on the total ion current in order to have unbiased 
values reflecting what has been actually measured using the mass spectrometer rather than 
using the peptide count.  
Comparing SS at risk of developing MALT-L to healthy control sample has identified 45 over 
expressed proteins in the first run and 17 proteins in the second run. 22 proteins were found 
up-regulated when SS sample was compared to healthy control in the first run while 15 were 
identified in the second run (figures 4-5 and 4-7). 
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Attention should be taken in interpreting the results that some proteins were only seen in one 
group (either SS or SS at risk of MALT-L) but not in healthy control group, this might be due 
under sampling of low abundance proteins by MS.  
There were no proteins with a fold change ratio of ≤0.5 of the first run when sample of SS 
patient at risk of MALT-L was compared to SS sample or to control sample but only 5 proteins 
had a decreased fold change when SS sample was compared to healthy control. On the other 
hand, the second run has revealed 11 down-regulated proteins when SS was compared to 
healthy and 17 were identified when patient at risk of MALT-L was compared to healthy control 
sample while 19 proteins had a decreased fold change ratio when samples from at risk patient 
was compared to SS sample.  
It is important to note that due to the small number of patient samples this comparison is 
relative and does have possible errors thus data can't be normalised. The list of proteins had 
to be subjected to a more stringent criterion using an additional comparison method through 
logging the protein ratios which further reduced the proteins from eleven to four (Actin 
cytoplasmic 2, Ig γ-1 chain C region, S100-A8, and S100- A9) (figure 4-6).  
This final selection has an increased fold change of at least 2 in both SS and MALT-L risk 
patients when compared to control samples in both runs. Only S100-A9 was not detected in 
control sample but was present in both diseased samples of the first run. Actin and Ig γ-1 
chain C region had an increased fold change in the first run while protein S100-A8 and A9 had 
a higher fold change in the second run when SS patients at risk of developing lymphoma was 
compared to SS patients (table 4-2). 
Due to differences in proteomics analysis techniques and variations in saliva collection 
methods, it might be difficult to compare results from different studies. As a general rule, whole 
mouth saliva (WMS) and parotid saliva (PS), can lead to different proteomics profile results; 
thus, different biomarkers are expressed. This does not seem to be the case for at least SS 
reported in a review by an American group comparing 5 studies 3 of which used WMS while 
2 used PS and reporting similar biomarker findings among them  (Al-Tarawneh et al., 2011). 
However, it is reasonable to say that whole mouth saliva will be more informative combining 
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different sources of secretion. On the other hand, the levels of many analytes are higher in the 
general circulation than in saliva and if blood was to leak into saliva, it will affect the actual 
levels of salivary analytes.  
Also, stimulating parotid saliva may be required to obtain sufficient amounts of saliva 
(uncontaminated with blood), in cases where salivary flow is diminished such as SS thus 
providing more specific information regarding the gland itself (Al-Tarawneh et al., 2011).  
Table 4-9 summarises more relevant information on those 5 proteomic studies of saliva 
together with our results. All the studies have compared SS to healthy controls. Moreover, one 
of these studies has included non-SS sicca syndrome and SS patients with other autoimmune 
diseases (Baldini et al., 2011b). Another study has comprised dry mouth patients (Ryu et al., 
2006).  
 A recent study by Deutsch et al., (2015) analysing pooled WMS saliva from SS and healthy 
control patients. Amongst them Ig γ-1chain C region and S100-A8 were reported with an 
increased fold change ratio which corresponds well to our findings.  
In another study conducted using comparable methods to those applied in the present study, 
pooled parotid saliva samples from 5 SS subjects and 5 healthy controls were analysed using 
LC-MS/MS. Among the identified proteins, Actin cytoplasmic 2, S100-A8, and S100- A9 were 
present supporting our results (Ambatipudi et al., 2012). 
With regards to proteomic analysis on SS/MALT-L patients, none have investigated subjects 
at risk of developing MALT-L, but in a case report by Baldini and colleagues, a correlation was 
reported between the salivary proteomic profile and the clinical course of the disease in a 
patient with SS and B-cell lymphoma (MALT-L) for the first time. Changes in the levels of 
several types of immunoglobulin levels including Ig alpha-1 chain C region were detected 
(Baldini et al., 2011a). 
In another study conducted by Hu and colleagues, parotid samples from SS patients and SS 
with MALT-L where analysed and compared to non-SS control subjects. They have found that 
many of the up-regulated proteins in SS/MALT-L and SS patients were related to immune 
responses and actin was amongst them (Hu et al., 2009). 
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Since the first proteomic study on parotid saliva of SS patients in 1999 by Beeley and Khoo 
(1999), saliva proteomics remained one of the most promising approaches to human disease 
biomarker identification with definite advantages in terms of non-invasiveness. It is important 
to note that stability of a normal saliva proteome is unknown and the characterization of it is 
of great importance. Furthermore, standardization of sample handling and collection is still 
required together with combining different proteomic analyses to achieve more reliable results 
and a significant effort, especially for validating salivary biomarkers, is still needed. Also, it 
would be of interest to perform an integrated proteomic analysis of the glandular tissue and 
compare it to saliva proteome results. 
Finally, it is worth noting that this study is small thus the results should be regarded as 
preliminary and would be considered as a proof of concept thus it was followed by a larger 
(ELISA) study. And it would be of great significance to conduct the same comparison on larger 
group of patients using the same proteomic analysis to check for the reproducibility of the 
results. However, it is important to mention that most of the preliminary proteins have been 















Table 4-9 Studies of salivary proteome in SS including our results 
Modified from Katsiougiannis and Wong, (2016) and Al-Tarawneh etal., (2011). 
Study references 
 Baldini  
et al.,  
2011b 



























































✓ 1  ✓ 1 ✓ 2 ✓ 1 ✓ 
Ig γ-1 chain C 
region 
 




   ✓ 3 ✓ ✓ 
Protein 
S100-A9 
✓ ✓ ✓ ✓ ✓ ✓ 
UWMS; unstimulated whole mouth saliva, SPS; stimulated parotid saliva, SWSF; stimulated whole 
mouth saliva, SSMLS; stimulated submandibular and sublingual saliva, SS; Sjögren’s syndrome, 
CT; healthy controls, non SS; sicca patients not SS, SecSS; SS patients with other autoimmune 
disease, DM; dry mouth patients, 2D DIGE; two-dimensional difference gel electrophoresis, SELDI-
TOF; surface enhanced laser desorption ⁄ ionization time-of-flight mass spectrometry, 2DE, two-
dimensional gel electrophoresis, MALDI-TOF; matrix-assisted laser desorption ⁄ ionization time-of-
flight mass spectrometry, HPLC; high-performance liquid chromatography, ESI; electrospray 
ionization, LC-MS; liquid chromatography-mass spectrometry, MS/MS; Tandem mass 
spectrometry. 
1. Alpha and Beta Actins    
2. Alpha Actin   
3. Down regulated 
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 Candidate biomarker selection 
Choosing the candidate protein was challenging as all of them have been previously reported 
in SS literature (table 4-9) and all of them are up-regulated in both disease groups (figure 4-
6). In exploring proteins individually, the literature is found to be rich with studies correlating 
some if not all with malignancy as well. So, it is justifiable to write a brief description of each 
protein with a great emphasis on the selected ones and the reason behind selecting them. 
The first protein is Actin cytoplasmic 2 or Actin γ 1 (42 kDa) which is one of the most 
condensed forms of protein ubiquitously expressed in all eukaryotic cells. It is a key 
cytoskeletal protein involved in various types of cell motility, and maintenance of the 
cytoskeleton. Previous studies have described the presence of the other isoforms of Actin 
(Alpha and Beta). However, actin, beta and gamma co-exist in most cell types thus 
comparison was done across the studies (table 4-9).  De Jong et al., (2010) identified Actin 
as a promising salivary biomarker in differentiating pre- malignant and malignant oral lesions 
and has supported their results by a number of studies. In the present study patients who are 
at risk of developing MALT-L were compared to SS patients. There was a discrepancy 
between each run where in the first run there was a of 2.4 fold change ratio in SS at risk of 
MALT-L development compared to SS sample while in the second run was 1 (table 4-2), thus 
this protein was excluded despite its great potential. In further work, it may be appropriate to 
investigate actin levels in further patients at risk of developing MALT-L. 
The second protein is Ig γ-1 chain C region or IgG1 (36 kDa) which is the constant region of 
one of the four subclasses of immunoglobulin (Ig). It is the most abundant class of 
immunoglobulin found in the plasma but only 5-15% of salivary Ig is made up of mainly IgG 
and IgM which are to some extent, derived from gingival crevicular fluid (GCF) or from plasma 
leakage (Chiappin et al., 2007). However, >70% of IgG in saliva is thought to be of local origin 
(Edgar et al., 2004). Other than the aforementioned studies (table 4-9), a study by Donadio et 
al., (2013) has reported an up-regulation of IgG and Protein S100-A9 in benign tumour of 
parotid glands linking it to autoimmunity and inflammation, thus supporting our findings. Also, 
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it was attributed to B cell activation in periphery according to Katsiougiannis and Wong, (2016). 
However, the fold change ratio (1.004) was below the cut- off when SS at risk of MALT-L was 
compared to SS sample in the second run as shown in table 4-2 and it was omitted as well. 
The last two proteins which are pro-inflammatory members of the Alarmin family, they are 
myeloid-related, calcium binding proteins; S100-A9 (Calgranulin B) (11 kDa) and S100-A8 
(Calgranulin A) (13 kDa) which are predominantly found as S100A8/A9 heterodimer having a 
broad range of intracellular and extracellular functions; e.g. playing a prominent role in the 
regulation of inflammation (chronic and acute) inducing leukocyte chemotaxis and adhesion.  
Originally, S100A8/A9 was discovered as an immunogenic protein expressed by neutrophils 
with potent anti-microbial properties referred to by its former name calprotectin in 1990 
(Fagerhol et al., 1990). It has been reported as being up-regulated in many cancers including 
melanoma, gastric cancer, breast cancer and colorectal cancer  (Bresnick et al., 2015, Salama 
et al., 2008). Furthermore, changes in S100A9 protein expression levels are known in 
literature to be linked with autoimmune and inflammatory diseases such as arthritis, 
rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus (Foell and Roth, 
2004).  
S100A8 and S100A9 were differently expressed in SS patients in the present study as well as 
other studies as shown in table 4-9.  
Both proteins were increased in diseased samples when compared to controls in both runs 
and the fold change ratio was 2.4 and 9.6 for S100A8 while it was 2.1 and 12.1 for S100A9 in 
the first and second runs respectively, when samples of patients at risk of developing 
lymphoma were compared to SS samples seen in table 4-2. Therefore, it was decided to 




 Preclinical validation of selected protein 
Can one of the candidate proteins identified in the proteomics study be selected for a large 
cohort of subjects and might it be able to discriminate between different groups of SS 
subjects? Moreover, are there associations between the candidate proteins and the overall 
impairment of salivary gland function? 
Immunoassays, such ELISA or western blotting, are the most frequently used methods for 
validation of saliva biomarkers and if properly used, ELISA is a sensitive, accurate and rapid 
detection method. It is especially effective when large numbers of samples must be assayed 
thus it was selected. 
 Salivary S100A8/A9 levels and their associations  
The ELISA analysis indeed supported the proteomics findings, showing similar expression 
profile trends being higher in parotid saliva of SS groups compared to healthy controls in 
addition to the newly added disease controls (figure 4-12). Although the levels in whole mouth 
saliva were higher (6.8 times) than parotid saliva for SS patients which might be expected as 
it is released from other sources, but they were not high enough to be significantly different 
than the healthy and disease controls (figure 4-14) (whole saliva is 38 times higher in healthy 
controls and 29 higher in disease controls than parotid saliva).  
A possible explanation is that despite being strict in selecting age- matched healthy controls 
who were not on any xerostomic medication, it might be that influences on oral health status 
(e.g. caries, periodontal disease, fungal infection and ulcers) affected S100A8/A9 levels in 
whole mouth saliva.  Furthermore, it is extremely difficult to collect a true unstimulated whole 
saliva sample without oral musculature movement (shedding cells) which may contribute to 
the higher readings. Also, it is worth noting that almost half of the SS subjects didn’t produce 





In general, our results were comparable to previously published work by Sweet et al., (2001), 
reporting higher levels of S100A8/A9 (calprotectin) in whole saliva of SS patients in 
comparison to healthy controls. Our results showed higher values but not significant enough 
as explained previously. Interestingly, Sweet and colleagues have reported no correlation 
between parotid and whole saliva levels attributed to not being of a salivary gland origin and 
this is supporting our findings regarding the healthy control group, where no correlation was 
found between parotid and whole saliva levels. On the other hand, it contrasted with findings 
in SS patients suggesting that it might be of salivary gland origin or neighbouring tissue since 
they are the major site of inflammation in this group (weak correlation). 
It is important to note that there was a wide range of calprotectin levels (200-18000 ng/mL)  in 
whole saliva reported by this group (Sweet et al., 2001). It is similar to our findings but the 
parotid saliva levels that they found in SS patients were not found.  Levels in parotid saliva of 
healthy controls were comparable to ours and to another study by Muller et al., (1993) where 
they compared parotid saliva levels of calprotectin in controls and HIV patients.  They have 
reported that it might be derived from squamous epithelial cells lining the large parotid ducts 
also from stromal granulocyte and macrophages. 
Cuida and co-workers studied calprotectin levels in LSG of SS patients, as well as for the 
salivary levels (stimulated whole mouth saliva) in SS and healthy subjects, they reported no 
differences between control and SS levels (Cuida et al., 1993). Their other study reported a 
positive correlation between plasma and whole mouth levels of SS patients despite being 
higher in the latter. Also, there was a weak negative correlation with the flow rate and this was 
comparable to our parotid saliva results where a weak negative correlation was found between 
parotid flow rate and salivary parotid levels whereas our whole mouth results showed no 
correlation between flows and S100A8/A9 levels (Brun et al., 1994). 
Furthermore, they analysed levels of calprotectin in different oral fluids of healthy subjects.  
They have showed greater levels in whole mouth saliva than parotid saliva and mucosal 
transudate had even higher levels than both types of saliva. Their reported parotid values were 
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ten- fold higher than our findings and the aforementioned studies which could be due to 
different collection methods since we stimulated the flow while they analyse unstimulated 
saliva which can have higher protein concentrations (Cuida et al., 1995). In their later study  
they have added the comparison of parotid and whole saliva levels in SS patients and controls 
and reported a positive correlation between parotid levels and the focus score of SS patients 
(Cuida et al., 1997). Furthermore, it should be noted that in the present study none of the flow 
rates correlated with USS. Salivary levels of the above-mentioned studies are summarised in 
table 4-10 together with our results. 
Subgrouping of SS has revealed significant differences in parotid S100A8/A9 levels of SS 
patients who developed and are at risk of developing MALT-L in comparison to healthy 
controls (figure 4-12). While S100A8/A9 levels in whole mouth saliva were significantly 
elevated in SS patients who developed lymphoma when compared to both disease and 
healthy controls as well as to SS group (figure 4-14). This confirms the important link of 
S100A8/A9 to cancer as an amplifier of not only inflammation but associated to tumour 
development which has been previously reported (Salama et al., 2008, Bresnick et al., 2015). 
Interestingly it was noted that when comparing left and right glands of 2 patients at risk of 
developing MALT-L, that the swollen glands showed increased level of S100A8/A9 compared 










Table 4-10 Summary of salivary levels of calprotectin in literature  
 
     















     






























Cuida et al. 1995 uParotid  3200 - - 
 sWhole  22000 - - 
     
Cuida et al. 1997 sParotid  2700 5500 No 
 sWhole   15200 36300 No 
     
Sweet et al. 2001 sParotid  300 Not written Not found 
 uWhole 2000 14000 Yes 
     
our results sParotid 251.4 1968.8 Yes 
 uWhole 9545.2 13401 No 
*median, uWhole; unstimulated whole saliva, sWhole; stimulated whole saliva, sParotid; 










 Receiver operator characteristic (ROC) curve 
The diagnostic accuracy of the S100A8/A9 ELISA test in differentiating SS group from the 
control subjects has identified rather a fair cut-off levels in both whole and parotid saliva 
demonstrating better accuracy of parotid saliva vs. whole saliva; 82 % sensitivity vs. 73% and 
56% specificity vs. 50%. 
While a good diagnostic accuracy was found in differentiating the SS subgroups via whole 
saliva levels which could differentiate between SS with developed MALT-L and controls as 
well as SS subgroup having slightly higher sensitivity and specificity when compared to 
controls (85% sensitivity and 80% specificity). 
These readings (cut-offs) might be of significance since the sensitivity and the reproducibility 
of the actual test (ELISA) was further done demonstrating an acceptable recovery readings. 
 Salivary flow rates and the total protein concentration 
A diminished mean flow of WFR was evident in the overall SS patients particularly those who 
are at risk or already developed MALT-L (figure 4-8), specifically where almost half of the 
patients could not provide a sample of WMS, evidence from the literature was mentioned 
previously in chapter 3.  On the other hand parotid saliva flow rates did not differ between 
control groups and the overall SS group as well as the SS subgroup (figure 4-9), and again 
this has been reported by others (Fox et al., 1987, Thorn et al., 1989, Skopouli et al., 1989, 
Atkinson et al., 1990, Atkinson, 1993, Carpenter et al., 2000, van den Berg et al., 2007) but 
not by other studies such as Stuchell et al., (1984), Kalk et al. (2001a), (2002c) and Pedersen 
et al., (2005). Although the underlying mechanism is not yet understood, a possible 
explanation for it is the involvement of the submandibular and sublingual glands in SS at first 
as mentioned previously. However, lymphoma patients did have lower parotid flows compared 
to the controls and patients at risk of MALT-L had lower but not statistically significant, 




It is worth noting that the original cohort of parotid samples was even larger and included 
mucous like secretions (mucus plugs), obtained mostly from the SS patients who were at risk 
or had already developed lymphoma and in some SS patients with longer disease duration.  
These samples were excluded since the mucus interfered with ELISA. Furthermore, in chapter 
3 a significant difference was found between overall SS patients and disease control patients 
and this is largely due to the inclusion of more patients in the previous study especially at risk 
patients and those who developed MALT-L. 
Regarding the total protein concentration it was noted that there was higher values in whole 
mouth saliva of SS compared to controls (figure 4-10) which is supported by other studies 
(Fox et al., 1987, van der Reijden et al., 1996, Thorn et al., 1989, Hernandez-Molina et al., 
2011). On the other hand, parotid total protein concentration did not change between the 
groups (figure 4-11), which is in agreement with the findings of others (Carpenter et al., 2000, 
Kalk et al., 2001a) but contrast with Hu et al., (2007a) who found a higher concentrations in 
SS group.  A negative correlation was observed between flow and total protein concentration 
of whole saliva, while the parotid parameters did not correlate (table 4-4), in agreement with 
Carpenter et al., (2000). 
In conclusion, this study supports previous reports indicating the value of saliva as a diagnostic 
tool of disease activity and progression in Sjögren’s syndrome. The preliminary results of 
parotid saliva proteomic analysis indicate a list of candidate markers of SS and SS at risk of 
lymphoma. Salivary levels of S100A8/A9 tend to reflect more local inflammatory activity 
showing the greatest difference between groups in parotid saliva. Furthermore, the changes 
in sialochemical analysis (total protein concentration) and sialometric analysis (flow rate) seen 
with SS patients were indicated by previous studies. Further studies are needed to better 
clarify the relationship of salivary S100A8/A9 with the focus score and possibly tear fluid to 
better understand SS glandular disease activity. Analyses of S100-A8 and -A9 individually 
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5 Salivary cytokines in Sjögren’s syndrome 
 Introduction 
Cytokines are small, soluble peptides or proteins that are produced by a variety of cells that 
participate in the immune response, including T cells, B cells, macrophages and others . They 
are powerful immune regulators constituting the communication network of the immune 
system. Any alteration in cytokine expression may lead to inflammation, allergy, immune 
deficiency or autoimmunity. Exocrine glands are assumed to be the target of lymphocytic 
hyperactivity in primary SS. Therefore, we found it of significance to study the salivary glands’ 
secretions to better understand the disease activity. Saliva in particular would be of interest, 
since collection of this body fluid is a non-invasive procedure. Cytokine environment provides 
important visions into pathological processes and can potentially serve as biomarkers for 
Sjögren’s syndrome (Zhang and An, 2007, Roescher et al., 2009). Furthermore they play 
important roles in B-cell activation, proliferation and apoptosis and thus may be etiologically 
related to risk of B-cell non-Hodgkin lymphoma (Dong et al., 2013). (See chapter one 
subsection 1.4.2.2 and 1.6.3.1). 
Several investigators have measured specific cytokine concentrations in the saliva in SS 
showing that alterations in salivary cytokine profiles may be useful for both its diagnosis and 
progression (Ohyama et al., 2015, Moriyama et al., 2012, Hernandez-Molina et al., 2011, Fox 
et al., 1994, Kang et al., 2011, Rhodus et al., 1998, Nguyen et al., 2008). Therefore, in this 
chapter we have focused on cytokine levels in saliva and reviewed the literature regarding 
cytokines in some of the other biological samples of SS patients in general. 
Due to the heterogeneous nature of SS, it has been suggested that no single marker is likely 
to be sufficient for the prediction of a disease state and a panel of biomarkers should be 
identified. This could be accomplished by utilizing proteomic approaches on saliva samples 
that have the capacity of profiling multiple biomarkers. While cytokines detection was 
challenging via the aforementioned proteomic analysis (described in chapter 4) owing to their 
low abundance, the proteome profiler human cytokine array test (membrane-based sandwich 
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immunoassay) and luminex multiplexed assay (bead-based assays) provided the alternative 
solutions; enabling the identification of the relative expression of multiple cytokines in a single 
test.  These antibody- based methods allow greater sensitivity of detection. Cytokine antibody 
arrays that bind and detect proteins from samples (semi-quantitatively) and multiplex antibody 
based assay using bead- based systems that allow a more sensitive simultaneous 
quantification of multiple proteins. These are particularly useful for cytokines and growth 
factors which are low abundant proteins. 
In this study, cytokine profiles of parotid samples from healthy, SS, SS at risk and those who 
already developed lymphoma were explored via a cytokine antibody array. Bead- based 
assays were then used for measuring the levels of selected cytokines in a larger group of 
subjects with the addition of disease control patients (SNOX). Furthermore, the list of cytokines 
was narrowed and measured via more sensitive performance bead-based assays; where 
















 Aims and objectives 
Given the important role of cytokines in Sjögren’s syndrome (SS), the hypothesis behind the 
study described in this chapter was: 
Cytokines are present in saliva and can differentiate between SS, healthy controls and other 
forms of dryness (SNOX), further they can distinguish different subgroups of SS. Thus, the 
aims were as follow: 
1. Identify parotid salivary cytokine biomarkers for SS using a cytokine antibody array 
approach to determine whether they are involved in SS, SS at risk or already 
developed lymphoma via comparison to healthy control samples. 
2. Use the selected cytokines and compare their levels in SS to healthy and disease 
controls (SNOX) via bead- based multiplex antibody assays. 
3. Compare their levels in SS groups of different subgroups; SS, SS at risk and those 
who already developed lymphoma via bead- based assay. 
Also in this study, the group of selected cytokines were further narrowed and tested via more 
sensitive assays and the specific aims were under taken: 
1. Verify the above-mentioned aims to identify saliva indicators which are associated with 
the different subgroups of SS. 
2. Assess whole mouth salivary cytokines in relation to the above-mentioned groups of 
patients and compare to levels in parotid saliva. 
3.  Establish whether there is an association between the candidate cytokines with the 




 Materials and methods 
 Study group 
Twelve age and sex matched subjects from 4 groups (healthy controls (n=3), SS (n=3), SS at 
risk of developing MALT-L (n=3) and SS who already developed it (n=3)) were included in the 
proteome profiler analysis. 
For further analysis via multiplex immunobead- assays (Luminex, R & D Systems, 
Minneapolis, MN), samples were included to a total number of 76 for initial screening assays 
then incorporated additional samples reaching to 82 samples for performance assay and 57 
whole mouth saliva samples. For both assays a fifth group was added which is the disease 
control (SNOX) group.  
 Saliva sample collection 
Stimulated parotid saliva samples (n=76 for screening) and (n=82 for performance) were 
collected and stored as outlined in chapter 2, subsection 2.1.4 and Appendix 4& 5. 
Unstimulated whole mouth saliva samples were collected as well (n=57) and analysed using 
the performance assay only. All samples were kept on ice and stored until required. Their 
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Luminex Assay         
20 analytes  Magnetic Performance 
Luminex Assay                   
6 analytes  
 Figure 5-1 Schematic presentation of the work flow for cytokine analyses  
Involving proteome profiler followed with 2 types of Luminex assays (screening then 




 Laboratory analyses 
 Proteome ProfilerTM Human XL Cytokine Array 
Three sets (kits) of parotid saliva samples (4 samples each) were analysed; their cytokine 
levels were determined semi-quantitatively with a multi-cytokine (n=102) membrane array (R 
& D Systems, Minneapolis, MN). The kit (cat. no. ARY022) was used according to 
manufacturer’s instructions (further details are found in chapter 2 subsection 2.2.6 and 
Appendix 7). 
 Luminex® xMAP Assays  
 Magnetic Screening Luminex Assay 
Two multiplex bead- based kits (R&D Systems, Minneapolis, MN) were used to measure the 
concentrations of a total of 20 cytokines in parotid saliva. The first kit (cat. no. LXSAHM-3) 
was used to measure IL-3, and ST2. While the second kit (cat. no. LXSAHM-19) measured 
IFN-γ, TNF-α, IL-1α, -1β, -2, -4, -5, -6, -10, -12p70, -17A, -22, -23 and -33) and chemokines 
(MCP-1, MCP-3, IP10 and IL8). Samples were thawed directly on the day of analysis and the 
assays were performed as previously described (chapter 2 subsection 2.2.7.1 and Appendix 
8). 
 Magnetic Performance Luminex Assay 
Commercial customised panel (R&D Systems, Minneapolis, MN) (cat. no. FCSTM03) was 
used to measure the levels of selected six cytokines (IL-1α, -1β, -4, -6, -8 and MCP1) in parotid 
and whole mouth saliva samples, using a similar protocol to the screening assay. (Refer to 
chapter 2 subsection 2.2.7.2 and Appendix 8). 
 Statistical analysis 
All statistics were evaluated using SPSS, and GraphPad Prism® 6 (GraphPad Software Inc., 
California, USA) was used for the graphical presentation, where all the Data were transferred 




 Results  
 Proteome ProfilerTM Human XL Cytokine Array 
 Study group 
Table 5-1 Characteristics of patients included in the proteome profiler 
The mean densities of spots on the membranes were quantified by ImageJ software, an 
example of one kit with 4 membranes is shown in (figure 5-2) and difference between the 
respective cytokine levels is represented as fold change and p-values which is seen in later 









     
Groups  Controls SS  SS at risk SS/ MALT-L 
Age 51.7±7 53.3±7.4 50±8.6 52.7±11.8 
Gender F F F F 

























Figure 5-2 Represents an example of one sample per membrane of cytokine 
antibody array (n=4) 
(A) Healthy control 
(B) Sjögren’s syndrome (SS)  
(C) SS at risk of developing mucosa associated lymphoid tissue lymphoma (MALT-L) 
(D) SS developed MALT-L. 
Examples of over-expressed cytokines/proteins are seen; (1) IL-10, (2) trefoil factor 3 












































Based on the cytokine array profiling, cytokines (proteins) were ranked at first according to 
their relative expression in samples; first ranked proteins were defined as being identified in 
all 12 samples (45/102 cytokines); second ranked proteins were identified in 11 samples 
(37/102) and the third ranked proteins were identified in 10 or less samples (20/102). 
Then these three ranks were classified individually by fold change with an arbitrary cut-off of 
1.5, starting with comparisons between control samples to all of the disease samples (SS, SS 
at risk and those with MALT-L). For the first ranked proteins, 3 were up-regulated when SS 
was compared to healthy while 4 were down- regulated. Eight proteins were up-regulated 
when SS at risk was compared to control samples. Twenty-one proteins were up-regulated 
when SS with MALT-L was compared to the healthy control group.  
Comparisons of SS to the rest of the disease samples have revealed; 14 up-regulated proteins 
when SS at risk was compared to SS while one was down-regulated. Twenty-six proteins were 
up-regulated when patients with MALT-L were compared to SS and one was down- regulated. 
Fourteen proteins were up- regulated, when SS patients with MALT-L were compared to those 
who are at risk of developing it.  
For the second ranked proteins, in SS to controls comparisons there were 2 up-regulated 
proteins and 5 down-regulated. There were 13 and 19 up-regulated proteins when SS at risk 
and SS who already developed the cancer were compared to controls respectively. Twenty-
eight proteins were up-regulated when SS at risk and confirmed MALT-L were compared to 
SS group each. Nine up-regulated while 3 down-regulated proteins were identified when the 
SS group with MALT-L was compared to the SS at risk group. 
In the third raked proteins, 5 proteins were down-regulated when SS was compared to control 
subjects while 3 and 7 up-regulated proteins were identified when SS at risk and SS with 
MALT-L were compared to controls correspondingly. Comparisons of SS at risk and SS with 
MALT-L to SS group have identified 16 and 14 up-regulated proteins respectively, while none 
were found when SS with lymphoma was compared to SS at risk group. 
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To increase the stringency of results, these proteins were further ranked by p-value (one- way 
ANOVA followed by Tukey HSD post hoc test); 2 proteins (ST2 and vitamin D BP) and 3 
proteins (ST2, Endoglin and IL-22) were significantly different when SS at risk was compared 
to control and SS groups individually, while one protein (CD30) was statistically different when 
SS with MALT-L was compared to SS patients from the first ranked proteins. 
From the second ranked proteins; one protein (MCP-1) was significantly different when 
comparison between SS at risk and control groups was done, while 4 proteins (MCP-1, -3, IL-
10 and IL-32α/β/γ) were different when SS at risk was compared to SS patients. None of the 
third ranked proteins were statistically different between the groups.  Summary of the results 
is found in (figure 5-3). 
An example of the first ranked (45) cytokines/proteins ordered by fold change and p-value is 
shown in tables 5-2 &5-3 when compared to controls then when compared to SS. The second 
and third protein summaries are found in Appendix 14 to 17. 
Data were plotted as fold change (log2 fold change ratio) and significance (-log10 p-value) in a 
volcano plot for the first and second rank proteins (figures 5-4 and 5-5) while the third rank 

















Figure 5-3 Work flow of the different type analyses generated on data obtained from the proteome profiler.  
CT; healthy controls, SS; Sjögren’s syndrome, MALT-L risk; SS at risk of developing MALT-L, MALT-L;          
mucosa associated lymphoid tissue lymphoma. * a common protein. 
CT compared to disease which are SS, SS at risk and with MALT-L.                                                                                       




Table 5-2 Summary of the first rank cytokines-proteins ordered by fold change and p-
value when compared to controls 
Fold change in the first group (A) is ≥ 1.5 in all disease groups. In the second group (B) it is increased 
in 2 of the disease groups. While the third group (C) fold change is increased in one group only. NS; 
not significant, CT; healthy controls, SS; Sjögren’s syndrome, MALT-L; mucosa associated lymphoid 
tissue lymphoma. IL-1 receptor-like 1(ST2) and Vitamin D BP were significantly different when 
compared to controls (one- way ANOVA followed by Tukey HSD post hoc test). Blue up-regulated 
red down- regulated. 
First ranked proteins were defined as being identified in all 12 samples 
 
 












































VEGF >-1.5, <1.5 NS 2 NS 3.9 NS 
Resistin >-1.5, <1.5 NS 1.9 NS 6.4 NS 
MMP-9p >-1.5, <1.5 NS 1.8 NS 5.6 NS 
IL-18 Bpa >-1.5, <1.5 NS 1.6 NS 2.9 NS 
IL-33 >-1.5, <1.5 NS 1.6 NS 1.7 NS 
IP-10 3.7 NS >-1.5, <1.5 NS 4.7 NS 
IL-16 2 NS >-1.5, <1.5 NS 2.5 NS 
 
 













RBP4 >-1.5, <1.5 NS >-1.5, <1.5 NS 5.4 NS 
uPAR >-1.5, <1.5 NS >-1.5, <1.5 NS 3.7 NS 
IL-19 >-1.5, <1.5 NS >-1.5, <1.5 NS 3.5 NS 
ENA-78 >-1.5, <1.5 NS >-1.5, <1.5 NS 3.4 NS 
Endoglin >-1.5, <1.5 NS >-1.5, <1.5 NS 2.4 NS 
GDF-15 >-1.5, <1.5 NS >-1.5, <1.5 NS 2.1 NS 
Fas Ligand >-1.5, <1.5 NS >-1.5, <1.5 NS 1.7 NS 
Complement factor D -1.9 NS >-1.5, <1.5 NS 1.6 NS 
HGF -2.2 NS >-1.5, <1.5 NS 1.6 NS 
EMMPRIN -1.5 NS >-1.5, <1.5 NS 1.5 NS 
IL-4 -3.3 NS >-1.5, <1.5 NS 1.6 NS 
Serpin 
 





























Table 5-3 Summary of the first rank cytokines-proteins ordered by fold change and p-
value when compared to SS 
Fold change in the first group (A) is ≥ 1.5 in all disease groups. In the second group (B) it is increased 
in 2 of the disease groups. While the third group (C) fold change is increased in one group only. NS; 
not significant, CT; healthy controls, SS; Sjögren’s syndrome, MALT-L; mucosa associated lymphoid 
tissue lymphoma. Endoglin, IL-1 receptor-like 1(ST2), CD30 and IL-22 were significantly different 
when compared to SS (one- way ANOVA followed by Tukey HSD post hoc test). Blue up-regulated 
red down- regulated. First ranked proteins were defined as being identified in all 12 samples 
 
 





























GDF-15 1.6 NS 3.4 NS 1.8 NS 
IL-19 2.3 NS 4.8 NS 2.6 NS 















Fas Ligand 2 NS 3.1 NS >-1.5, <1.5 NS 
HGF 1.6 NS 2.6 NS >-1.5, <1.5 NS 
IL-33 2.5 NS 2.6 NS >-1.5, <1.5 NS 
IL-22 3.5 0.03* 2.8 NS >-1.5, <1.5 NS 
ST2 2 0.007* 1.9 NS >-1.5, <1.5 NS 
IL-6 2.3 NS 2.2 NS >-1.5, <1.5 NS 
IL-11 2 NS 1.5 NS >-1.5, <1.5 NS 
TfR 2.5 NS 2.4 NS >-1.5, <1.5 NS 
EMMPRIN >-1.5, <1.5 NS 3 NS 1.6 NS 
Resistin >-1.5, <1.5 NS 5.8 NS 4.4 NS 
RBP4 >-1.5, <1.5 NS 4.6 NS 4.5 NS 
uPAR >-1.5, <1.5 NS 4.6 NS 3.4 NS 
MMP-9 >-1.5, <1.5 NS 4.2 NS 3.8 NS 
Vitamin D BP >-1.5, <1.5 NS 4.1 NS 3.4 NS 
MIG >-1.5, <1.5 NS 3.6 NS 3.9 NS 















CD30 >-1.5, <1.5 NS 2 0.05* >-1.5, <1.5 NS 
IL-18 Bpa >-1.5, <1.5 NS 2.7 NS >-1.5, <1.5 NS 
Complement factor D >-1.5, <1.5 NS 2.6 NS >-1.5, <1.5 NS 
Thrombospondin-1 >-1.5, <1.5 NS 2 NS >-1.5, <1.5 NS 
GM-CSF >-1.5, <1.5 NS 1.5 NS >-1.5, <1.5 NS 
IL-16 >-1.5, <1.5 NS -1.7 NS 1.5 NS 




































Figure 5-4 Volcano plot representing the significance (−log10 (p-value)) and the fold 
change of the first rank cytokines/proteins (45/102) identified in all diseased groups 
when compared to controls (A) and to SS (B).  
CT; healthy controls, SS; Sjögren’s syndrome, MALT-L; mucosa associated lymphoid tissue 
lymphoma. 






















































Figure 5-5 Volcano plot representing the significance (−log10 (p-value)) and the fold 
change of the second rank cytokines/proteins (37/102) identified in all diseased 
groups when compared to controls (A) and to SS (B).  
CT; healthy controls, SS; Sjögren’s syndrome, MALT-L; mucosa associated lymphoid tissue 
lymphoma. 





















































 Luminex Screening Immunobead assay 
 Study group 
Seventy- six subjects were included for this study and their parotid samples were analyzed, 
demographics and diagnosis break down are summarised in table 5-4.  Salivary levels of 20 
cytokines were compared among SS patients and control subjects. The cytokines (n=20) 
assayed included: IFN-γ, TNF-α, IL-1α, -1β, -2, -3, -4, -5, -6, -8, -10, -12p70, -17A, -22, -23, -
33, IP10, MCP-1, MCP-3 and ST2.    
 
Table 5-4 Demographic and clinical characteristics of the SS patients and control 




    
Groups Age sex SPFR (ml/min)  
 
CT (n=17) 50.2±2.9 1M   16F 0.34±0.04 
 
SNOX (n=10) 63.4±1.8 0M   10F 0.34±0.09 
 
Overall SS (n=49) 52.5±1.7 1M   48F 0.28±0.03 
 
SS (n=20) 51.5±2.7 1M   19F 0.36±0.06 
 
SS at risk (n=18) 51.9±3.01 0M   18F 0.26±0.05 
 
SS/ MALT-L (n=11) 55.2±3.2 0M   11F 0.15±0.05* 
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjögren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma,  SPFR; 
stimulated parotid flow rate. Data are reported as mean±SEM. * SS/MALT-L is significanlty 






 Cytokine levels: 
Values for cytokines in many samples were too low and outside of the standard curve.  Out of 
the 20 cytokines, 3 were not detectable in parotid saliva of all the subjects; IL-5, -10, and -17, 
while IL-12p70 was detected in only 2 patients (SS and SS at risk) whereas it was not detected 
in the rest of subjects.  Few were not detected in some subgroups. On the other hand, levels 
of IP10 in all the samples exceeded the dynamic range and required further dilution. Levels of 
IL-8 and MCP-1 in few patients were above the detection limit which also needed further 
dilution.  
IL-1α level was found to be statistically higher in the overall SS group compared to the 
diseased control group (p=0.002). Subgrouping revealed increased levels of IL-1α in SS 
patients at risk and those who already developed lymphoma compared to SNOX patients 
(p=0.046 and 0.003 respectively) (figure 5-6). Increases in IL-4, -6 and MCP-1 levels in overall 
SS group relative to SNOX group was identified (p=0.018, >0.0001 and 0.011). IL-6 was 
statistically higher in overall SS group in comparison to healthy controls as well (p=0.009). 
Interestingly levels of MCP-1 were lower in SNOX patients compared to healthy controls 
(p=0.027). While IL-8 was not significantly different in overall SS group compared to controls 
(figures 5-6 and 5-7). 
Furthermore, levels of MCP-1 were higher (p=0.024) in SS patients who developed MALT-L 
relative to SNOX group while levels of IL-8 were higher in SS patients at risk of developing 
lymphoma compared to SNOX (P=0.012) and even SS group (p=0.009) when SS patients 
were subgrouped. Levels of IL-6 was elevated in the MALT-L group compared to healthy 
(p=0.028) and disease (p=0.001) controls. While the levels in SS and MALT-L risk groups 
were higher than the disease control group (p=0.024 and 0.004 correspondingly). On the other 
hand, IL-4 levels were high in the MALT-L group but it was not significant (p=0.051) (figures 
5-6 and 5-7). The other cytokines showed no significant differences between groups. 
Moreover, almost all positive samples were very close to the low sensitivity point of the kit. 








Figure 5-6 Concentration of cytokines in parotid saliva from different groups when SS 
groups are combined (A) and subgrouped (B) measured via screening assays. (n=76) 
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjögren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma. Data are 
represented as median± interquartile range (IQR) and expressed as pg/ml. *P <0.05, 


























Figure 5-7 Concentration of cytokines in parotid saliva from different groups when SS 
groups are combined (A) and subgrouped (B) measured via screening assays. (n=76) 
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; 
Sjögren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma. Data are 
represented as median± interquartile range (IQR) and expressed as pg/ml. *P <0.05, 


























 Healthy   controls                        Disease controls  SS   SS at risk  SS and MALT-L  Overall SS  





Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) Median (Q1-Q3) 
 1    IL-1α   16.9 (12.02- 29.5) 0 (0-12.8) 17.8 (2- 34.5) 17.7 (12.3- 32.3) 24.3 (12.7- 47.7) 18.7(12.2 -35)** 
 2    IL-4  30.1 (18.9- 69.11) 0 (0- 25.2) 31.63 (4.318- 45.82) 29.1 (21.8- 48.07) 39.2 (29- 74.1) 32.02 (21.52- 53.7) * 
 3    IL-6  1.9 (1- 4.1) 1.1 (0.1- 2.3) 4.1 (1.9- 24.9) 6.9 (2.2- 16.4) 9.6 (5.7- 14.4) 5.2 (2.3- 14.8) ** 




5    MCP-1 417.2 (229.4- 667.5) * 161.9 (51.94- 302.9) 376.8 (140.6- 805.9) 519.6 (123.3- 787.9) 890.2 (229.1- 1301) * 470.9(174.8- 874.5) 
 6    IL-1β  0 0 0 (0- 19.8) 0 (0- 18.9) 0 (0- 19.1) 0 (0- 18.4) 
 7    IFN-γ  0 (0- 3.8) 0 0 0 0 0 
 8    TNF-α  0 (0- 16.7) 0 0 (0- 17.8) 0 (0- 15.3) 14.2 (0- 19.4) 0- (0- 17.8) 
 9    IL-2  77.6 (40.9- 96.5) 58.5 (38.2- 89.9) 56.1 (47.6- 107.3) 84.51 (47-124.6) 82.13 (42.8- 123.1) 72.4 (46.1- 121.6) 
 10  IL-3  0 0 0 ND 0 0 
 11  IL-22  0 (0- 20.3) 0 (0- 5.3) 0 (0- 21.9) 0 (0- 4.6) 0 0 
 12  IL-23  0 (0- 482) 0 (0- 265.3) 0 (0- 491.2) 263.7 (0- 357.3) 332.2 (0- 561.5) 252.9 (0- 441.3) 
 13  IL-33  0 0 0 ND 0 0 




15  ST2   0 0 0 0 0 0  
 16  IL-5   ND ND ND ND ND ND 
 17  IL-10  ND ND ND ND ND ND  
 
 18  IL-12p70 ND ND ND+ ND+ ND ND   
 19  IL-17A  ND ND ND ND ND ND 
 
 
 29  IP-10   ^ ^ ^ ^ ^                                               ^       
CT; healthy controls, SNOX; sialadenitis, nodular osteoarthritis and xerostomia, SS; Sjogren’s syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma, 
ND; not detected, ND+; one sample detected, ^; needed further dilution. Cytokines were either showing differences between the groups (A), not showing differences 
(B) or not detected in samples (C). Q1; first quartile, Q3; third quartile. 




























 Luminex Performance Immunobead Assay 
 Study group 
This study included 82 subjects, where parotid samples in addition to whole mouth saliva 
samples (n=57) were analysed.  Demographics and clinical characteristics are found in table 4-
2 in chapter 4. The numbers of samples for each group differ slightly owing to low sample 
volume or poor performance of assay. Analytes that showed significant differences between the 
groups according to the screening assay were selected for this assay; (IL-1α, -4, -6, -8 and 
MCP1). 
 Cytokine levels in parotid saliva  
The median (pg/ml) levels (Q1- Q3) of IL-1α of the groups were as follows; the overall SS group 
was 5.3 (2.1- 17.38) while the disease and healthy controls were 2.5 (1.8- 6.8) and 6.4 (1.6- 14) 
respectively. The subgroups means were 5.3 (2.31- 15.05), 6 (1.73- 33.42) and 5.1 (1.7- 60) for 
SS, SS at risk and SS who developed MALT-L separately. Despite the difference in their means, 
there was no significant difference between the groups as shown in (figure 5-8).  
On the other hand, the mean level of IL-1β was significantly higher (p=0.041) in the overall SS 
group (1.5 (0.045- 16.69)) when compared to the healthy control group (0.1 (0- 1.2)) but not the 
disease controls (0.3 (0- 2.6)). Subgrouping SS patients did not show any significant differences 
between them (1.04 (0.19- 10.48), 3.4(0.12- 18.35) and 5.6 (0- 17.84)) for SS, SS at risk and 
those who developed MALT-L (figure 5-9).  
IL-4 levels of the overall SS group were significantly higher (p=0.027) than the disease control 
group (17.7 (10.7- 25.8) vs. 12 (6.1-15), while they were not significantly higher than the healthy 
controls (13 (9.5- 16.3). No statistically significant differences were noted across the groups 
(p=0.053), when SS was subgrouped (17.7 (9.7-26.8), 18.7 (11.6- 23.4) and 14.5 (11.9-34.2) 




The levels of IL-6 showed a statistically significant difference between the overall SS group (2.5 
(1.43-13.19) in relation to both healthy (1.6 (0.58- 1.95)) and disease controls (1.4 (1.3- 1.9)) 
(p=0.12 and 0.022 respectively). When SS was subgrouped the means for SS, SS at risk and 
those who developed MALT-L were 2.54 (1.42- 11.39), 4.92 (1.38- 20.15) and 2.5 (1.37- 16.54), 
yet again no differences were detected among the groups (pairwise) despite the overall 
significant difference across the 5 groups (p values were corrected via post hoc test shifting 
them from being significant) (figure 5-11) and Appendix 18. 
Mean IL-8 and MCP-1 levels of overall SS groups (109.9 (62.51- 373.8) and 355.2 (138.7-1025)) 
were not significantly different than healthy controls (58.02 (35.83- 151.5) and 286 (128.7- 
615.1)) or the disease controls (58.11 (43.46- 150.9) and 157.4 (106.8- 296.1)) (p=0.06 and 
p=0.08 respectively). Neither were the subgroups different where the means for SS, SS at risk 
and SS with MALT-L were 101.4 (49.76- 206.6), 196.9 (75.35- 387.9) and 93.26 (28.92- 615.6) 
for IL-8 (p=0.12 across the groups) and 332.6 (138- 1264), 444.4 (234.2- 936.9) and 361.4 
(108.6- 1673) for MCP-1 (p=0.2) (figures 5-12 and 5-13). 
No difference was detected between SS subject groups according to the presence or absence 
of another autoimmune (marked in blue and red) nor SS patients at high or low risk of developing 
















Figure 5-8 Concentration of IL-1α in parotid saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=82) 
Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis and xerostomia (n=15), SS; 
Sjögren’s syndrome (n=19), at risk of (n=17) or with developed MALT-L (mucosa associated 
lymphoid tissue lymphoma) (n=13), -/+ with or without an accompanying AID (autoimmune 
disease). Data are reported as median ± (IQR) and expressed as pg/ml.  
























Figure 5-9 Concentration of IL-1β in parotid saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=82) 
Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis and xerostomia (n=15), SS; 
Sjögren’s syndrome (n=19), at risk of (n=17) or with developed MALT-L (mucosa associated 
lymphoid tissue lymphoma) (n=13), -/+ with or without an accompanying AID (autoimmune 
disease). Data are reported as median ± (IQR) and expressed as pg/ml.  

























Figure 5-10 Concentration of IL-4 in parotid saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=82) 
Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis and xerostomia (n=15), SS; 
Sjögren’s syndrome (n=19), at risk of (n=17) or with developed MALT-L (mucosa associated 
lymphoid tissue lymphoma) (n=13), -/+ with or without an accompanying AID (autoimmune 
disease). Data are reported as median ± (IQR) and expressed as pg/ml.  

























Figure 5-11 Concentration of IL-6 in parotid saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=82) 
Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis and xerostomia (n=15), SS; 
Sjögren’s syndrome (n=19), at risk of (n=17) or with developed MALT-L (mucosa associated 
lymphoid tissue lymphoma) (n=13), -/+ with or without an accompanying AID (autoimmune 
disease). Data are reported as median ± (IQR) and expressed as pg/ml.  


























Figure 5-12 Concentration of IL-8 in parotid saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=82) 
Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis and xerostomia (n=15), SS; 
Sjögren’s syndrome (n=19), at risk of (n=17) or with developed MALT-L (mucosa associated 
lymphoid tissue lymphoma) (n=13), -/+ with or without an accompanying AID (autoimmune 
disease). Data are reported as median ± (IQR) and expressed as pg/ml.  


























Figure 5-13 Concentration of MCP-1 in parotid saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=82) 
Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis and xerostomia (n=15), SS; 
Sjögren’s syndrome (n=19), at risk of (n=17) or with developed MALT-L (mucosa associated 
lymphoid tissue lymphoma) (n=13), -/+ with or without an accompanying AID (autoimmune 
disease). Data are reported as median ± (IQR) and expressed as pg/ml.  



















 Cytokine levels in whole mouth saliva 
The concentration (median (Q1-Q3) of IL-1α was significantly higher in the overall SS group 
(951.6 (500.7- 1714)) when compared to healthy controls (476 (116- 786)) (p=0.02) but it was 
not significantly different when compared to SNOX (568 (244- 1036)). Only SS with MALT-L 
had significantly higher levels (1708 (951.6- 1720)) (p=0.03) while SS (774.5 (341.1- 1680)) and 
SS at risk (777.5 (481.7- 1861)) were not significantly different despite having high levels (figure 
5-14). 
On the other hand, no significant differences detected between the concentration of IL-1β of the 
overall SS group (859.2 (324- 2169)) healthy (409 (164- 720.5)) and disease controls (516 (351- 
1097)) (p=0.07 across the groups). While subgrouping revealed higher levels in SS with MALT-
L group (2086 (732- 3614)) when compared to healthy controls (p=0.04) but the other subgroups 
of SS (394.1 (272.7- 1043)) and SS at risk (1127 (753.9- 2683)) did not show any significant 
differences (figure 5-15). 
There was a significant difference in IL-4 levels between overall SS group (50.92 (36.9- 62.11)) 
and healthy (36.5 (29.75- 41.75)) as well as the disease control groups (33 (27- 43.5)) (p=0.009 
and 0.04 respectively). There was an overall significant difference across the subgroups 
(p=0.02) but not between them where SS, SS at risk and who developed lymphoma were (46 
(35.78- 57.39), 61.2 (36.6- 73.8) and 52.24 (37- 63.6)) (figure 5-16).  
IL-6 concentration was statistically higher in overall SS group (31.2 (15.57- 64.01)) than the 
healthy controls (10 (5.75- 14.5)) (p=0.003) but slightly higher than the disease control (23 (4.5- 
44)). Once more, SS group who developed MALT-L shows elevated levels (40.4 (15.81- 113.4)) 
compared to healthy controls while SS (31.22 (12.02- 51.18)) and SS at risk (27.8 (14.84- 
63.78)) did not (figure 5-17). 
Levels of IL-8 in whole saliva of overall SS patients (1930 (1057- 4878)) was significantly 
elevated (p=0.002) compared to healthy controls (880 (515.8- 1133)) and not significantly 
different than the disease controls (1361 (517.5- 2334)). While subgrouping has revealed 
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significant difference between healthy controls and SS at risk of developing lymphoma (4826 
(1164- 5242)) as well as those who developed MALT-L (2366 (1911- 5091)) (p=0.022 and 0.012 
separately). SS had slightly high levels (1226 (1021- 2295)) (figure 5-18). 
MCP-1 concentration was statistically elevated in overall SS group (545.8 (289.6- 1036)) in 
comparison to both healthy and disease controls (278 (163.5- 442.5) and 270 (86- 357)) 
(p=0.049 and 0.014 correspondingly). Although significant change across the groups was 
detected (p=0.037) there was no significant differences detected between the subgroups SS 
(480.4 (322.4- 766.4)) SS at risk (1153 (253- 1791)) and SS who developed MALT-L (533 
(297.3- 864.7)) (figure 5-19). 
No statistically significant differences were found between patients with or without another 
autoimmune disease or between patients at high or low risk of developing lymphoma as marked 
on all the graphs. 















Figure 5-14 Concentration of IL-1α in whole mouth saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=57) 
WMS; whole mouth saliva, Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis 
and xerostomia (n=13), SS; Sjögren’s syndrome (n=12), at risk of (n=7) or with developed 
MALT-L (mucosa associated lymphoid tissue lymphoma) (n=7), -/+ with or without an 
accompanying AID (autoimmune disease). Data are reported as median ± (IQR) and 
expressed as pg/ml.  




































Figure 5-15 Concentration of IL-1β in whole mouth saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=57) 
WMS; whole mouth saliva,Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis 
and xerostomia (n=13), SS; Sjögren’s syndrome (n=12), at risk of (n=7) or with developed 
MALT-L (mucosa associated lymphoid tissue lymphoma) (n=7), -/+ with or without an 
accompanying AID (autoimmune disease). Data are reported as median ± (IQR) and 
expressed as pg/ml.  

































































Figure 5-16 Concentration of IL-4 in whole mouth saliva from different groups when SS groups are 
combined (A) and when subgrouped (B) measured via performance assays. (n=57) 
WMS; whole mouth saliva,Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis 
and xerostomia (n=13), SS; Sjögren’s syndrome (n=12), at risk of (n=7) or with developed 
MALT-L (mucosa associated lymphoid tissue lymphoma) (n=7), -/+ with or without an 
accompanying AID (autoimmune disease). Data are reported as median ± (IQR) and 
expressed as pg/ml.  




























Figure 5-17 Concentration of IL-6 in whole mouth saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=57) 
WMS; whole mouth saliva,Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis 
and xerostomia (n=13), SS; Sjögren’s syndrome (n=12), at risk of (n=7) or with developed 
MALT-L (mucosa associated lymphoid tissue lymphoma) (n=7), -/+ with or without an 
accompanying AID (autoimmune disease). Data are reported as median ± (IQR) and 
expressed as pg/ml.  





































Figure 5-18 Concentration of IL-8 in whole mouth saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=57) 
WMS; whole mouth saliva,Healthy controls (n=18), SNOX; sialadenitis, nodular osteoarthritis 
and xerostomia (n=13), SS; Sjögren’s syndrome (n=12), at risk of (n=7) or with developed 
MALT-L (mucosa associated lymphoid tissue lymphoma) (n=7), -/+ with or without an 
accompanying AID (autoimmune disease). Data are reported as median ± (IQR) and 
expressed as pg/ml.  




































Figure 5-19 Concentration of MCP-1 in whole mouth saliva from different groups when SS groups 
are combined (A) and when subgrouped (B) measured via performance assays. (n=57) 












Healthy c ntrols (n=18), SNOX; sialadenitis, nodular osteoarthritis and xerostomia (n=13), 
SS; Sjögren’s syndrome (n=12), at risk of (n=7) or with developed MALT-L (mucosa 
associated lymphoid tissue lymphoma) (n=7), -/+ with or without an accompanying AID 
(autoimmune disease). Data are reported as median ± (IQR) and expressed as pg/ml.  













 Associations of cytokines levels 
 Whole and parotid saliva levels 
There was a positive correlation between parotid and whole mouth salivary levels of IL-1α, -4, -
6  and MCP-1 of the subjects group (n=57), while there was no correlation between the salivary 
levels of the other cytokines (IL-1β and IL-8). A correlation was noted as well when SS 
subgroups were only included (n=26) for just IL- 4, -6 and MCP-1. On the other hand, no 
association was found in control group (n=18) except for IL-1α, results are summarised in table 
5-6. 
 
Table 5-6 Summary of correlations between parotid and whole mouth salivary levels of 




























levels   
All subjects 
(n=57)   
SS patients  








0.042   0.232 0.254   0.489* 0.046 
 




0.122   0.288 0.284   0.402 0.122 
 
IL-4   
 
0..279* 0.035   0.411* 0.037   0.044 0.861 
 




0.000   0.502** 0.009   0.43 0.075 
 




0.244   0.12 0.559   0.284 0.254 
MCP-1   
 
0.213* 0.012   0.458
*
 0.018   0.022 0.93 
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 Associations in relation to clinical parameters 
Cytokine levels were associated with the flow rates and ultrasound scores (USS). A negative 
correlation was found between all of the cytokines concentrations and flow rates (parotid and 
whole saliva) and it was statistically significant between IL-1α, -4, -8 and MCP-1 concentrations 
in parotid saliva and the parotid flow rate as well as between IL-4, -6 and MCP-1 levels in whole 
mouth saliva and whole flow rate. However, no correlation was found between cytokine levels 
in whole mouth saliva and USS but there was a positive correlation between parotid levels of 
only IL-6 and -8 and USS. A summary of findings is shown in table 5-7. 
Table 5-7 Clinical parameters in relation to cytokine levels in parotid and whole mouth 
saliva 
PFR; parotid flow rate, WFR; whole flow rate, USS; ultrasound score. *P <0.05, **P<0.01. 
 




















































































































































 Receiver operator characteristic (ROC) curve of cytokine levels 
ROC curves were constructed for the data (CT vs. overall SS), (CT vs. each subgroup 
individually) and (SS vs. the other 2 groups individually and grouped). Overall almost all of the 
cytokines (4/6) in parotid saliva can differentiate between the control group and SS groups but 
none were significant enough to differentiate between the SS group and the SS subjects who 
are at risk or developed lymphoma. The same finding was found regarding cytokine levels in 
whole mouth saliva where all of the cytokines where able to differentiate between CT groups 
and SS groups but none differentiated the SS subgroups from each other. A summary of their 
cut-offs and sensitivity, specificity is found in tables 5-8 and 5-9. 
 
Table 5-8 ROC curve analysis on cytokines in parotid saliva 
 
CT; healthy controls, SS; Sjögren’s syndrome, SS/MALT-L; SS with mucosa associated 
lymphoid tissue lymphoma, SS at risk; at risk of MALT-L, AUC; area under the curve. 
 
 
Salivary biomarkers in parotid saliva 
 










IL-1β       
CT vs.  overall SS 
 
> 0.735 60.42 65.63 67 0.01 
CT vs. SS at risk 
 
> 0.95 58.82 68.75 68 0.04 
IL-4      
CT vs.  overall SS 
 
> 14.15 65.31 66.67 70 0.002 
CT vs. SS/ MALT-L 
 
> 14.69 53.85 66.67 69 0.05 
IL-6       
CT vs.  overall SS 
 
> 1.60  65.31 63.64 74 0.0003 
CT vs. SS at risk 
 
> 2.51  52.94 90.91 67 0.05 
CT vs. SS/MALT-L 
 
> 2.8  53.85 93.94 81 0.001 
IL-8       
CT vs.  overall SS 
 
> 88.64 65.31 60.61 65 0.02 
CT vs. SS/ MALT-L 
 
> 88.6  69.23 60.61 72 0.02 
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Table 5-9 ROC curve analysis on cytokines in whole mouth saliva 
 
DCT; disease controls, SS; Sjögren’s syndrome, SS/MALT-L; SS with mucosa associated 

















CT vs.  overall SS 
 
> 624 73.08 60 70 0.003 
CT vs. SS/ MALT-L 
 
> 858.6 100 80 90 0.0009 
IL-1β  
     
CT vs.  overall SS 
 
> 552.6 64 60 65 0.05 
CT vs. SS at risk 
 
> 720.5 85.71 66.67 78 0.02 
CT vs. SS/ MALT-L 
 
> 844.5 85.71 80 86 0.003 
IL-4 
     
CT vs.  overall SS 
 
> 37.25 73.08 64.52 75 0.001 
CT vs. SS at risk 
 
> 38.65 71.43 70.97 83 0.006 
CT vs. SS/ MALT-L 
 
> 42.2  85.71 74.19 83 0.007 
IL-6       
CT vs.  overall SS 
 
> 14.4  80.77 64.52 74 0.001 
CT vs. SS at risk 
 
> 18.74 71.43 67.74 77 0.02 
CT vs. SS/ MALT-L 
 
> 27.49 100 77.42 85 0.004 
IL-8       
CT vs.  overall SS 
 
> 1376  69.23 70.97 75 0.001 
CT vs. SS at risk 
 
> 1995  85.71 80.65 91 0.0009 
CT vs. SS/ MALT-L 
 
> 1843  57.14 80.65 76 0.03 
MCP-1       
CT vs.  overall SS 
 
> 312.8 73.08 64.52 74 0.002 
CT vs. SS at risk 
 
> 316.  71.43 64.52 77 0.02 
CT vs. SS/ MALT-L 
 


































Figure 5-20 Schematic presentation of the work flow done in this study 
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 Discussion  
This study investigated whether an individual’s Sjögren’s syndrome (SS) phenotype could be 
defined on the basis of salivary cytokine biomarkers, whether it is related to risk of developing 
lymphoma and whether these cytokines are associated with parameters of salivary gland 
function. The approach taken was to screen saliva samples for a range of cytokines using 
different high throughput immunoassays and to try and quantify few via more sensitive assay. 
 Screening of cytokines 
 Cytokine antibody array 
A human cytokine array was utilized to evaluate various cytokines (102) providing guidance for 
the subsequent analyses, to the best of our knowledge, this is the first study on the discovery 
of candidate cytokine markers in parotid saliva of SS patients at different subgroups using the 
proteome profiler approach. 
It is worth noting that another study by Hu et al., (2011) have utilized the same approach; 
although the microarrays were designed to detect salivary autoantibodies rather than cytokines; 
however, the authors followed the assay by validation using ELISA similarly to the present study 
(multiplex assay). 
The data suggested a range of cytokines were up- regulated using a cut- off of 1.5 fold change, 
when SS, SS at risk and those who developed lymphoma were compared to each other and to 
healthy controls. Cytokines were easily visualised and tracked when ranked, and in order to 
narrow the selected cytokines, further comparisons via ANOVA and post-hoc tests were done 
to increase the power of analysis (tables 5-2 and 5-3). Results were prioritized, and from those 
assigned highest priority candidate cytokines biomarkers were selected for further validation; 
accordingly, ST2, vitamin D BP, CD30, Endoglin, IL-10, -22, - 32α/β/γ, MCP-1 and -3 were the 
final selection (figures 5-4 and 5-5).  
Bearing in mind the qualitative nature of this test where false positives and false negatives are 
easily included/excluded and the relatively limited number of samples (n=3 per group), the final 
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selection was viewed with caution. Reviewing the literature supported most of the findings but 
since the targets were primarily cytokines/chemokines; Endoglin (CD105 or TGF-β receptor), 
CD30 and vitamin D BP were excluded (refer to Appendix 19 for the relevance of these 
cytokines in published literature). The final selection was ST2, MCP-1, -3, IL-10, -22 and -
32α/β/γ. 
The next phase was to analyse those markers via a more quantitative test that has the capacity 
of measuring multiple markers at the same time. Bead- based assays (screening Luminex 
assays) were chosen and 15 cytokines were included after reviewing the literature and a total 
of 21 cytokines were selected. 
Unfortunately, IL-32α/β/γ was not available commercially as part of the analytes supplied with 
the Luminex kits, thus it was excluded (leaving 20 cytokines for analysis). However, it is worth 
noting that this pro-inflammatory cytokine was linked to SS through its over-expression in the 
cellular infiltrate of minor salivary glands of SS patients in comparison to healthy controls (Sfriso 
et al., 2007). Also, it was correlated to degree of inflammation (Murray-Brown et al., 2013). 
Interestingly Suppression of Tumorigenicity 2 (ST2) or (interleukin IL- receptor like 1) which is a 
Th2 related, cardiac biomarker and a specific ligand of IL-33 was found significantly increased 
when SS and control samples were compared to SS at risk of developing lymphoma (p=0.007 
and 0.005 correspondingly). The ST2- IL-33 axis has a role in SS pathogenesis and it has been 
reported in a number of studies; Awada et al., (2014) found increased levels of both IL-33 and 
ST2 in SS sera when compared to controls and up-regulated IL-33 expression in salivary glands 
of SS patients while ST2 expression was down-regulated. Similar findings regarding the serum 
levels were reported by Zhao et al., (2013) where even higher levels were observed in SS 
patients with interstitial lung disease and correlated with Rheumatoid factor and anti-SSB levels. 
Another study by Jung et al., (2015) has noted similar findings to the first study where serum 
levels and salivary gland expression of IL-33 and ST2 were higher in SS patients reporting a 
reduced expression in advanced inflammatory cases and some associations to clinical 
parameters. A more recent study has confirmed higher serum levels and a positive correlation 
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with disease activity (Margiotta et al., 2016). In addition, several studies have linked IL-33 and 
ST2 to cancer according to a recent review (De la Fuente et al., 2015). Taken together, the 
studies reported indicate the necessity of exploring the levels of IL-33 and ST2 in saliva as well, 
thus they were selected for the next assay. While the relevance of the rest of the cytokines (IL-
10 and -22) and chemokines (MCP-1 and -3) will be discussed further in detail in the following 
sections. 
 Review of literature 
Exploring Sjögrens Syndrome literature has identified a wealth of research suggesting several 
cytokines as potential biomarkers in SS activity and progression. Cytokines were frequently 
measured in serum and salivary gland biopsies which might be beyond the scope of this study 
but worth mentioning. The selection of additional cytokines for multiplex bead assays was based 
mainly on their relevance in saliva from other studies whilst stating their relevance in some of 
the other biological samples as well. Different methods were used to measure their levels, such 
as ELISA and multiplexed assays. (Summary of the identified cytokines in different samples of 
SS patients is found in Appendix 20 to 25. 
In regards to cytokines in saliva several studies were found, it was noticed that BAFF, TNF-α, 
IFN-γ, IL-1α, -1β, -2, -4, -5, -6, -8, -10, -12p70, -17A, -23, MCP-1, MIP-1α, MIP-1β, RANTES, 
TARC, MDC, MIG, IP-10, SDF-1α, and BCA-1 were the most studied cytokines/chemokines.  
From these published studies, IFN-γ, TNF-α, IL-1α, -1β, -2, -3, -4, -5, -6, -8, 12p70, -17A, -23 
and IP10 were selected. In addition to the analytes selected according to the cytokine antibody 
array results; IL-10, -22, -33, MCP-1, MCP-3 and ST2 were added. Their levels in relation to 






 Luminex Screening Immunobead assay 
 Several studies have used multiplex immunobead-based assays for detection of salivary 
cytokine biomarkers in different diseases such as oral cancer (Arellano-Garcia et al., 2008), 
periodontitis (Teles et al., 2009), alveolar bone loss (Ng et al., 2007), peri-implantitis (Fonseca 
et al., 2014), systemic lupus erythematosus (Marques et al., 2016), rheumatoid arthritis 
(Mirrielees et al., 2010), in even healthy individuals (Khan, 2012) and many others. 
Multiplex bead-based assays were selected to measure salivary cytokines because they are 
fast and convenient and can measure many analytes in small volumes which is very useful for 
some patients with diminished saliva volume (such as MALT-L risk and MALT-L patients). 
Furthermore, it is based on the ELISA principle, and multiplexing itself does not affect the 
sensitivity of assays (dupont et al., 2005).  
The results obtained from this study (screening of 20 cytokines) have revealed that several 
cytokines were below the lower detection limit of the assay (IL-5, -10, -17, and IL-12p70) and 
only one was above the higher limit of detection (IP-10), while the majority were detected at the 
lower end of the standard curve (table 5-5).  Only 5 cytokines (figures 5-6 and 5-7) have shown 
differences between the groups; IL-1α, -4, -6 and MCP-1 were increased in the overall SS group 
compared to the SNOX group where most of the readings were extremely low and even levels 
of MCP-1 in this group were lower than healthy controls. Difference in levels of IL-1α, -6, -8 and 
MCP-1 were detected between SS subgroups and SNOX as well. A possible explanation for the 
lower levels of cytokines in the SNOX group might be the presence of mucins or substances 
that interfered with the detection of these cytokines via screening assays.  Another more 
reasonable explanation is that these assays were not sensitive enough to detect them and this 
was confirmed by the later performance assays which extended the dynamic range of the 
cytokine assayed. Unfortunately, IL-10 was not detected in any sample while ST2 and IL-33 
were almost not detected in most of the samples according to the screening assay which 
contradicted the results acquired from the cytokine array. Unlike the cytokine array, no 
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differences were detected in levels of IL-22 and MCP-3 and only MCP-1 continued to show 
significant differences between the groups. 
Compared to the literature it was found that according to Bertorello et al., (2004), salivary levels 
of IL-10 in parotid saliva were increased in most of their SS patients (11/14) which contrasted 
our results obtained from our screening assays where IL-10 was not detected in all of the 
samples; this might be due to the semi-quantitate nature of our test (screening assays) versus 
more sensitive test (ELISA) used by their group. IFN-γ was increased in some patients (4/14), 
which is similar to our finding where we could detect it in some samples as well; healthy controls 
(4/17), SS patients (4/49) and none from the SNOX group. It would be worth re-testing IL-10 
and IFN-γ by performance assays to ascertain these results.  
On the other hand, Bertorello et al., (2004) study has reported the absence of IL-2 and -4 from 
parotid saliva which was different to our findings where we have detected IL-2 levels and they 
were not showing significant differences between the groups. In addition, differences in IL-4 
levels were detected in parotid saliva by screening then confirmed by the following performance 
assay favouring our results. And equivalent levels of IL-6 in parotid saliva were noticed when 
comparing our results obtained from the following performance assays to a study done by 
Grisius et al., (1997). Fox et al., (1994) have reported elevated levels of their measured 
cytokines in parotid saliva of SS patients when compared to healthy controls. Some of them 
supported our findings while some did not (e.g. reporting the absence of IL-4 and -5, while it 
agreed with our findings for IL-5 being below the detection limit but it contrasted IL-4. In addition, 
IP-10 levels were found to be higher in the SS group in comparison to healthy controls 




 Quantification of cytokine levels in SS 
 Parotid saliva 
To assess the accuracy of the results obtained from the Luminex screening assays more 
sensitive Luminex performance assays were performed on a narrower selection of cytokines 
(IL-1α, -4, -6, -8 and MCP1) which were chosen based on the significant differences detected 
between the groups according to the screening assays IL-1β was selected to evaluate the 
precision of the results (figures 5-8 to 5-13). Data acquired from the performance assays has 
confirmed the differences seen in parotid saliva levels of IL-4 and -6 between the overall SS 
group and SNOX and only IL-6 levels of overall SS group were elevated in comparison to 
healthy controls, which is similar to screening assay results. Though that was not the same for 
IL-1α, -8 and MCP-1 where insignificant higher levels were found. Surprisingly IL-1β levels have 
shown significant differences between overall SS and healthy controls even though it did not 
before via screening assays which might question the readings of other cytokines and might 
indicate the importance of re-analysing all the cytokines via performance assays specially (ST2, 
IL-10, -22, -33 and MCP-3) which were significant according to the cytokine array but not via 
Lumniex screening assay. None of the subgroups were showing significant differences but 
higher levels were found in all of the SS groups in comparison to controls.  
 It was noted that data was not as spread out as in screening assays with more comparable 
medians of healthy and disease groups being little higher in the healthy group (a possible 
explanation for the higher levels was mentioned in chapter 4). Correlation between screening 
and performance assays was not claimed by the company and was not advisable thus it was 






 Whole mouth saliva 
Given their detectable levels in parotid saliva, it was tempting to determine their levels in whole 
mouth saliva, thus it was done and the results have highlighted that the analysis of whole saliva 
can be more informative than the single gland-derived saliva. When the levels of those cytokines 
were measured in whole saliva via performance assays, higher levels of all cytokines were 
observed and this was explained previously in chapter 4. All analytes (IL-1α, -4, -6, 8 and MCP-
1) were significantly higher in overall SS group compared to healthy controls while only IL-4 and 
MCP-1 were higher compared to SNOX as well. IL-1β was insignificantly higher in overall SS 
group when compared to both control groups. Subgrouping has revealed some significant 
differences in IL-1α, -1β, -6 and -8 levels between SS patients who developed lymphoma and 
healthy controls and only IL-8 levels were significantly increased in SS patients who are at risk 
of developing lymphoma when compared to healthy controls (figures 5-14 to 5-19). Some 
potential outliers in parotid saliva data were re-analysed while those of whole mouth saliva were 
not. 
Taken together, the data obtained from the above-mentioned assays have shown no statistically 
significant differences between SS subgroups although elevated levels of most of the cytokines 
(in parotid and whole mouth saliva) was noted in the patients who are at risk or have developed 
lymphoma when compared to SS group. Increasing the sample size per group will be more 
informative in further studies. The low levels of cytokines in parotid saliva relate to the fact that 
this site is relatively free from bacteria and it might not be the major contributor of these 
cytokines. Whilst most of the cytokines have previously been measured in other biological 
tissue/fluids including whole mouth saliva of SS patients the present study is the first to measure 
them in parotid saliva of SS patients at different subgroups and compare with the SNOX disease 
control group. 
Comparing our results to the literature has identified comparable mean levels of IL-6 in whole 
mouth saliva obtained from our assays to those reported by Rhodus et al., (1998) for both SS 
and healthy control groups which was higher in the SS group. Furthermore, they have found 
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significant differences between SS and control groups regarding IL-2 levels, while we did not 
measure it in whole mouth saliva. On the other hand, higher IL-6 readings than ours were 
reported by Tishler et al., (1999) for SS group but comparable to control group.  Yet again it was 
significantly higher in the SS group. A similar finding was reported by Nguyen et al., (2008); IL-
6 was 3 fold increased more in SS group having again equivalent readings to ours. Another 
study by Streckfus et al., (2001) have found elevated levels of salivary IL-2 and -6 in SS patients 
than the control and SS patients with another autoimmune disease. Comparison between our 
results to theirs was not applicable due to differences in units (pg/ml vs pg/mg). In addition Boras 
et al., (2004) have found elevated salivary IL-6 levels in SS when compared to controls while 
serum levels did not differ. 
Median levels of MCP-1 in whole mouth saliva of SS patients were higher than healthy controls 
which reinforced by the results of a study by Hernandez-Molina et al., (2011), the medians of 
both groups were comparable to our values being slightly higher in their group as seen on table 
5-11. No differences were reported between SS groups with or without autoimmune disease 
and this supported the findings of the present study. Furthermore, in contrast to the present 
study, Lee et al., (2010) have reported insignificant higher MCP-1 levels in SS group compared 
to healthy and non-SS sicca controls whilst IL-8 was significantly different supporting our results.  
A Japanese group conducted two studies that explored the levels of multiple cytokines in SS 
(Moriyama et al., 2012). They have found that levels of IL-1β, -4, -6 and -8 were higher in SS 
when compared to controls; this was similar to the present results except for IL-1β which was 
insignificantly higher in the SS group.  More recently, the same group found that IL-10 and  -4 
were higher in patients with strong focus scores and included 2 more groups (radiation induced 
xerostomia and xerostomia associated with neuropsychiatric disorders and or drugs) reporting 
higher levels of all of the measured cytokines (Ohyama et al., 2015). Again IL-4 was elevated 
in patients with high focus scores together with IL-5, -1β and -12p70 per the previous study. 
Kang et al., (2011) have reported higher levels of all of their measured cytokines when SS was 
compared to sicca and control groups.  Interestingly the above two studies have found higher 
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levels of IL-17 in SS compared to controls but their mean readings differed; ~1.3 pg/ml in Kang 
et al., (2011) vs. 420 pg/ml in Ohyama et al., (2015) for SS group. On the other hand Nguyen 
et al., (2008) have found no differences between groups demonstrating low levels of IL-17 (~2.5 
pg/ml) in whole mouth saliva. It is worth noting that IL-17 levels were not detected in parotid 
saliva when screening assays were done in the present study and IL-17 levels were extremely 
low and almost undetectable in parotid and whole mouth saliva of a few samples when the 
performance assay (trial kit) was used (data not shown). It would be interesting to measure their 
levels in whole mouth saliva of a larger group and compare them with other studies. 
 Interestingly a previous study compared both types of saliva in healthy individuals and found 
similar cytokine levels in both while some such as IL-1α were higher in whole mouth saliva being 
a pro-inflammatory cytokine that is produced by epithelial cells in which is in agreement with our 
results (Wozniak et al., 2002). 
The above-mentioned studies are summarised in tables 5-10 and 5-11, that show a list of 
reports indicating the readings of cytokines; those studies included 3 studies on parotid saliva 
and 8 studies on whole mouth saliva together with results obtained from the present study for 
detailed comparisons. Levels of salivary cytokines stated in those studies have varied widely, 
and it would seem that much of this apparent discrepancy might be due to differences in saliva 
handling and processing. It has been suggested that mucins or related components in saliva 
may interfere with cytokine detection (Ng, et al. 2007, Wozniak, et al. 2002). This might explain 
the absence of readings for some uncentrifuged samples in the present study. The effect of 
centrifugation was viewed where it was noted that better readings with sufficient number of 
beads were obtained when samples where centrifuged (data not shown), this was found not 





The role of the measured cytokines in SS pathogenesis was mentioned in chapter 1where we 
have demonstrated the apparent activation of the different classes (Th1/Th2) exerting their 
effect at different stages of the disease; Th1 being dominant response (initiation phase) as 
reported by the previous studies while Th2 is involved in disease progression during the early 
stages of inflammation, provoking B cell activation and autoantibody production, which may 
diminish during more advanced phases, but possibly re-emerge in the event of lymphoma 
development. Furthermore, chemokines play important roles in the induction of local 
inflammation. It is worth mentioning that although the Th1/Th2 concept is useful in 





Table 5-10 Cytokine levels measured in parotid saliva of SS patients by other studies 
ELISA; enzyme-linked immunosorbent assay, Gp; group, CT; healthy controls, SS; Sjögren’s syndrome, PBS, primary biliary cirrhosis, SNOX; 











Mean  Subjects IL-1α IL-1β IL-4 IL-6 IL-8 MCP-1 
Fox et al  
1994 
  ELISA   Mean ± SEM pg/ml   CT  (n=11) 35±18  ----- ND 14±7  ----- ----- 




















       PBC (n=31) ----- ----- ----- 1.07 ----- ----- 
       SS  (n=15) ----- ----- ----- 16.21* ----- ----- 
Bertorello 













































112.2± 28.2  
 
418.9± 84.4 
      SNOX (n=15) 12.4± 5.2  3.4± 2 11.6±1.2 1.5± 0.2 96.8± 19.4  231.3± 47.8 
      SS (n=49) 27.5± 9.4 19.6± 7.2* 21.2± 2.4*  13.8± 3.4* 944.4± 584.4   879.6± 190.4 
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Mean ± SEM pg/ml 
 
CT  (n=10)  ----- 
 
 ----- 
 ----- ----- 11.6± 2.8 ----- ----- 






Mean ± SEM pg/ml 
 
CT  (n=19)  ----- ----- ----- 12.6± 6.8 ----- ----- 
      
SS  







  Luminex 
assay  
  Mean  pg/ml   CT  (n=19)  -----  ----- ----- ~ 10  ----- ----- 
      SS  (n=21)  -----  ----- ----- ~ 30*  ----- ----- 






 Median pg/ml  CT  (n=25)  -----  ----- ----- ----- ~ 250 ~ 500  
  sicca (n=30)  -----  ----- ----- ----- ~ 400 ~ 400  
  SS  (n=30)  -----  ----- ----- ----- ~ 700* ~ 1500 







Mean ± SEM pg/ml 
 CT  (n=25)  -----  ----- ~ 0.1 ~12± 1.5  ----- ----- 
   sicca (n=30)  -----  ----- ~12± 5* ~14± 1  ----- ----- 













CT (n=32)  -----  -----  -----   -----  ----- 376.8(14.7-3502)    
pre-  (n=14)  -----  -----  -----  -----  ----- 1015(203-10000)*    
SS (n=44)  -----  -----  -----  -----  ----- 738.8(3.2-13773)*    
SS+ (n=30)  -----  -----  -----  -----  ----- 1068(15.9-10802)* 
      SAD (n=49)  -----  -----  -----  -----  ----- 784(60.4-14277)* 
Moriyama 




Mean ± SD pg/ml 
 CT  (n=15) ----- ~ 50± 50 ~ 10± 0.1 ~ 40± 5 ~ 80± 50 ----- 
      SS  (n=36) ----- ~ 340± 40* ~70± 40* ~280± 10* ~480± 50* ----- 
Ohyama et 
al. 2015   
CBA  
  
Mean ± SD pg/ml 
  
 
CT (n=36) ----- ~370± 60 ~10± 20 ~60± 15 ~480± 40 
  
----- 
       RX (n=22) ----- ~100± 40 ~2± 2 ~45± 10 ~260± 40 ----- 
       XND (n=30) ----- ~240± 40 ~1± 1 ~40± 5 ~500± 100 ----- 
























(n=18) 528.9± 117.5 462.6± 87.6 39± 3.1 16.2± 4.7 1108.9± 221.1 408.4± 100.1 
    
  
 
SNOX (n=12) 633.4± 134 759.3±180.3 34.9± 2.2 25.4± 6.6 1307.3± 263.7 250.7± 39.6 
    
  
 
SS (n=25) 1154.6± 164 1445.2± 314.2 50.8± 3.2 53.4± 12.8 2696.7± 378.7 810.9± 151.9 
      
Median   
  




    
  
 
SNOX (n=12) 1353 270.3 
       
SS (n=25) 1930 545 
Table 5-11(Continued) 
ELISA; enzyme-linked immunosorbent assay, Gp; group, CT; healthy controls, SS; Sjögren’s syndrome, SS+; SS with other autoimmune disease, 
pre; preclinical SS, SAD; systemic autoimmune disease, RX, radiation induced xerostomia, XND; xerostomia associated with neuropsychiatric 






Correlating whole and parotid levels obtained from performance assays has identified a 
positive correlation of IL-1α, -4 and -6 when all groups were compared and that correlation 
was found with the SS groups in levels of IL-4 -6 and MCP-1 while IL-1α was correlated in the 
healthy group. This suggests that parotid glands might be a major contributor of these 
cytokines especially in case of local inflammation as in SS patients. The lack of specific 
correlations of the other cytokines between whole and parotid saliva in matched samples from 
the same subjects suggests that contributions to saliva by the parotid gland can vary from 
subject to subject and amongst the cytokines themselves having different sources (table 5-6). 
Relating cytokine levels with the clinical parameters has shown a generalised negative 
correlation between flow rates and cytokine levels in parotid and whole mouth saliva and it 
was statistically significant for IL-4 and MCP-1 in both types of saliva while parotid levels of 
IL-1α and -8 were correlated with the parotid flow rate whereas IL-6 levels in whole mouth 
saliva was correlated with the flow rate suggesting that the they might be related to salivary 
function.  
Their association with ultrasound score has revealed an interesting positive correlation 
between IL-6 and -8 parotid levels and ultrasound scores of matched disease subjects while 
none of the whole mouth saliva cytokines were correlated (table 5-7). This might confirm their 
roles as mediator in inflammation specifically being of glandular origin. To our knowledge this 







 ROC analysis 
To know the possibility of using cytokines for monitoring SS, Roc curve analysis was done 
and has demonstrated that the diagnostic accuracy of cytokine levels in both parotid and whole 
mouth saliva had rather a generalised poor-fair ability in differentiating control subjects and 
SS (overall and subgroups). However, IL-6 levels of parotid saliva had a good ability to 
differentiate between controls and SS patients who developed MALT-L with 93.9% specificity 
and a low sensitivity of 53% even a higher cut off in whole mouth saliva levels with a good 
ability to differentiate between the same groups (CT vs. SS/MALT-L).  
IL-1β, IL-1α, IL-4, IL-8 and MCP-1 have shown a similar good accuracy in differentiating 
between the same groups, while only IL-4 and IL-8 could differentiate between controls and 
SS at risk of developing MALT-L being good for IL-4 and even excellent for IL-8. Cytokine 
levels could not differentiate between control groups and SS neither between SS subgroup 
and those who are at risk or developed MALT-L (tables 5-8 and 5-9).  
Despite having performed the test for diagnostic accuracy, the readings (cut- offs) should be 












Cytokine array system and bead-based assays might become powerful tools to extensively 
describe the SS cytokine profile and to assess the role of these proteins in the pathogenesis 
of the disease. Reliable quantification of a cytokine is crucially dependent on its abundance 
which is true for sensitive performance assay where different concentrations were noted 
between different types of samples. On the other hand, an important downside of bead-based 
technologies such as Luminex is that by having predefined proteins of interest, researchers 
may introduce a major selection bias into their study but this was only partially true for our 
study where panels were customised based on selected cytokines and following reviewing the 
literature (Maecker et al., 2012). 
A lot of research has been published in the last decade linking SS with cytokines and 
chemokines in human body fluids or in tissues. Although the mechanism(s) by which these 
disease indicators come to exist in saliva has not been explained fully, our findings indicate 
that saliva may represent a significant source of discriminatory biomarkers for local, systemic 
inflammation in SS. However, it is important to note that lack of specificity of these molecules 
for a given disease; being pleiotropic, exhibiting a very similar pattern in different clinical 
circumstances and their rapidly changing levels are the major limitations of cytokine 
measurement in practical clinical setting. Nonetheless these cytokines would be very useful 
in preliminary stratification of SS patients for clinical trials for example allowing the exploration 
of an immune, an inflammatory reaction or even a precancerous and cancerous involvement 
where it takes place such as in parotid glands in SS patients. Furthermore, it ought to enhance 
the design of special, individualized, cytokine targeted therapy for these patients (Bienvenu et 
al., 2000). It would be interesting to explore the cytokine levels of the other salivary glandular 
origins for comparisons in further studies. In addition, correlating the salivary and serum levels 





Furthermore, tests using ELISAs where each cytokine is measured individually could be 
undertaken in future studies. However it is worth noting that some studies have shown a good 
association between the two techniques (multiplex and ELISAs), at least for some cytokines 
(dupont et al., 2005, Dossus et al., 2009). While some have not (Liu et al., 2005). Similarly to 
inconsistencies existing between ELISA kits from different companies due to their differences 
in antibody pairs (dupont et al., 2005); a low association between these two techniques may 
be due to the different antibodies used as well. Even though the possibility of using ELISA 
assays would have identified additional associations between SS and cytokines measured via 
screening assays, in particular those with levels below the limit of detection of the assay, i.e., 
IL-5, -10, -17, and IL-12p70, it should be noted that if high-sensitivity assays (performance) 
were used for these cytokines they might have been detected and this warrants further 
investigation. Still it is not clear that current ELISA assays would have been better able to 
measure the very low levels of these cytokines than the multiplex assay used, a comparison 













 Problems encountered with methods 
It was planned to evaluate the levels of the rest of the cytokines/chemokines found in the 
literature with the intention of focusing on BAFF, SDF-1α, and BCA-1 due to their relevance 
in MALT-L via Luminex screening assays. However, the results obtained from the screening 
assays needed further investigation thus it was decided to proceed with the performance 
assays instead of doing more screening assays and it would be of great importance to study 
the rest of the cytokines in parotid saliva in future studies. 
An attempt to extrapolate the standard curve for Luminex screening assays to involve 
cytokines with readings below the lower limit of detection according to the manufacture’s 
recommended dynamic range appeared to have overestimated the differences between the 
groups thus it was omitted and the usual protocol (standard curve) was followed. Another 
attempt to evaluate the accuracy of the results obtained from the Luminex screening assays 
via spike and recovery tests was unsuccessful (data not shown). It is assumed that some 
precision is sacrificed in exchange for more flexibility in panel creation with a broader selection 
of analytes (20 cytokines). Despite that it is argued that the sample values generated between 
different lots of screening assays will be consistent to each other and would therefore be a 
useful tool for longer term studies. 
Upon selecting the cytokines for the final Luminex performance assays, IP-10 required an 
additional panel which was not possible due to sample volume restriction thus it would be of 
great importance to measure it in future studies. 
Our preliminary trials (data not shown) where some mucus plugs (from parotid glands) were 
tested have shown no results.  Those samples were analysed in different condition; either 
diluted and centrifuged with ceramic beads or filtered, yet again no results were obtained, a 
possible explanation for some samples was due to their small volume thus they became over 
diluted or fixed on filter papers as for other samples it might be that they needed even more 
treatment. Therefore, it would be most interesting to find a way to treat these samples and 
successfully analyse them in future studies.  
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6 General discussion and future work  
 General discussion 
In Sjögren’s syndrome, functional assessments such as salivary flow and ultrasound are 
amongst the inter-related factors which describe glandular hypofunction. Because it 
represents an ideal milieu for diagnosing a disease that affects the salivary glands, there is a 
great interest towards using saliva itself as a diagnostic fluid for SS. Parotid saliva is of great 
importance in cases of longer disease duration and those with or at risk of MALT-L.  Although 
some of these clinical parameters and salivary biomarkers have been investigated before, 
researches have focused on one clinical aspect at a time and involved whole saliva rather 
than individual glandular saliva, this thesis has explored these clinical parameters and 
biomarkers and comparisons were done between whole and parotid gland saliva. The novelty 
of this thesis relies on analysing different SS subgroups and comparing them to a SNOX 
disease control group which has not commonly been reported by other studies. MALT-L is one 
of the most serious manifestations of SS thus identifying/predicting it is of great significance 
and this was examined throughout the thesis where patients who were defined as being at 
risk of developing lymphoma and those who had already developed it were compared to SS 
patients. 
 The overall aim of this thesis was to enable a better understanding of the disease activity and 
progression via identifying different biomarkers whether they were clinical or laboratory/ 
sialochemical biomarkers.   
 Clinical markers 
Chapter 3 investigated the potential use of the salivary gland assessment tests (WFR, PFR, 
CODS and USS) in discriminating SS and non- SS sicca patients as well as to differentiate 
between the different subgroups of SS and determine whether there is an overall association 
between them. All parameters of the overall SS group showed a significant difference when 
compared to disease controls attributed mainly to the advanced subgroups of SS (SS at risk 
and MALT-L groups) which showed even differences when compared to the SS subgroup 
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mainly the MALT-L group in all parameters while at risk group was showing a difference in 
USS and WFR but not the others. No differences were detected between SS subgroup and 
disease control group regarding WFR and PFR which is in agreement with other studies (van 
den Berg et al., 2007, Osailan et al., 2012, Ohyama et al., 2015, Billings et al., 2016). 
Differences were detected between SS subgroup and disease controls regarding CODS 
similarly to Osailan et al., (2012) and USS as well and the latter is a novel finding. All of the 
parameters showed no differences between at risk and MALT-L groups.  There was a strong 
negative correlation observed between CODS and flow rates and a positive correlation with 
USS suggesting the reliability of using CODS as a sensitive tool that can be easily done and 
this was supported by another study (Osailan et al., 2012).  The positive correlation between 
WFR and PFR was found which is a similar finding to Vissink et al., (2003) and Kalk et al., 
(2002a), while it contrasted other studies  (Kalk et al., 2001a, Kalk et al., 2002c, van den Berg 
et al., 2007). These studies have found no relation between flow rates attributed to the 
involvement of parotid glands in the later stages but in our study a lot of the patients were 
considered at their later stages and the correlation was stronger in case of the advanced 
stages of SS.  A moderate negative correlation was noted between both flow rates and USS 
reflecting an association between the output of the gland and its clinical picture. The diagnostic 
accuracy of USS and its relation to focus score of biopsy results was investigated.  It can be 
concluded that USS would be the ideal non-invasive test to discriminate and monitor SS 
patients in general (showing high sensitivity and specificity) replacing sialography and 
scintigraphy with a good correlation and agreement with focus score in concordance to others 
(Cornec et al., 2013, Delli et al., 2015, Jousse-Joulin et al., 2016, Astorri et al., 2016).  The 
present study suggested a score of 4 was found to be an optimum cut- off that could 
differentiate SS from non- SS patients while higher scores usually reflecting advanced stages. 
A longitudinal study on dry mouth patients at 5 and 10-year time-points was completed to 
investigate worsening in salivary function over time. In patients with a longer disease duration 
it SS is a slowly progressing disease and this was proven in this follow- up study where all of 
the parameters remained relatively the same over the period of 5 years although some 
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individuals may display flare ups and remissions as in other rheumatic diseases which is in 
agreement with other studies (Bouma et al., 2003 , Theander et al., 2005, Pijpe et al., 2007, 
Haldorsen et al., 2008).  The small number of patients involved in the 10-year follow- up study 
precludes definitive conclusions but the result was in agreement with other studies showing 
no significant differences between time 0 and 10 years later (Gannot et al., 2000, Haga, 2002).  
Although these clinical markers might be able to differentiate between different SS subgroups 
at one point (cross-sectional), the lack of change in clinical parameters in the longitudinal study 
suggests that these clinical biomarkers may give limited utility in identifying patients at risk or 
having MALT-lymphoma.   
 Sialochemical biomarkers 
Initially a proteomics analysis of saliva was performed since this approach can identify novel 
potential protein biomarkers which might differentiate SS patients from those who are at risk 
of developing MALT-L and discriminating both disease groups from healthy controls.  The 
proteomics data generated by LC-MS/MS analysis of both runs suggested that a range of 
proteins were up-regulated and down-regulated when different subgroups of SS were 
compared to healthy controls; focusing on the logged transformed cut- offs and the up- 
regulated proteins in both disease groups (SS and SS at risk) when compared with healthy 
controls, Actin cytoplasmic 2, Ig γ-1 chain C region, S100-A8, and S100- A9 were selected 
having considerable potential as biomarkers as reported previously (Al-Tarawneh et al., 2011, 
Katsiougiannis and Wong, 2016). Further selection of candidate biomarker was based on 
having cut- off of ≥ 2 when SS patients were compared to SS patients at risk in both runs, thus 
S100-A8, and S100- A9 were the final selection and S100A8/A9 heterodimer was chosen. 
Candidate biomarker was verified by ELISA; stratification of different stage of SS (SS, at risk 
and MALT-L subgroups) as well as differentiating them from healthy and disease control 
(SNOX) groups. S100A8/A9 ELISA analysis of parotid saliva supported the proteomics 
findings showing significant differences between overall SS group and both disease and 
healthy controls. Although subgrouping SS has revealed that only SS patients at risk and those 
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who already developed MALT-L were increased when compared to healthy controls only but 
not disease controls while SS subgroup has shown no significant difference.  S100A8/A9 
ELISA analysis of whole mouth saliva has revealed a no significant difference in the overall 
SS group when compared to both healthy and disease control groups showing similar values 
to Muller et al., (1993) and Sweet et al., (2001). Similar trends were found by another group 
who reported values that were 10 fold higher than ours which might be due to different sample 
collection and handling (Cuida et al., 1993, Brun et al., 1994, Cuida et al., 1995, Cuida et al., 
1997). Only SS who already developed MALT-L subgroup has shown a difference when 
compared to both healthy and disease control groups as well as to SS sub group suggesting 
its important link to cancer development (Salama et al., 2008, Bresnick et al., 2015). 
Investigation of the association between S100A8/A9 and overall salivary gland function 
revealed a weak negative correlation between PFR and S100A8/A9 parotid levels. However, 
no association was found between WFR and S100A8/A9 levels in whole saliva which may be 
due to other contributions to levels in WMS. USS showed no correlation to both saliva (parotid 
and whole) levels.  A strong correlation was found between parotid and whole saliva levels of 
S100A8/A9 in SS patients suggesting a salivary gland origin or neighbouring tissue source 
since the glands are the major site of inflammation in this group. On the other hand, controls 
showed no correlation.  Proteomics is less effective in identifying cytokine biomarkers which 
tend to be present at lower levels in saliva and other biofluids.  Therefore, potential parotid 
salivary cytokine biomarkers were examined using a cytokine antibody array approach to 
identify SS sub groups (SS, SS at risk and already developed MALT-L) and to differentiate 
them from healthy controls.  Using a cut- off of 1.5 fold change and p- value, a range of 
cytokines were up- regulated when SS, SS at risk and those who developed lymphoma were 
compared to each other and to healthy controls (9 cytokines/proteins and 5 cytokines were 
included).  Further screening of the selected cytokines as well as other cytokines (relevant to 
literature) was performed and levels were compared in SS subgroups to healthy and disease 
controls (SNOX) via bead- based multiplex antibody assays.  Most of the cytokines were at 
the lower end of detection showing no differences between the groups but IL-1α, -4, -6 and 
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MCP-1 showed differences between the overall SS group and SNOX while only IL-6 was 
increased in comparison to healthy controls as well. The cytokines have shown differences 
with controls when SS was subgrouped as well as for IL-8. No significant difference was found 
between all of SS subgroups, a tendency toward increased levels of salivary cytokines was 
noted in MALT-L sub group. Verification of the previously significant cytokines while adding 
one more cytokine (IL-1β) from the non-significant group (total 6 cytokines) using more 
sensitive assays (bead- based performance) on a slightly larger number of samples yet similar 
groups (healthy, disease controls and all three SS subgroups) was done with comparisons 
between parotid levels and whole mouth levels.  Some cytokines such as IL-6, -4 continued 
to show significant difference compared to SNOX and IL-6 compared to healthy group as well. 
Interestingly IL-1β showed significant increase of the overall SS group. Subgroups of SS 
showed no differences when compared to other control groups or between each other, 
however, a tendency toward increased levels was observed in MALT-L subgroup.  All cytokine 
levels in whole mouth saliva were significantly increased in the overall SS group compared to 
healthy control this time while only 2 cytokines were increased in comparison to SNOX (IL-4 
and MCP-1). Subgrouping of SS has revealed several differences especially in the MALT-L 
subgroup.  Despite using different techniques a number of studies reported similar findings 
(Fox et al., 1994, Grisius et al., 1997, Tishler et al., 1999, Bertorello et al., 2004, Nguyen et 
al., 2008, Lee et al., 2010, Kang et al., 2011, Moriyama et al., 2012, Ohyama et al., 2015 ). 
The association between those 6 cytokines with overall salivary gland function as well as 
between its parotid and whole saliva levels was investigated and generalised negative 
correlation between flow rates and cytokine levels in parotid and whole mouth saliva was 
observed. A positive correlation between ultrasound scores and IL-6 and -8 levels in parotid 
saliva was noted while none of the whole mouth saliva cytokines were correlated suggesting 
that parotid cytokines were mediators in inflammation specifically of glandular origin.  Some 
parotid and whole salivary cytokines levels correlated while others did not suggesting that 
contributions to saliva by the parotid gland can vary from subject to subject and that glands 
might be a major contributor of correlating cytokines especially in case of local inflammation 
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as in SS patients ,which might be linked with disease activity in different subjects. It is worth 
noting that levels of cytokines and S100-A8/A9 were detected in patients with previous 
lymphoma, in most cases in complete remission. This increase in saliva level could be, at least 
in part, not related to the activity of the lymphoma, but could be constitutional and persist after 
the lymphoma was cured which could be genetically linked.  The diagnostic accuracy for each 
test mentioned in all of the chapters was done establishing a test threshold for disease 
detection by providing test sensitivity and specificity. Therefore, in this study we used Receiver 
Operating Characteristic (ROC) curve in order to determine the best cut-off point for a given 
biomarker values to generate an optimum cut-off that provides a maximum sensitivity and 
specificity. The differences between the levels of different markers measured in parotid saliva 
could not be attributed to an increased protein concentration in patients with deficient saliva, 
because their protein concentrations were similar in all groups (figure 4-11, chapter 4). 
Although protein concentration of whole mouth saliva did differ between the groups (especially 
SS with MALT-L) (figure 4-11) a comparison of protein S100A8/A9 levels between the groups 
was done after adjusting the values to ng/mg and showed no major differences between those 
obtained via ng/ml. Cytokine values were not adjusted thus their levels for MALT-L group might 
be related to the high total protein concentrations of saliva and possibly reduced fluid 
secretion.  The biomarker studies have a limitation since patients may have been under 
immunosuppressor therapy. This notwithstanding, the studies showed that no difference was 
found between treated and untreated patients but it might be due to the insufficient power of 
the study to determine an effect of drugs in this rather small and heterogeneous group of 
patients. However, the difference between treated and untreated patients was not verified 
regarding the clinical parameters (chapter 3).   Studies that have been carried in this thesis 
were the first that have compared the levels of salivary cytokines and S100-A8/A9 in different 
SS subgroups; at risk and those who developed MALT-L in SS patients as well as in SNOX 
patients, that contribute to a better understanding of disease activity and progression.  The 
applicability of sialometry and sialochemistry as diagnostic instruments varies in different 
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clinical SS subgroups.  While the former might be informative in case of advanced disease, 
the latter is often useful in the early phases of the disease.  
In the present studies, we have focused on the advanced subgroups of SS indicating that both 
sialometry and sialochemistry are useful tools; proteomic analysis, cytokine array system and 
screening bead-based assays are becoming powerful tools to extensively describe the SS 
protein/cytokine profile assessing their role in SS pathogenesis. While ELISA remains one of 
the gold standard tests in analysing biological samples, multiplex assays might offer several 
advantages as well exhibiting a good correlation with ELISA. One of the more captivating 
aspects in the search of salivary biomarkers is information achieved from oral saliva and 
immunologic factors. Therefore, we found it of importance to study the salivary glands and 
their secretions to better understand the inflamed processes involved. Although the 
mechanism by which these disease markers come to exist in saliva has not been clarified fully, 
our findings suggest that it may represent a significant source of discriminatory biomarkers for 
















 Future work 
This thesis has shed light on the potential use of multiple biomarkers in differentiating SS 
subgroups. It can be taken further by focusing on the patients at risk group in order to 
understand the mechanisms behind the observed compositional changes.  Furthermore, an 
assessment of a possible relationship between individual salivary components such as the 
SA100A8/A9 and candida count might provide a further insight as to whether this biomarker 
is of significant functional relevance. 
Moreover, the results of this thesis give rise to further areas that need investigation: 
1. Further analysis of the variations in the parameters (WFR, PFR, CODS and USS) 
assessed in this thesis are necessary and the inter- and intra- individual and observer 
variability should be considered in order to estimate whether differences observed are 
the result of individual variations of the examination technique or real individual 
variations.  
2. The diagnostic accuracy of USS should be investigated on a larger cohort of patients 
and further its correlation with histology especially major salivary gland biopsy 
assessed in order to further reinforce results obtained from the present study indicating 
its usefulness as a simple non-invasive test. Different USS scoring systems should be 
compared in order to develop a consensus with consistent procedures.  
3. Further follow- up longitudinal studies of greater than 10 years on larger group of 
patients are required in order to establish whether there is functional loss over time.  
4.  Further studies of more SNOX patients compared with SS are required in order to 
further verify it as a distinct disease entity.  
5. Considering the presence of other disease modifying factors such as the effect of 
treatment on the outcome measures; differences between treated and untreated 
patients should be studied fully. Among the most used treatments; steroids, 
immunosuppressants and hydroxyquinoline would be included. Patients would be 
categorised according to the duration of treatment. Standardization of sample 
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handling, collection and processing is still required for further studies and special 
attention to the effect of centrifugation would be of great importance.  
6. Further analysis with different proteomic methods would achieve more reliable results 
especially for validating salivary biomarkers an example of which would be Tandem-
mass-tagging or labelling methods. An integrated proteomic analysis of the glandular 
tissue or another exocrine secretion such as tears should be performed and compared 
with saliva to investigate the differences between their pathological involvements.   
7. The relationship of salivary S100A8/A9 with the focus score and possibly tear fluid 
S100A8/A9 levels should be clarified to better understand SS glandular disease 
activity as well as analysing other glandular salivary S100A8/A9 levels (e.g. 
submandibular/sublingual glands) in order to identify the possible analyte origins and 
to compare the differences between the glandular secretions. Individual levels of S100-
A8 and -A9 should be analysed in order to determine their relative abundance in 
relation to the heterodimer of both.  
8. Performing cytokine array tests on whole mouth saliva with comparison to results 
obtained from the multiplex bead- based assays would give some insight about the 
reliability of these tests as first-choice screening tests. Re-testing cytokine levels 
(showing low levels or 0 values) which were tested via screening bead- based assays 
via more sensitive bead-based assays to ascertain their levels. Testing the accuracy 
and reproducibility of bead- based assays is required via spike and recovery tests in 
order to verify the applicability of using these tests for further research. Special interest 
in measuring BAFF, SDF-1α, and BCA-1 levels in parotid saliva would be of great 
importance since they were frequently linked to advanced subgroups of SS. Re-
measuring chemokine levels especially CXCL10 (above the detection limit) would 
provide further insight to the extent of chemokine involvement. Considering other 
salivary/exocrine sources of cytokines will further aid in understanding of their 
pathogenic roles.  Re-analysing the same tests specifically ELISA and bead-based 
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performance tests could be performed on a larger cohort of patients in order to improve 
the reliability of these tests and demonstrate their utility. 
9.  It may well be that a multifactorial model including salivary biomarkers and clinical 
parameters may have better accuracy than the result of a salivary test alone in order 
to relate the pathologic process with the clinical picture of this disease where saliva 
would be the most logical sample for correlation.  
10. Important consideration would be proper testing and handling of mucoid plugs since it 
was found in a considerable number of patients specially those who are with longer 
disease duration, at risk or already developed MALT-L, these plugs would provide 



















In conclusion, it is known that SS is a slowly progressing disease and the present follow- up 
study has shown that all of the clinical parameters remained relatively the same over a period 
of time in patients with longer disease duration. The data implicate a greater role of these 
clinical parameters in differentiating SS subgroups from other dry mouth patients especially 
the advanced SS subgroups (at risk and who developed MALT-l). Furthermore, it can be 
concluded that USS would be the ideal non-invasive test to discriminate and monitor SS 
patients in general especially in the advanced subgroups. 
The aim of developing salivary diagnostics remains an important goal which offers a number 
of potential applications. The present study evaluated the use of some potential salivary 
biomarkers (cytokines and SA100A8/A9). This study supports previous reports indicating the 
value of saliva as a diagnostic tool in Sjögren’s syndrome. Salivary levels of S100A8/A9 reflect 
more local inflammatory activity showing the greatest difference between groups in parotid 
saliva. Salivary cytokine levels were not clear as with the S100A8/A9 levels, no pattern could 
be drawn from the changes in cytokine levels. However, levels of IL-6 and -4 in parotid saliva 
continued to show significant differences using different immune-based assays. The levels of 
cytokines tend to show more prominent differences in whole mouth saliva due to the 
contribution from their other sources. Further work is required particularly to improve the 
sensitivity of their diagnostic applications and to explore further combining these results with 
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Revised international classification criteria for Sjögren’s syndrome 
I. Ocular symptoms: a positive response to at least one of the following questions: 
• Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
• Do you have a recurrent sensation of sand or gravel in the eyes? 
• Do you use tear substitutes more than 3 times a day? 
II. Oral symptoms: a positive response to at least one of the following questions: 
• Have you had a daily feeling of dry mouth for more than 3 months? 
• Have you had recurrently or persistently swollen salivary glands as an adult? 
• Do you frequently drink liquids to aid in swallowing dry food? 
III. Ocular signs: that is, objective evidence of ocular involvement defined as a positive result for at 
least one of the following two tests: 
• Schirmer’s I test, performed without anaesthesia (<5 mm in 5 minutes) 
• Rose bengal score or other ocular dye score (>4 according to van Bijsterveld’s scoring 
system) 
IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal 
lymphocytic sialoadenitis, evaluated by an expert 
• histopathologist, with a focus score >1, defined as a number of lymphocytic foci (which 
are adjacent to normal-appearing mucous acini and contain more than 50 lymphocytes) 
per 4 mm2 of glandular tissue 
V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a 
positive result for at least one of the following diagnostic tests: 
• Unstimulated whole salivary flow (<1.5 ml in 15 minutes) 
• Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or 
destructive pattern), without evidence of obstruction in the major ducts 
•  Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed 
excretion of tracer. 
 
VI. Autoantibodies: presence in the serum of the following autoantibodies: 
• Antibodies to Ro(SSA) or La(SSB) antigens, or both 
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Appendix 3 (continue) 



















Revised rules for classification 
For primary SS 
In patients without any potentially associated disease, primary SS may be defined as follows: 
a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item IV 
(Histopathology) or VI (Serology) is positive 
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, VI) 
c. The classification tree procedure represents a valid alternative method for classification, 
although it should be more properly used in clinical-epidemiological survey 
For secondary SS 
In patients with a potentially associated disease (for instance, another well-defined connective 
tissue disease), the presence of item I or item II plus any 2 from among items III, IV, and V may be 
considered as indicative of secondary SS 
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Pre-weighed and labelled 20 ml tubes and lids  
Clock or timer 
 
1. The unstimulated whole saliva collection procedure should be done before the stimulated 
parotid collection procedure.  
 
2. During the collection period, the subject shall be seated straight up with eyes open and 
head tilted slightly forward.  
 
3. The subject will be instructed to minimize oro-facial movements to minimize influence on 




4. Then the patient allows the saliva to accumulate in the floor of the mouth for 60 seconds 
without swallowing.  
 
5. The patient empties the entire accumulated saliva into the pre-weighed container for 10 
minutes. 
 
6. The collection vial is weighed both before and after collection, and both pre- and post-
collection weights are recorded.  
 
 
7. Calculate flow rate on a ml/minute basis. 
 
 













Appendix 5:  Stimulated Parotid Flow Rate and Collection 
 
Materials:  
Pre-weighed and labelled 20 ml tubes and lids  
2% Citric acid solution (2 g in 100 ml sterile water, kept refrigerated) (2 ml) 
Parotid saliva collector (lashley cup)  
Tygon tubing (10.2 cm for the collecting tube from the inner circle of the parotid saliva collector, 
and 30.5-40.6 cm to connect the parotid collector to syringe) 
10 ml syringe  
Medium Binder Clip (clamp)  
Ice and container 
Timer or clock  
Balance  
1. The orifice of the parotid duct is located on the buccal mucosa opposite the upper second 
molar tooth; dry the area with gauze for better vision.  
2. The parotid collector is placed on the mucosa so that the inner ring surrounds the duct 
orifice.  
3. The collector is held on the mucosa by suction from the outer ring, created by pulling back 
on the syringe and allowing the pressure to come to equilibrium.  
a) Syringe can then be rested on the patient’s shoulder.  
b) A medium binder clip is attached to the tygon tubing going from the collector to the 
syringe to “lock-in” the air in the tubing. The suction created should be sufficient to hold 
the cup in place without occluding the inner chamber of the parotid collector with tissue 
(i.e., not too much suction).  
 
4. Saliva from the parotid gland then flows passively into the inner ring and through the 
attached tubing into pre-weighed tube.  
5. 2% citric acid solution is applied to the posterior lateral surfaces of the tongue, bilaterally, 
using 2 drops every 30 seconds to stimulate secretion.  
6. Flow may not begin for a minute or two after stimulation has been applied.  
7. A maximum of 5 minutes is allowed for saliva to appear in the clear portion of the tubing.  
8. If saliva flow is observed during this 5-minute period, an additional 10 minutes is allowed 
for the saliva to reach the end of the tubing and the 10-minute collection period begins when 
saliva begins to exit the Tygon tube. 
9. Calculate flow rate on a ml/minute basis. 
 




Appendix 6: Human S100A8/S100A9 Heterodimer Quantikine ELISA 
protocol:  
(cat. no. DS8900) 
All reagents and samples were brought to room temperature and prepared as directed in 
chapter 2 subsection 2.2.5.  
Fifty μL of Assay Diluent RD1-34 was added to each well. Then 50 μL of Standard and sample 
is added in duplicates and incubated for 2 hours at room temperature on a horizontal orbital 
microplate shaker (0.12" orbit) set at 500 ± 50 rpm. 
After washing (four times), 200 μL of Human S100A8/S100A9 Heterodimer Conjugate is 
added and incubated for another 2 hours at room temperature on the shaker. 
Subsequently another wash was done and 200 μL of Substrate Solution is added and 
incubated for 30 minutes at room temperature on the benchtop protecting it from light.  
The colour is stopped by the addition of 50 μL of Stop Solution to each well.  
The optical density is determined using a microplate reader  set to 540 nm at first and 












Appendix 7:  Proteome Profiler Human XL Cytokine Array protocol:   
  (cat. no. ARY022) 
 
All reagents and samples were brought to room temperature and prepared as directed in 

























The membranes are ready for the Chemidoc followed by ImageJ for measurement. 
 
Pipet 2 mL of Array Buffer 6 into each well of the 4-Well Multi-dish. 
(Array Buffer 6 serves as a block buffer)  
Place each membrane in a separate well.  
(The number on the membrane should be facing upward) 
 
 
Remove membranes and place into individual containers (plates) with 20 mL of 1X Wash Buffer 
(Rinse the 4-well multi-dish with distilled water and dry) 
Wash each membrane with 1X Wash Buffer for 10 minutes  
on a rocking platform shaker (three times) 
Add 30 μL of Detection Antibody Cocktail to 1.5 mL of 1X Array Buffer 4/6 for each array  
 Pipette 1.5 mL per well of diluted Detection Antibody Cocktail into the 4-Well Multi-dish  
Remove membranes from their washing plates and put back in the dish 
     Remove membranes and repeat the wash step 
 Pipette 2 mL of 1X Streptavidin-HRP into each well of the 4-Well Multi-dish. 
 
        
Remove membranes and repeat the wash step 
 Place membranes on the bottom sheet of plastic protector 
Pipette 1 mL of the prepared Chemi Reagent Mix evenly onto each membrane 
Cover with the top sheet of plastic protector 
 
Squeeze out the reagent mix  
Leave membranes on bottom sheet  
Cover with plastic wrap on top and around the back 
 Smooth out air bubbles  
Aspirate Array Buffer 6 from the wells and add the diluted  
samples. 
 
Incubate for one hour on a rocking platform shaker 
Incubate overnight at 2-8 °C on a rocking platform shaker 
Incubate for one hour on a rocking platform shaker 
Incubate for 30 minutes at room temperature on a shaker 
Incubate for one minute. 
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Appendix 8: Luminex Human Magnetic Assay protocols: 
Screening Human Magnetic Assay protocol: 
(Premixed multi-analyte kit) (cat. no. LXSAHM) 
Microparicle Cocktail (beads) preparation is done by vial centrifugation, vortexing then diluting 
(250 μL of the cocktail + 2.5 mL Diluent RD2-1). Biotein antibody cocktail is treated similarly. 
Streptavidin-PE is diluted with wash buffer (110 μL+ 2.7 mL). 
After sample /standards /reagents preparation the beads are re-suspeneded before adding 
them to the wells (25 μL). Samples and standards are then added (25 μL) and incubated on 
shaker at room temperature for two hours. The wells are washed using magnetic device 
intended to accommodate the plate (three times). Diluted antibody cocktail is then added (25 
μL) and incubated for one hour on the shaker. Wash step is repeated and followed by the 
addition of diluted streptavidin-PE (25 μL) with an incubation period of 30 minutes. Wash step 
is repeated and the beads are re-suspended by adding 100 μL of wash buffer to each well 
and incubated for two minutes on the shaker. The plate is now ready to read. 
 
Performance Human Magnetic Assay protocol: 
(Cytokine kit A) (cat. no. FCSTM03) 
In general, it is the same as the screening assay with different volumes, diluents (more 
sensitive) and incubation time.  Bead preparation is mentioned before; the dilution is (12.5 μL 
from each microparticle vial + 2.5 mL microparticle diluent). Biotein antibody cocktail is 
prepared likewise with its relevant diluent. Streptavidin-PE is diluted with wash buffer (30 μL+ 
3 mL). The first incubation period of beads and samples/standards is three hours. The 






Appendix 9: Preliminary proteins identified by LC-MS/MS proteomics analysis 
and selected per fold change ratio (first run)  
CT; healthy control, SS; Sjögren’s syndrome, SS at risk of lymphoma of developing mucosa‐associated 
lymphoid tissue. Proteins were present in all groups but up-regulated in disease sample, not present in 
control sample or not present in control and SS samples. ND; not detected, *could not be calculated. 
Highlighted are the common up-regulated proteins when SS was compared to control (n=6). Underlined 

















 Total ion current 
(TIC) 
Fold change ratio 
NO  Selected proteins CT SS SS at risk   
 
SS/CT SS at risk/ 
CT 
SS at risk/ 
SS 
1 Annexin A1  15860.7 73230 1513363.2 4.6 95.4 20.7 
2 Actin, cytoplasmic 2 93043.9 1580633.9 3826055.5 17 41.1 2.4 
3 Ig γ-1 chain C region 335437.5 2676308.9 13318238.8 8 39.7 5 
4 Protein S100-A8  26224.7 299185.7 712901.1 11.4 27.2 2.4 
5 Lactotransferrin  18742385.1 7150834.6 69818117 0.4 3.7 9.8 
6 Thrombospondin-1  112670 723090 2951800 6.4 26 4.1 
7 Thioredoxin  ND 221771.9 139336.5 * * 0.6 
8 14-3-3 protein 
zeta/delta  
ND 392907.5 384322 * * 1 
9 Protein S100-A9 ND 616106.3 1301008.8 * * 2.1 
10 Golgi apparatus 
protein 1  
ND ND 156208.9 * * * 
11 Matrilysin ND ND 141751.1 * * * 
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Appendix 10: Preliminary proteins identified by LC-MS/MS proteomics analysis 
and selected per fold change ratio (second run) 
CT; healthy control, SS; Sjögren’s syndrome, SS at risk of developing lymphoma of mucosa‐associated 
lymphoid tissue. Proteins were present in all groups but up-regulated in disease sample, not present in 
control sample or not present in control and SS samples. ND; not detected, *could not be calculated. 
Highlighted are the common up-regulated proteins when SS was compared to control (n=6). Underlined 
are the final proteins from which the selected proteins were further analysed via ELISA. 
 
 












 Total ion current 
(TIC) 
Fold change ratio 
NO  Selected proteins CT SS SS at risk   
 
SS/CT SS at risk / 
CT 
SS at risk/ 
SS 
1 Annexin A1  10026 9689.43 1180842.4 1 117. 8 121.9 
2 Actin cytoplasmic 2  210492.7 878628 850867.97 4.2 4.04 1 
3 Ig γ-1 chain C 
region  
211505.2 7948508.2 7981574.9 37.6 37.7 1.004 
4 Protein S100-A8  14250.3 119945.89 1149673.8 8.4 80. 7 9.6 
5 Lactotransferrin  12328407.3 90109906.93 47019126.6 7.3 3.8 0.5 
6 Protein S100-A9 89449.2 363782 4414986.4 4.07 49.4 12.1 
7 Thioredoxin  43669.5 58756.5 511520.5 1.3 11.7 8.7 
8 14-3-3 protein 
zeta/delta 
ND 11870.75 518438.4 * * 43.7 
9 Thrombospondin-1  ND 1572522.32 462161 * * 0.3 
10 Golgi apparatus 
protein  
ND 89355.6 38873.2 * * 0.4 
11 Matrilysin  ND 268531.1 85661.4 * * 0.3 
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Appendix 11: Statistical (SPSS) analysis of S100A8/A9 (Calprotectin, 
CalpP) levels in parotid saliva (overall SS and control groups)  
Case Processing Summary 
GP11 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
CalpP CT 18 100.0% 0 0.0% 18 100.0% 
SNOX 14 100.0% 0 0.0% 14 100.0% 

















Tests of Normality 
GP11 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
CalpP CT .347 18 .000 .585 18 .000 
SNOX .321 14 .000 .661 14 .000 




























GP11 Statistic Std. Error 






Bound 4.0507   
Upper 
Bound 498.7053   
5% Trimmed Mean 174.4082   
Median 31.8955   
Variance 247358.954   
Std. Deviation 497.35194   
Minimum 0.00   
Maximum 1888.21   
Range 1888.21   
Interquartile Range 273.19   
Skewness 2.600 .536 
Kurtosis 6.937 1.038 






Bound 43.8780   
Upper 
Bound 364.6499   
5% Trimmed Mean 167.1028   
Median 208.9451   
Variance 77162.253   
Std. Deviation 277.78094   
Minimum 0.00   
Maximum 1077.43   
Range 1077.43   
Interquartile Range 265.30   
Skewness 2.605 .597 
Kurtosis 8.292 1.154 






Bound 1222.3757   
Upper 
Bound 2715.2485   
5% Trimmed Mean 1721.5018   
Median 743.1429   
Variance ##########   
Std. Deviation 2653.95340   
Minimum 0.00   
Maximum 8948.86   
Range 8948.86   
Interquartile Range 3435.00   
Skewness 1.337 .333 
















Appendix 12: Statistical (SPSS) analysis of S100A8/A9 (Calprotectin, 
CalpP) levels in parotid saliva (SS sub groups and control groups) 
Case Processing Summary 
GP22 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
CalpP CT 18 100.0% 0 0.0% 18 100.0% 
SNOX 14 100.0% 0 0.0% 14 100.0% 
SS 19 100.0% 0 0.0% 19 100.0% 
AT RISK 18 100.0% 0 0.0% 18 100.0% 
5.00 14 100.0% 0 0.0% 14 100.0% 
 
Tests of Normality 
GP22 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
CalpP CT .347 18 .000 .585 18 .000 
SNOX .321 14 .000 .661 14 .000 
SS .318 19 .000 .647 19 .000 
AT RISK .290 18 .000 .764 18 .000 
5.00 .262 14 .010 .825 14 .010 


















GP22 Statistic Std. Error 






Bound 4.0507   
Upper 
Bound 498.7053   
5% Trimmed Mean 174.4082   
Median 31.8955   
Variance 247358.954   
Std. Deviation 497.35194   
Minimum 0.00   
Maximum 1888.21   
Range 1888.21   
Interquartile Range 273.19   
Skewness 2.600 .536 
Kurtosis 6.937 1.038 






Bound 43.8780   
Upper 
Bound 364.6499   
5% Trimmed Mean 167.1028   
Median 208.9451   
Variance 77162.253   
Std. Deviation 277.78094   
Minimum 0.00   
Maximum 1077.43   
Range 1077.43   
Interquartile Range 265.30   
Skewness 2.605 .597 














Bound 257.6001   
Upper 
Bound 2070.1467   
5% Trimmed Mean 871.7872   
Median 506.0000   
Variance 3535510.254   
Std. Deviation 1880.29526   
Minimum 0.00   
Maximum 7585.30   
Range 7585.30   
Interquartile Range 946.86   
Skewness 2.611 .524 
Kurtosis 7.466 1.014 






Bound 895.4732   
Upper 
Bound 3969.6033   
5% Trimmed Mean 2205.6615   
Median 666.8104   
Variance 9553621.187   
Std. Deviation 3090.89327   
Minimum 0.00   
Maximum 8948.86   
Range 8948.86   
Interquartile Range 5511.19   
Skewness .989 .536 
Kurtosis -.654 1.038 






Bound 812.4564   
Upper 
Bound 4117.5631   
5% Trimmed Mean 2279.3600   
Median 937.4286   
Variance 8191873.956   
Std. Deviation 2862.14499   
Minimum 0.00   
Maximum 8271.71   
Range 8271.71   














Appendix 13: S100A8/A9 levels in (A) parotid and (B) whole mouth saliva 







No significant differences were detected between treated (whole/parotid) (n=19/38) and 
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Appendix 14:  Summary of the second ranked cytokines-proteins ordered by 
fold change and p-value when compared to controls (proteome profiler) 
Fold change in the first group (A) is ≥ 1.5 in all disease groups. In the second group (B) it is increased 
in 2 of the disease groups. While the third group (C) fold change is increased in one group only. NS; 
not significant, CT; healthy controls, SS; Sjögren’s syndrome, MALT-L; mucosa associated lymphoid 
tissue lymphoma. MCP-1 is significantly different when compared to controls (one- way ANOVA 
followed by Tukey HSD post hoc test). 
Second ranked proteins were identified in 11 samples of 12  
 
 

























































Pentraxin-3 >-1.5, <1.5 NS 1.6 NS 2.7 NS 
SDF-1α >-1.5, <1.5 NS 1.6 NS 2.1 NS 
TGF-α >-1.5, <1.5 NS 1.6 NS 1.6 NS 
MIP-3β >-1.5, <1.5 NS 1.6 NS 5.5 NS 
IL-2 >-1.5, <1.5 NS 1.5 NS 1.6 NS 












>-1.5, <1.5  
 
NS 
IL-32α/β/γ -2 NS 1.7 NS >-1.5, <1.5 NS 
MCP-1 >-1.5, <1.5 NS 2.1 0.04* >-1.5, <1.5 NS 
IL-23 >-1.5, <1.5 NS 2.1 NS >-1.5, <1.5 NS 
IL-24 >-1.5, <1.5 NS >-1.5, <1.5 NS 1.5 NS 
GRO-α >-1.5, <1.5 NS >-1.5, <1.5 NS 4.2 NS 
Chitinase 3-like 1 >-1.5, <1.5 NS >-1.5, <1.5 NS 3.6 NS 
MIP-1α/MIP-1β >-1.5, <1.5 NS >-1.5, <1.5 NS 2.3 NS 
FGF basic >-1.5, <1.5 NS >-1.5, <1.5 NS 1.7 NS 
BAFF >-1.5, <1.5 NS >-1.5, <1.5 NS 1.5 NS 
C-Reactive protein >-1.5, <1.5 NS >-1.5, <1.5 NS 2.9 NS 
G-CSF -2 NS >-1.5, <1.5 NS 1.8 NS 
Complement C5/C5a -1.9 NS >-1.5, <1.5 NS 2.3 NS 
ICAM-1 
 

















Appendix 15: Summary of the second ranked cytokines-proteins ordered by 
fold change and p-value when compared to SS (proteome profiler) 
  




MALT-L vs. MALT-L 




























I-TAC 2 NS 4.6 NS 2.6 NS 
MIP-3β 1.5 NS 5.4 NS 4 NS 
C-Reactive protein 2.4 NS 4 NS 1.6 NS 
Complement C5/C5a 
 














IL-32α/β/γ 3.6 0.02* 2 NS -1.7 NS 
MIP-1α/MIP-1β 2.6 NS 3.6 NS >-1.5, <1.5 NS 
Dkk-1 3 NS 3.3 NS >-1.5, <1.5 NS 
BDNF 2.5 NS 3.3 NS >-1.5, <1.5 NS 
Angiopoietin-2 2.8 NS 3.1 NS >-1.5, <1.5 NS 
TNF-alpha 1.5 NS 3 NS >-1.5, <1.5 NS 
FGF basic 2.2 NS 2.5 NS >-1.5, <1.5 NS 
IL-15 2.2 NS 2.5 NS >-1.5, <1.5 NS 
IL-34 2 NS 2.2 NS >-1.5, <1.5 NS 
BAFF 1.5 NS 2 NS >-1.5, <1.5 NS 
IL-24 2.6 NS 2.8 NS >-1.5, <1.5 NS 
G-CSF 3.4 NS 3.9 NS >-1.5, <1.5 NS 
TARC 2.3 NS 2.1 NS >-1.5, <1.5 NS 
Cripto-1 2.9 NS 2.6 NS >-1.5, <1.5 NS 
TGF-α 2.3 NS 2.3 NS >-1.5, <1.5 NS 
IL-12 p70 2.9 NS 2 NS >-1.5, <1.5 NS 
GRO-α >-1.5, <1.5 NS 5.6 NS 4.3 NS 
MIP-3α >-1.5, <1.5 NS 4 NS 4.6 NS 
SDF-1α >-1.5, <1.5 NS 1.6 NS 2.1 NS 
Chitinase 3-like 1 
 


















Appendix 15 (Continued) 
 
Fold change in the first group (A) is ≥ 1.5 in all disease groups. In the second group (B) it is 
increased in 2 of the disease groups. While the third group (C) fold change is increased in one 
group only. NS; not significant, CT; healthy controls, SS; Sjögren’s syndrome, MALT-L; mucosa 
associated lymphoid tissue lymphoma. IL-32α/β/γ, MCP-1, IL-10 and MCP-3   are significantly 
different when compared to SS (one- way ANOVA followed by Tukey HSD post hoc test). 
 





MALT-L risk vs. 
SS 
MALT-L vs. SS 
MALT-L vs. MALT-L 
risk    
Analytes Fold 
change 
p-      
value 




















IL-10 2.2 0.04* >-1.5, <1.5 NS >-1.5, <1.5 NS 
IL-13 2.1 NS >-1.5, <1.5 NS >-1.5, <1.5 NS 
MCP-3 2.1 0.05* >-1.5, <1.5 NS >-1.5, <1.5 NS 
RANTES 1.9 NS >-1.5, <1.5 NS >-1.5, <1.5 NS 
PDGF-AB/BB 1.8 NS >-1.5, <1.5 NS >-1.5, <1.5 NS 
Pentraxin-3 >-1.5, <1.5 NS 2.5 NS >-1.5, <1.5 NS 
IL-2 
 
























Appendix 16: Summary of the third ranked cytokines-proteins ordered by 
fold change and p-value when compared to controls (proteome profiler) 
Fold change in the first group (A) is ≥ 1.5 in 2 of the disease groups. While the second group (B) fold 
change is increased in one group only. NS; not significant, CT; healthy controls, SS; Sjögren’s 
syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma. No significant differences 
detected when compared to controls (one- way ANOVA followed by Tukey HSD post hoc test).  





































































IL-5 -3.2 NS >-1.5, <1.5 NS 2 NS 
IGFBP-2 -1.6 NS >-1.5, <1.5 NS 4.7 NS 
IL-8 -1.6 NS >-1.5, <1.5 NS 4.9 NS 































Appendix 17: Summary of the third ranked cytokines-proteins ordered by 
fold change and p-value when compared to SS (proteome profiler) 
  





























MIF 3.2 NS 3.8 NS >-1.5, <1.5 NS 
IL-3 3.3 NS 3.9 NS >-1.5, <1.5 NS 
IL-5 4.1 NS 5.1 NS >-1.5, <1.5 NS 
IGFBP-3 1.8 NS 1.6 NS >-1.5, <1.5 NS 
IL-1β 1.9 NS 1.6 NS >-1.5, <1.5 NS 
PF4 2.6 NS 1.7 NS >-1.5, <1.5 NS 
RAGE 2.7 NS 2.2 NS >-1.5, <1.5 NS 
IL-31 3.4 NS 2.7 NS >-1.5, <1.5 NS 
FGF-7 3.3 NS 2.8 NS >-1.5, <1.5 NS 
IL-1α 3.8 NS 2.9 NS >-1.5, <1.5 NS 
Angiopoietin-1 1.5 NS 3 NS >-1.5, <1.5 NS 
Aggrecan 1.9 NS 3.2 NS >-1.5, <1.5 NS 




























IFN-γ 1.9 NS >-1.5,<1.5 NS >-1.5, <1.5 NS 
Fold change in the first group (A) is ≥ 1.5 in 2 of the disease groups. While the second group (B) 
fold change is increased in one group only. NS; not significant, CT; healthy controls, SS; Sjögren’s 
syndrome, MALT-L; mucosa associated lymphoid tissue lymphoma. No significant differences 
detected when compared to SS (one- way ANOVA followed by Tukey HSD post hoc test).  

































Case Processing Summary 
Group2 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
IL6P CT 18 100.0% 0 0.0% 18 100.0% 
SNOX 15 100.0% 0 0.0% 15 100.0% 
SS 19 100.0% 0 0.0% 19 100.0% 
AT 
RISK 
17 100.0% 0 0.0% 17 100.0% 












Bound 1.0176   
Upper 
Bound 1.8290   
5% Trimmed Mean 1.4104   
Median 1.5900   
Variance .666   
Std. Deviation .81584   
Minimum .16   
Maximum 2.92   
Range 2.76   
Interquartile Range 1.40   
Skewness -.031 .536 
Kurtosis -.706 1.038 






Bound 1.0783   
Upper 
Bound 1.9004   
5% Trimmed Mean 1.4715   
Median 1.4000   
Variance .551   
Std. Deviation .74227   
Minimum .34   






Range 2.62   
Interquartile Range .62   
Skewness .199 .580 
Kurtosis .000 1.121 






Bound 2.4416   
Upper 
Bound 34.1247   
5% Trimmed Mean 14.1246   
Median 2.5400   
Variance 1080.259   
Std. Deviation 32.86729   
Minimum .63   
Maximum 110.79   
Range 110.16   
Interquartile Range 9.97   
Skewness 2.084 .524 
Kurtosis 3.367 1.014 
AT 
RISK 






Bound 3.3214   
Upper 
Bound 19.6056   
5% Trimmed Mean 9.3989   
Median 4.9200   
Variance 250.776   
Std. Deviation 15.83592   
Minimum .42   
Maximum 59.67   
Range 59.25   
Interquartile Range 18.77   
Skewness 2.067 .550 
Kurtosis 4.592 1.063 






Bound 1.1120   
Upper 
Bound 19.3788   
5% Trimmed Mean 8.5776   
Median 2.5400   
Variance 228.440   




  Minimum .51  
  
Maximum 50.00   
Range 49.49   
Interquartile Range 15.17   
Skewness 1.929 .616 




Appendix 19:  Analytes excluded from further validation via Luminex 
screening assay 
















(Bassig et al., 2015)  
 
 
(Gerli et al., 1999, 















Vitamine D BP 
(1ST rank) 
 































SS; Sjögren’s syndrome, NHL; Non-Hodgkin lymphoma, PS; parotid saliva, WMS; whole mouth 
saliva, GCF; gingival crevicular fluid, ESI; electrospray ionization, MS/MS; Tandem mass 





















Appendix 20: Cytokines identified previously in serum of SS subjects 
using different methods 












IL-2, srIL-2, IL-6 and IL-10 (Garcic-
Carrasco et 
al., 2001) 
SS Serum ELISA All increased 
 
IL-10 (Anaya et 
al., 2002) 
SS Serum ELISA Increased 
BAFF (Mariette et 
al., 2003) 
 
SS Serum ELISA  
 
Increased 
IL-1β, IL-2, IL-4, IL-5, IL-6, 
IL-8, IL-10, IL-12p40, IL-13, 
IL-15, IL-17, IFN-γ, TNF-α, 
EGF, VEGF, FGF, G-CSF, 
GM-CSF, MCP-1, Eotaxin, 
MIP-1α, MIP-1β, RANTES, 




SS Serum 25-plex,bead- 
based assay 
IL-1β, IL-6, IL-8, IL-12 
p40, IL-15, TNF- α, EGF, 
MIP-1 β, MCP-1, 
Eotaxin, and RANTES 
were increased 
IL-1α, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-8, IL-10, IL-12p40, 
IL-13, IL-15, IL-17, IFN-γ,  
IFN-α, TNF-α, GM-CSF, 
MCP-1, Eotaxin, MIP-1α 
















IL-1β, IL-2, IL-6, IL-15, 
IFN- γ and MIP-1 β were 
increased in both SS± 
GC  
 
IL-4, IL-10, GM-CSF, 
IFN- α, MIP-1α, Eotaxin 
and BAFF were 
increased in SS +GC 
 
BAFF and APRIL (Jonsson et 
al., 2005) 
 
SS± GC Serum ELISA Increased 
BAFF 
 
(Pers et al., 
2005b) 
SS Serum ELISA  Increased  
BAFF and β2 
microglobulin 
(Gottenberg 
et al., 2005) 
SS Serum  ELISA Both were not 
associated  
 
BAFF was associated 
with ENA but not with 
systemic manifestation 
IL-4, IL-10, and IFN-γ (Szodoray et 
al., 2008) 
SS Serum  ELISA IL-4 not different to CT 
IL-10 decreased while 
IFN-γ increased 
IL-1β , IL-1Ra, IL-2, IL-2R, IL-
4, IL-5, IL-6, IL-7, IL-8, IL-10, 
IL-12p40/p70, IL-13, IL-15, 
IL-17, IFN-α, IFN-γ, TNF-α, 
MCP-1, MIP-1α, MIP-1β, 
RANTES, Eotaxin, MIG, 




and ± FS 
Serum 25-plex, bead- 
based assay 
IL-1beta, IL-4, IL-12p40, 
IL-15, IL-17, IL-1RA, 
MIP-1α, MIP-1β, 
Eotaxin and IFN-α were 
increased in SS+GC 
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SS; Sjögren’s syndrome, NHL, non- Hodgkin’s lymphoma, TTT; rituximab treatment, GC; germinal 
centers, FS; focus score, ELISA; enzyme-linked immunosorbent assay, ENA; extractable nuclear 
antibodies (anti-SSA/SSB) 
 
Appendix 20 (Continued)  
      
Biomarkers Study Disease 
 
Sample Method Finding 
FLT3LG (Tobon et 
al., 2010) 











FLT3LG (Tobon et 
al., 2013) 
SS±NHL Serum  ELISA Increased levels were 
associated with history of 
lymphoma 
 
BAFF and APRIL (Pollard et 
al., 2013b) 
SS and TTT Serum ELISA Both increased in SS  
BAFF increased after TTT 
IL-1β , IL-1Ra, IL-2, IL-2R, IL-
4, IL-5, IL-6, IL-7, IL-8, IL-
10,IL12p40/p70, IL-13, IL-
15, IL-17, IFN-α, IFN-γ, 
TNF-α, MCP-1, MIP-1α, 
MIP-1β, RANTES, Eotaxin, 
MIG, GM-CSF and IP-10 
(Pollard et 
al., 2013a) 
SS and  
TTT 
Serum 25-plex, bead- 
based assay 
Nearly all of the 
cytokines were increased 
in SS except for IL-8, IFN-
γ and RANTES 
TTT affected GM-CSF, IL-
1Ra, IL-6, IL-10, IFN-α, 
TNF-α, MIP-1β and MIG 
levels  
BAFF (Quartucci
o et al., 
2013) 
 
SS± NHL Serum ELISA  
 
Increased levels were 
associated with history 
and at risk of lymphoma 
and higher disease 
activity 
BAFF (Gottenber
g et al., 
2013) 
SS+NHL Serum ELISA  
 
Increased levels 
associated with higher 
disease activity scores 
and history of lymphoma 
IL-17 (Alunno et 
al., 2015)  
 
SS Serum  ELISA 
 
Detected in some 
samples 
Eotaxin and  BCA-1 (Nocturne 
et al., 
2015) 
SS± NHL Serum Multiplex assay BCA-1 increased in NHL 
and associated with 
higher disease activity 
scores 
BAFF and IL-17A (Deng et 
al., 2016) 
SS Serum  ELISA Both increased 
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Appendix 21: Cytokines identified previously in serum and salivary 
glands of SS subjects using different methods 
SS; Sjögren’s syndrome, NHL; non- Hodgkin’s lymphoma, MSG; minor salivary glands, SMG*; 
submaxillary glands, PBMCs; peripheral blood mononuclear cells, PGx; parotid glands, ELISA; 
enzyme-linked immunosorbent assay, IHC; immunohistochemistry, PCR; polymerase chain 
reaction.  
 
      
Biomarkers Study Disease 
 
Sample Method Finding 























































IL-2, IL-4 ,IL-6, IL-12, IL-
17,IFN-γ and TGF-β1 
 
















IHC / PCR 
Increased 
 
All increased except 
IFN-γ 
 
mRNA and protein 
levels of IL-6, -17A and -
23 were increased 
 
IL-17 producing cells 
 
IL-6, IL-17 and IL-23  
 
 
























mRNA and protein 




IL-17 producing cells 
































Aberrant expression of 
IL-22R1 linked to IL-18  
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Appendix 22: Cytokines identified previously in salivary glands of SS 
subjects using different methods 












IL-1α, IL-1β, IL-4, IL-6 
TNF-α, TNF-β and  IFN- 
γ 




IHC IL-1β, IL-6 TNF-α and IFN- γ 
were over-expressed in SS  
 
IL-1α, IL-4 and TNF-β were 
not detected 
IL-2, IL-6, IL-10 and 
TGF- β 










mRNA levels of all cytokines 
are expressed in mod-severe 
lesions 
 
IL6 and -10 were detected 
IL-1β, IL-2, IL-3, IL-4, IL-
6, IL-6R, IL-9, IL-10, IL-
12, TNF-α, IFN-γ and 
TGF-β 




PGx PCR mRNA levels of all cytokines 
were expressed in all groups 
 
 IL-4 absent in MESA but 
present in some of SS with 
NHL 
 
IFN- γ, IL-2, IL-4 and IL-
5 
(Konttinen et al., 
1999) 
 





IFN- γ, IL-2 were expressed in 
both in SS and CT 
 
mRNA levels of IFN- γ, IL-2 
and IL-4 were expressed in 
SS and CT  
 
IL-2, IL-4, IL-10, IL-12, 
IL-18, TGF- β, TNF-α, 
IFN- γ 
(Kolkowski et al., 
1999) 
SS MSG IHC / PCR mRNA levels of Th1 
cytokines were expressed   
 
IL-4 was absent  
 
IL-10 and TGF-β were 
expressed in majority 
 
SDF-1 and BCA-1 (Amft et al., 2001) 
 
SS±GC MSG IHC BCA-1 was expressed in SS 
not CT 
SDF-1 was expressed in both 
IP-10, MIG and SDF-1 (Ogawa et al., 
2002) 
 
SS MSG IHC / PCR-
ELISA 
mRNA levels of IP-10 and 
MIG were increased 
 
SDF-1, BCA-1 and SLC (Salomonsson et 
al., 2003) 
SS±GC MSG IHC No association with GC 
 
 
I-TAC (Ogawa et al., 
2004) 
 
SS MSG IHC / PCR-
ELISA 
Expressed in the presence of 
IN-γ 
BAFF (Lavie et al., 2004) SS MSG IHC / PCR Strong expression in SS 
































BCA-1 and SLC (Barone et al., 
2005) 
 
SS±GC MSG IIHC Both expressed with 
high focus score  




MSG Double IHC 
 
Both were expressed 
in SS not CT 
 




MMSG Double IHC  
flow cytometry 
SDF-1and SLC 
expressed in LESA 
 
BCA-1 in MALT-L 
 
MCP-1 (Iwamoto et al., 
2010) 
SS MSG IHC / PCR mRNA and protein 
levels were increased 
 
IL-17, IL-22 and IL-23 (Ciccia et al., 
2012) 
SS MSG IHC / PCR mRNA and protein 
levels of all were 
increased 
 
IP-10 (Ruffilli, 2014) 
 
SS MSG IHC Increased expression 
MIG; Monokine induced by gamma interferon, I-TAC;  inducible T-cell alpha chemoattractant, 
BCA-1; B cell-attracting chemokine -1, SLC; Secondary lymphoid-tissue chemokine, SDF-1; 
stromal cell-derived factor 1, SS; Sjögren’s syndrome, MESA; myoepithelial sialadenitis, NHL; 
non- Hodgkin’s lymphoma, GC; germinal centers, MALT-L; mucosa associated lymphoid tissue 
lymphoma, LESA; lymphoepithelial sialadenitis, MSG; minor saligary glands, PGx; parotid 
glands, MMSG; major and minor salivary glands, IHC; immunohistochemistry, PCR; polymerase 
chain reaction, ELISA; enzyme-linked immunosorbent assay 
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Appendix 23: Cytokines identified previously in saliva of SS subjects 
using different methods 
 
















Saliva ELISA Both increased but 
decreased after TTT 
 













Saliva  ELISA IL-2 and -6 
increased but 
decreased after TTT 
IL-6 and bFGF (Boras et al., 
2004) 
SS Saliva  
 
Serum 
ELISA Both increased 
 
No difference 

















(Delaleu et al., 
2008) 




 75-plex, bead- 
based assay (MAP) 
 
82-plex, bead- 
based assay (MAP) 
34 detected in 
saliva 
 
38 detected in 
serum 
 








IL-17 and IL-23 
 
 
IL-17 and IL-6 



































Bead- based  
assay (human) 
Both expressed in 
later stages even 
mRNA levels 
 
low levels detected 






IL-6 only increased 
Both did not differ 
from CT 
MCP-1, MIP-1α, MIP-
1β, IL-8 and IP-10 




IL-8 and IP-10 were 
increased 
 
IL-1, IL-4, IL-6, IL-10,  
IL-12p40, IL-17, IFN-γ 
and TNF-α 
 






All were increased   
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Appendix 23 (Continued) 
SS; Sjögren’s syndrome, TTT; pilocarpine treatment, SMG; submandibular glands, MSG; minor 
salivary glands, PBMCs; peripheral blood mononuclear cells, ELISA; enzyme-linked 
immunosorbent assay, IHC; immunohistochemistry, PCR; polymerase chain reaction, CBA; 
cytometric bead assay, MAP; multianalyte profile, DFA; discriminant function analysis, GO; gene 









      





SDF_1α, BCA-1, IP-10, 






SS Saliva Luminex bead- 
based assay 
IP-10 and MCP-1 were 
increased  
IL-1β, IL-2, IL-4, IL-5, IL-6, 
IL-10, IL-12, TNF-α, IFN-
γ, RANTES, IL-8, MIG and 






IL-2, IFN-γ, IL-4, IL-5, IL 
10, IL-12, IL-17 and TGF-
β, IP-10, RANTS, TARC, 
MDC and MIP-1α 
(Moriyama 































IL-1 β, IL-8, IL-4, IL-6, IL-
10 and MDC were 
increased. 
 
IL-4, IL-10 and MDC 




mRNA levels of IL-2, IFN- 
γ, IL-4, IL-10, IL-17, IP-10, 
MIP-1α, RANTES, TARC 
and MDC were increased 
 
mRNA levels of IP-10 
was increased 
 
IL-1β, IL-2, IL-4, IL-5, IL-6, 
IL-10, IL-12p70, IL-17A, 
IFN-γ, and TNF-α 
(Ohyama et 
al., 2015) 
SS Saliva CBA All were increased 
 
187 analytes (Delaleu et 
al., 2015) 
SS Saliva 187-plex, bead-
based assay 
(MAP)DFA and 
GO-  analysis 
52 were increased in SS 
 
4- and 6- plex signature 
included IL-4 and IL-5 
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Appendix 24: Cytokines identified previously in parotid saliva of SS 
subjects using different methods 












IL-1α, IL-2, IL-4, IL-5, IL-6, 
IL-10, IFN-γ, and TNF-α 
(Fox et al., 
1994) 











All were increased in SS except 
IL-4 and -5 were not detected 
 
mRNA levels of IL-2, -10 and 
IFN-γ were detected in SS but 
not IL-4 and -5.  
TNF-α was detected in SS and 
normal  
IL-1α and -6 were detected in 
some 
 
IL-6 (Grisius et 
al., 1997) 
SS (P) saliva 
 
Serum 




IL-10, IL-2, IL-4 and IFN-γ  (Bertorello 
et al., 
2004) 
SS (P) saliva ELISA IL-10 increased in most 
IFN-  increased in some 
IL-2 and -4 are absent 
 
SS; Sjögren’s syndrome, (P); parotid saliva, MSG; minor salivary glands, ELISA; enzyme-linked 

















Appendix 25: Summary of the review of literature on cytokines   
The findings of the above- listed studies for chapter 5 can be summarised as follows; in 
serum, levels of IL-22, -10 were increased in SS patients with a direct correlation with some 
of the clinical parameters, e.g. autoantibody levels (Anaya et al., 2002, Lavoie et al., 2011). 
Levels of IL-6 were increased in SS patients when compared to controls (Grisius et al., 1997). 
While another study found no differences between IL-6 levels of SS and control groups (Tishler 
et al., 1999). IL-17 and linked cytokines (e.g. IL-6) were found to be up-regulated in SS in 
comparison to controls (Katsifis et al., 2009, Kwok et al., 2012). In addition to IL-17 (Fei et al., 
2014). BAFF was also found highly elevated in SS patients, both of which correlated with 
different SS phenotypes (Deng et al., 2016). BAFF and APRIL were elevated in SS patients 
(Pollard et al., 2013b). On the other hand, Alunno et al., (2015) reported detectable levels of 
IL-17 in 15/50 SS patients and that it was associated with longer disease duration which is a 
similar finding to Nguyen et al., (2008) where they have analysed levels of IL-17 and -23 in 
sera, saliva and glands of animal models and SS patients.  Serum levels of IL-18 in SS were 
higher than controls but similar to patients with rheumatoid arthritis (Bombardieri et al., 2004). 
Also, serum levels of several cytokines were measured by multiplex assays in SS patients 
identifying potential targets (Pollard et al., 2013a, Szodoray et al., 2005, Szodoray et al., 2004, 
Reksten et al., 2009, Moriyama et al., 2012). In minor salivary glands, protein and mRNA 
levels of IL-6, -17, 22, -23 and MCP-1 were increased in SS patients (Ciccia et al., 2012, 
Iwamoto et al., 2010, Katsifis et al., 2009, Kwok et al., 2012, Fei et al., 2014) In addition IL-18 
was expressed in SS patient’s glands but not in chronic sialadenitis glands (Bombardieri et 
al., 2004).  Th1 cytokines were identified in salivary glands of SS patients while IL-4 was 
absent and IL-10 was present in the majority of samples (Kolkowski et al., 1999). Similar 
findings were reported, demonstrating cytokine expression in healthy control samples as well 
(Konttinen et al., 1999). Expression of some chemokines was reported by Ogawa et al., (2004) 
and (2002) also the same group has looked at other cytokines as well (Ogawa et al., 1995).  
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Turning now to the non-Hodgkin lymphoma (NHL) literature, it can be seen that a considerable 
number of studies were done looking at the cytokine/chemokine levels in SS patients with 
lymphoma, correlating their levels with the predictive markers of lymphoma, where serum and 
salivary glands were their main targets; 
 In salivary glands of SS patients with non-Hodgkin lymphoma (NHL), there was an aberrant 
expression of IL-22R1 which is IL-18 dependent (Ciccia et al., 2015).  Several cytokines were 
detected in all SS stages (SS, SS with myoepithelial sialadenitis (MESA) and SS with NHL) 
but expression levels of IL-4 were lacking from patients with MESA while present in some 
salivary glands of SS and SS with NHL (De Vita et al., 1995). Some cytokines were increased 
more in mod-severe lesion (Ogawa et al., 1995).  IL-18 was positively correlated with other 
predictive markers while IL-12 was negatively correlated (Manoussakis et al., 2007). A number 
of chemokines (BCA-1 and SLC) were expressed in glands being higher with high focus 
scores (germinal centres) (Barone et al., 2005, Amft et al., 2001). Also BCA-1 expression was 
increased in salivary glands of SS patients with MALT-L (Barone et al., 2008).  However, 
Salomonsson et al., (2003) found no correlation between those cytokines and the formation 
of germinal centres. 
In serum, higher Fms-related tyrosine kinase 3 ligand (FLT3LG) levels were found in SS group 
in comparison to controls and they were associated with a history of lymphoma as well as with 
other predictive markers (Tobon et al., 2010, Tobon et al., 2013). Several studies have focused 
on BAFF levels in SS, correlating them with serological levels  (Pers et al., 2005b, Groom et 
al., 2002, Mariette et al., 2003, Lavie et al., 2008), with certain predictors of lymphoma 
development, with higher disease activity and with history of lymphoma (Gottenberg et al., 
2013, Quartuccio et al., 2013). In addition to BAFF, serum levels of APRIL were found 
increased in SS in relation to controls and both were positively correlated with focus score 
(Jonsson et al., 2005). Nocturne et al., (2015) reported elevated levels of BCA-1 in SS patients 
with NHL. The levels of several cytokines in SS patients with and without germinal centres 
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